General Information of This Antigen
Antigen ID
TAR0THKZD
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Gene Name
ERBB2
Gene ID
2064
Synonym
HER2; MLN19; NEU; NGL; Metastatic lymph node gene 19 protein;Proto-oncogene Neu;Proto-oncogene c-ErbB-2;Tyrosine kinase-type cell surface receptor HER2;p185erbB2;CD_antigen=CD340
Sequence
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV

    Click to Show/Hide
Family
Tyr protein family
Function
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.

    Click to Show/Hide
Uniprot Entry
ERBB2_HUMAN
HGNC ID
HGNC:3430
KEGG ID
hsa:2064
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
ADAPT6-ABD
ADC Info ADC Name Payload Target Linker Ref
ADAPT6-ABD-mcDM1
Mertansine DM1
Microtubule (MT)
Maleimidocaproyl (Ser3-Gly)3
[1]
Anbenitamab
ADC Info ADC Name Payload Target Linker Ref
Anbenitamab-ADC-Tb3-1
Anbenitamab-ADC-Tb3-1 payload
Undisclosed
Anbenitamab-ADC-Tb3-1 linker
[2]
Anbenitamab-ADC-Tb3-2
Anbenitamab-ADC-Tb3-2 payload
Undisclosed
Anbenitamab-ADC-Tb3-2 linker
[2]
Anbenitamab-ADC-Tb3-3
Anbenitamab-ADC-Tb3-3 payload
Undisclosed
Anbenitamab-ADC-Tb3-3 linker
[2]
Anbenitamab-ADC-Tb3-4
Anbenitamab-ADC-Tb3-4 payload
Undisclosed
Anbenitamab-ADC-Tb3-4 linker
[2]
Anbenitamab-ADC-Tb3-5
Anbenitamab-ADC-Tb3-5 payload
Undisclosed
Anbenitamab-ADC-Tb3-5 linker
[2]
Anbenitamab-ADC-Tb3-6
Anbenitamab-ADC-Tb3-6 payload
Undisclosed
Anbenitamab-ADC-Tb3-6 linker
[2]
Anbenitamab-ADC-Tb3-7
Anbenitamab-ADC-Tb3-7 payload
Undisclosed
Anbenitamab-ADC-Tb3-7 linker
[2]
Anbenitamab-ADC-Tb3-8
Anbenitamab-ADC-Tb3-8 payload
Undisclosed
Anbenitamab-ADC-Tb3-8 linker
[2]
Anbenitamab-ADC-Tb3-9
Anbenitamab-ADC-Tb3-9 payload
Undisclosed
Anbenitamab-ADC-Tb3-9 linker
[2]
Anbenitamab-ADC-Tb3-10
Anbenitamab-ADC-Tb3-10 payload
Undisclosed
Anbenitamab-ADC-Tb3-10 linker
[2]
ADC Info ADC Name Payload Target Linker Ref
An2-anti-HER2-Doxetaxel
Docetaxel
Microtubule (MT)
Undisclosed
[3]
Anti-HER2 1-alpha-hydroxyvitamin-D5-HER-2 Anti-ody conjugate mAb
ADC Info ADC Name Payload Target Linker Ref
Alpha-hydroxyvitamin-D5-HER2 antibody conjugate
Vitamin D
Undisclosed
Sulfosuccinimidyl 6-4 azido nitrophenylamido hexanode (SANPAH)
[4]
Anti-HER2 7C2 mAb
ADC Info ADC Name Payload Target Linker Ref
HER2-5 ADC
GNE-987 (R)
Bromodomain-containing protein 4 (BRD4)
Dolaflexin polymer
[5]
Anti-HER2 antibody 20507
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-28
WO2015095301A2 ADC-28 payload
Undisclosed
WO2015095301A2 ADC-28 linker
[6]
WO2015095301A2 ADC-29
WO2015095301A2 ADC-29 payload
Undisclosed
WO2015095301A2 ADC-29 linker
[6]
WO2015095301A2 ADC-30
WO2015095301A2 ADC-30 payload
Undisclosed
WO2015095301A2 ADC-30 linker
[6]
WO2015095301A2 ADC-31
WO2015095301A2 ADC-31 payload
Undisclosed
WO2015095301A2 ADC-31 linker
[6]
WO2015095301A2 ADC-32
WO2015095301A2 ADC-32 payload
Undisclosed
WO2015095301A2 ADC-32 linker
[6]
WO2015095301A2 ADC-33
WO2015095301A2 ADC-33 payload
Undisclosed
WO2015095301A2 ADC-33 linker
[6]
WO2015095301A2 ADC-34
WO2015095301A2 ADC-34 payload
Undisclosed
WO2015095301A2 ADC-34 linker
[6]
WO2015095301A2 ADC-35
WO2015095301A2 ADC-35 payload
Undisclosed
WO2015095301A2 ADC-35 linker
[6]
WO2015095301A2 ADC-36
WO2015095301A2 ADC-36 payload
Undisclosed
WO2015095301A2 ADC-36 linker
[6]
WO2015095301A2 ADC-37
WO2015095301A2 ADC-37 payload
Undisclosed
WO2015095301A2 ADC-37 linker
[6]
WO2015189791A1 ADC-27
WO2015189791A1 ADC-27 payload
Undisclosed
WO2015189791A1 ADC-27 linker
[7]
WO2015189791A1 ADC-28
WO2015189791A1 ADC-28 payload
Undisclosed
WO2015189791A1 ADC-28 linker
[7]
WO2015189791A1 ADC-29
WO2015189791A1 ADC-29 payload
Undisclosed
WO2015189791A1 ADC-29 linker
[7]
WO2015189791A1 ADC-30
WO2015189791A1 ADC-30 payload
Undisclosed
WO2015189791A1 ADC-30 linker
[7]
WO2015189791A1 ADC-31
WO2015189791A1 ADC-31 payload
Undisclosed
WO2015189791A1 ADC-31 linker
[7]
WO2015189791A1 ADC-32
WO2015189791A1 ADC-32 payload
Undisclosed
WO2015189791A1 ADC-32 linker
[7]
WO2015189791A1 ADC-33
WO2015189791A1 ADC-33 payload
Undisclosed
WO2015189791A1 ADC-33 linker
[7]
WO2015189791A1 ADC-34
WO2015189791A1 ADC-34 payload
Undisclosed
WO2015189791A1 ADC-34 linker
[7]
WO2015189791A1 ADC-35
WO2015189791A1 ADC-35 payload
Undisclosed
WO2015189791A1 ADC-35 linker
[7]
WO2015189791A1 ADC-36
WO2015189791A1 ADC-36 payload
Undisclosed
WO2015189791A1 ADC-36 linker
[7]
WO2015189791A1 ADC-37
WO2015189791A1 ADC-37 payload
Undisclosed
WO2015189791A1 ADC-37 linker
[7]
WO2015189791A1 ADC-40
WO2015189791A1 ADC-40 payload
Undisclosed
WO2015189791A1 ADC-40 linker
[7]
WO2015189791A1 ADC-61
WO2015189791A1 ADC-61 payload
Undisclosed
WO2015189791A1 ADC-61 linker
[7]
WO2015189791A1 ADC-63
WO2015189791A1 ADC-63 payload
Undisclosed
WO2015189791A1 ADC-63 linker
[7]
WO2015189791A1 ADC-64
WO2015189791A1 ADC-64 payload
Undisclosed
WO2015189791A1 ADC-64 linker
[7]
Anti-HER2 antibody 2H9-A121C
ADC Info ADC Name Payload Target Linker Ref
2H9-A121C-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
2H9-A121C-BMPEO-DM1 linker
[8]
Anti-HER2 DVD-Fab
ADC Info ADC Name Payload Target Linker Ref
Anti-HER2 DVD-Fab_MMAF
Monomethyl auristatin F
Microtubule (MT)
Dibromomaleimide-PEG4
[9]
Anti-HER2 DVD-Fab-h38c2-K99C
ADC Info ADC Name Payload Target Linker Ref
Anti-HER2 DVD-Fab-h38c2-K99C_MMAF
Monomethyl auristatin F
Microtubule (MT)
Dibromomaleimide-PEG4
[9]
Anti-HER2 DVD-IgG1
ADC Info ADC Name Payload Target Linker Ref
Anti-HER2 DVD-IgG1_MMAF
Monomethyl auristatin F
Microtubule (MT)
Dibromomaleimide-PEG4
[9]
Anti-HER2 DVD-IgG1-Tiancimycin
Tiancimycin
Microtubule (MT)
DVD-PEG4-Triazol
[10]
Anti-HER2 DVD-IgG1-H38c2-K99C
ADC Info ADC Name Payload Target Linker Ref
Anti-HER2 DVD-IgG1-h38c2-K99C_MMAF
Monomethyl auristatin F
Microtubule (MT)
Dibromomaleimide-PEG4
[9]
Anti-HER2 DVD-IgG1-h38c2-K99C TAMTA 3
5(6)-Carboxytetramethylrhodamine
Undisclosed
Dibromomaleimide-PEG3
[9]
Anti-HER2 DVD-IgG1-h38c2-K99C TAMTA 2
5(6)-Carboxytetramethylrhodamine
Undisclosed
Monobromomaleimide-PEG3
[9]
Anti-HER2 DVD-IgG1-h38c2-K99C TAMTA 1
5(6)-Carboxytetramethylrhodamine
Undisclosed
Mal-PEG3
[9]
Anti-HER2 DVD-IgG1-h38c2-K99C Fluorescein
Fluorescein derivative
Undisclosed
MS-PODA
[9]
Anti-HER2 IgG1(GH2-20)
ADC Info ADC Name Payload Target Linker Ref
IgG1 (GH2-20)-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[11]
Anti-HER2 IgG1(GH2-20) scFv
ADC Info ADC Name Payload Target Linker Ref
scFv(GH2-20)-PE38KDEL
Pseudomonas exotoxin PE38
Eukaryotic elongation factor 2 (EEF2)
Undisclosed
[11]
Anti-HER2 IgG1(GH2-20)-AL1
ADC Info ADC Name Payload Target Linker Ref
IgG1 (GH2-20)-AL1-MMAE
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
[11]
Anti-HER2 IgG1(GH2-61)
ADC Info ADC Name Payload Target Linker Ref
IgG1 (GH2-61)-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[11]
Anti-HER2 IgG1(GH2-61) scFv
ADC Info ADC Name Payload Target Linker Ref
scFv(GH2-61)-PE38KDEL
Pseudomonas exotoxin PE38
Eukaryotic elongation factor 2 (EEF2)
Undisclosed
[11]
Anti-HER2 IgG1(GH2-61)-AL1
ADC Info ADC Name Payload Target Linker Ref
IgG1 (GH2-61)-AL1-MMAE
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
[11]
Anti-HER2 IgG1(GH2-75)
ADC Info ADC Name Payload Target Linker Ref
IgG1 (GH2-75)-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[11]
Anti-HER2 IgG1(GH2-75) scFv
ADC Info ADC Name Payload Target Linker Ref
scFv(GH2-75)-PE38KDEL
Pseudomonas exotoxin PE38
Eukaryotic elongation factor 2 (EEF2)
Undisclosed
[11]
Anti-HER2 IgG1(GH2-75)-AL1
ADC Info ADC Name Payload Target Linker Ref
IgG1 (GH2-75)-AL1-MMAE
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
[11]
Anti-HER2 IgG1(H32)
ADC Info ADC Name Payload Target Linker Ref
IgG1 (H32)-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[11]
Anti-HER2 IgG1(H32) scFv
ADC Info ADC Name Payload Target Linker Ref
scFv(H32)-PE38KDEL
Pseudomonas exotoxin PE38
Eukaryotic elongation factor 2 (EEF2)
Undisclosed
[11]
Anti-HER2 IgG1(H32)-AL1
ADC Info ADC Name Payload Target Linker Ref
IgG1 (H32)-AL1-MMAE
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
[11]
Anti-HER2 mAb
ADC Info ADC Name Payload Target Linker Ref
Anti-HER2 ADC 12-3.1
Anti-HER2 ADC 12-3 payload
Undisclosed
Anti-HER2 ADC 12-3 linker
[12]
Anti-HER2 ADC 2-7
Anti-HER2 ADC 2-7 payload
Undisclosed
Anti-HER2 ADC 2-7 linker
[12]
Anti-HER2 ADC 3-4
Anti-HER2 ADC 3-4 payload
Undisclosed
Anti-HER2 ADC 3-4 linker
[12]
Anti-HER2 ADC 4-3
Anti-HER2 ADC 4-3 payload
Undisclosed
Anti-HER2 ADC 4-3 linker
[12]
Anti-HER2 ADC 5-3
Anti-HER2 ADC 5-3 payload
Undisclosed
Anti-HER2 ADC 5-3 linker
[12]
Anti-HER2 ADC 6-2
Anti-HER2 ADC 6-2 payload
Undisclosed
Anti-HER2 ADC 6-2 linker
[12]
Anti-HER2 ADC 7-1
Anti-HER2 ADC 7-1 payload
Undisclosed
Anti-HER2 ADC 7-1 linker
[12]
Anti-HER2 ADC 8-5
Anti-HER2 ADC 8-5 payload
Undisclosed
Anti-HER2 ADC 8-5 linker
[12]
Anti-HER2 ADC 9-4
Anti-HER2 ADC 9-4 payload
Undisclosed
Anti-HER2 ADC 9-4 linker
[12]
Anti-HER2 ADC 10-1
Anti-HER2 ADC 10-1 payload
Undisclosed
Anti-HER2 ADC 10-1 linker
[12]
Anti-HER2 ADC 11-5
Anti-HER2 ADC 11-5 payload
Undisclosed
Anti-HER2 ADC 11-5 linker
[12]
Anti-HER2 ADC 12-3.2
Anti-HER2 ADC 12-3 payload
Undisclosed
Anti-HER2 ADC 12-3 linker
[12]
Anti-HER2 ADC 13-7
Anti-HER2 ADC 13-7 payload
Undisclosed
Anti-HER2 ADC 13-7 linker
[12]
Anti-HER2 ADC 14-5
Anti-HER2 ADC 14-5 payload
Undisclosed
Anti-HER2 ADC 14-5 linker
[12]
Anti-HER2 ADC 15-5
Anti-HER2 ADC 15-5 payload
Undisclosed
Anti-HER2 ADC 15-5 linker
[12]
Anti-HER2 ADC 16-5
Anti-HER2 ADC 16-5 payload
Undisclosed
Anti-HER2 ADC 16-5 linker
[12]
Anti-HER2 ADC 17-2
Anti-HER2 ADC 17-2 payload
Undisclosed
Anti-HER2 ADC 17-2 linker
[12]
Anti-HER2 ADC 18-3
Anti-HER2 ADC 18-3 payload
Undisclosed
Anti-HER2 ADC 18-3 linker
[12]
Anti-HER2 ADC 19-5
Anti-HER2 ADC 19-5 payload
Undisclosed
Anti-HER2 ADC 19-5 linker
[12]
Anti-HER2 ADC 20-5
Anti-HER2 ADC 20-5 payload
Undisclosed
Anti-HER2 ADC 20-5 linker
[12]
Anti-HER2 ADC 21-5
Anti-HER2 ADC 21-5 payload
Undisclosed
Anti-HER2 ADC 21-5 linker
[12]
ADC2202
Undisclosed
Undisclosed
Undisclosed
[13]
Alpha-HER2-Duo 405
Duocarmycin 405
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[12]
HER2-HC-H-SS-PBD
SG2000
Human Deoxyribonucleic acid (hDNA)
H-disulfide linker
[14]
HER2-LC-H-SS-PBD
SG2000
Human Deoxyribonucleic acid (hDNA)
H-disulfide linker
[14]
HER2-HC-Me-SS-PBD
SG2000
Human Deoxyribonucleic acid (hDNA)
Me-disulfide linker
[14]
HER2-LC-Me-SS-PBD
SG2000
Human Deoxyribonucleic acid (hDNA)
Me-disulfide linker
[14]
Anti-HER2 mAb-Compound 9
Mertansine DM1
Microtubule (MT)
Anti-HER2 mAb-Compound 9 linker
[15]
Anti-HER2 mAb-Compound 17
Mertansine DM4
Microtubule (MT)
Anti-HER2 mAb-Compound 17 linker
[15]
Anti-HER2 mAb-Compound 25
Monomethyl auristatin E
Microtubule (MT)
Anti-HER2 mAb-Compound 25 linker
[15]
Anti-HER2 mAb-Compound 31
Auristatin 0101
Microtubule (MT)
Anti-HER2 mAb-Compound 31 linker
[15]
Anti-HER2 mAb-Compound 36
Monomethyl auristatin E
Microtubule (MT)
Anti-HER2 mAb-Compound 36 linker
[15]
Anti-HER2 mAb-Compound 43
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Anti-HER2 mAb-Compound 43 linker
[15]
Anti-HER2 mAb-Compound 49
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Anti-HER2 mAb-Compound 49 linker
[15]
Anti-HER2 mAb-Compound 55
Mertansine DM1
Microtubule (MT)
Anti-HER2 mAb-Compound 55 linker
[15]
Anti-HER2 mAb-Compound 59
Mertansine DM4
Microtubule (MT)
Anti-HER2 mAb-Compound 59 linker
[15]
Anti-HER2 mAb-Compound 64
Monomethyl auristatin E
Microtubule (MT)
Anti-HER2 mAb-Compound 64 linker
[15]
Anti-HER2 mAb-Compound 69
Monomethyl auristatin E
Microtubule (MT)
Anti-HER2 mAb-Compound 69 linker
[15]
Anti-HER2 mAb-Compound 74
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Anti-HER2 mAb-Compound 74 linker
[15]
Anti-HER2 mAb-Compound 75
Monomethyl auristatin E
Microtubule (MT)
Anti-HER2 mAb-Compound 75 linker
[15]
Anti-HER2 mAb-Compound 76
Monomethyl auristatin E
Microtubule (MT)
Anti-HER2 mAb-Compound 76 linker
[15]
Anti-HER2 mAb-Compound 77
Mertansine DM1
Microtubule (MT)
Anti-HER2 mAb-Compound 77 linker
[15]
Anti-HER2 mAb-Compound 78
Auristatin 0101
Microtubule (MT)
Anti-HER2 mAb-Compound 78 linker
[15]
Anti-HER2 mAb-Compound 79
Auristatin 0101
Microtubule (MT)
Anti-HER2 mAb-Compound 79 linker
[15]
Anti-HER2 mAb-Compound 80
Mertansine DM4
Microtubule (MT)
Anti-HER2 mAb-Compound 80 linker
[15]
CN110997010A ADC-1
CN110997010A ADC-1 payload
Undisclosed
CN110997010A ADC-1 linker
[16]
CN110997010A ADC-2
CN110997010A ADC-2 payload
Undisclosed
CN110997010A ADC-2 linker
[16]
CN110997010A ADC-3
CN110997010A ADC-3 payload
Undisclosed
CN110997010A ADC-3 linker
[16]
CN110997010A ADC-4
CN110997010A ADC-4 payload
Undisclosed
CN110997010A ADC-4 linker
[16]
CN110997010A ADC-5
CN110997010A ADC-5 payload
Undisclosed
CN110997010A ADC-5 linker
[16]
CN110997010A ADC-6
CN110997010A ADC-6 payload
Undisclosed
CN110997010A ADC-6 linker
[16]
CN110997010A ADC-7
CN110997010A ADC-7 payload
Undisclosed
CN110997010A ADC-7 linker
[16]
CN110997010A ADC-8
CN110997010A ADC-8 payload
Undisclosed
CN110997010A ADC-8 linker
[16]
Anti-HER2 mAb A114N
ADC Info ADC Name Payload Target Linker Ref
A114N-Mc-Val-Cit-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[17]
Anti-HER2 mAb A114N NNAS
ADC Info ADC Name Payload Target Linker Ref
A114N NNAS-Mc-Val-Cit-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[17]
Anti-HER2 mAb glutamine 295 (Q295)
ADC Info ADC Name Payload Target Linker Ref
VCit ADC 3a
Monomethyl auristatin F
Microtubule (MT)
DBCO-PEG-VCit-PABC
[18]
EVCit ADC 3c
Monomethyl auristatin F
Microtubule (MT)
DBCO-PEG-EVCit-PABC
[18]
Anti-HER2 mAb H-1
ADC Info ADC Name Payload Target Linker Ref
H-1-vcMMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[19]
Anti-HER2 mAb H-3
ADC Info ADC Name Payload Target Linker Ref
H-3-vcMMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[19]
Anti-HER2 mAb H-4
ADC Info ADC Name Payload Target Linker Ref
H-4-vcMMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[19]
Anti-HER2 mAb H32
ADC Info ADC Name Payload Target Linker Ref
H32-DM1_3.0
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[20]
H32-DM1_3.3
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[20]
H32-DM1_3.7
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[20]
H32-DM1_3.8
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[20]
H32-VCMMAE_2.1
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[20]
H32-VCMMAE_3.2
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[20]
H32-VCMMAE_3.8
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[20]
H32-VCMMAE_6.6
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[20]
Anti-HER2 mAb NNAS
ADC Info ADC Name Payload Target Linker Ref
NNAS-Mc-Val-Cit-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[17]
Anti-HER2 mAb S298N/T299A/Y300S
ADC Info ADC Name Payload Target Linker Ref
HER2 S298N/T299A/Y300S-Mc-Val-Cit-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[17]
Anti-HER2 mAb WT
ADC Info ADC Name Payload Target Linker Ref
HER2 WT-Mc-Val-Cit-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[17]
Anti-HER-AO-Cys-MC-VC-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Anti-HER-AO-Cys-MC-VC-PABC-MMAE linker
[17]
Anti-HER-MC-VC-PABC-PEG8-Dol10
Anti-HER-MC-VC-PABC-PEG8-Dol10 payload
Undisclosed
Anti-HER-MC-VC-PABC-PEG8-Dol10 linker
[17]
Anti-HER-AO-Cys-MC-VC-PABC-PEG8-Dol10
Anti-HER-AO-Cys-MC-VC-PABC-PEG8-Dol10 payload
Undisclosed
Anti-HER-AO-Cys-MC-VC-PABC-PEG8-Dol10 linker
[17]
Anti-HER2 NJH395 mAb
ADC Info ADC Name Payload Target Linker Ref
NJH-395
Tolllike receptor 7 agonist
Toll-like receptor 7 (TLR7)
Noncleavable linker
[21]
Anti-HER2 scFv-Fc (Ser396Sec)
ADC Info ADC Name Payload Target Linker Ref
Anti-HER2 scFv-Fc (Ser396Sec)-CN29
Monomethyl auristatin F derivative peptide (CN29)
Microtubule (MT)
Lodoacetamido-caproyl
[22]
Anti-HER2-D265C
ADC Info ADC Name Payload Target Linker Ref
Anti-HER2-D265C-30.2060
Amanitin 30.206
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mc-Val-Ala-PABC
[23]
Anti-HER2-D265C-30.2115
Amanitin 30.2115
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mc-Val-Ala-PABC
[23]
Anti-HER2-D265C-30.2347
Amanitin 30.2347
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mc-Val-Ala-PABC
[23]
Anti-HER2-D265C-30.1699
Amanitin 30.1699
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mc-Val-Ala-PABC
[23]
Anti-HER2-D265C-30.2371
Amanitin 30.2371
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mc-Val-Ala-PABC
[23]
Anti-HER2-D265C-30.0880
Amanitin 30.088
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Maleimido-caproyl
[23]
Anti-HER2-D265C-30.2867
Amanitin 30.2867
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Maleimido-caproyl
[23]
Anti-HER2/neu mAb 4D5
ADC Info ADC Name Payload Target Linker Ref
4D5-AF (CUAAC)
Auristatin F
Microtubule (MT)
N6-(2-azidoethoxy)carbonyl-L-lysine
[24]
Anti-human HER2 mAb
ADC Info ADC Name Payload Target Linker Ref
HER2-EC4 DAR7.8
NAMPT inhibitor 5
Nicotinamide phosphoribosyltransferase (NAMPT)
Open-chain glycine maleimide
[25]
HER2-EC5
NAMPT inhibitor 6
Nicotinamide phosphoribosyltransferase (NAMPT)
Open-chain glycine maleimide-PEG
[25]
HER2-EC4 DAR2.7
NAMPT inhibitor 5
Nicotinamide phosphoribosyltransferase (NAMPT)
Open-chain glycine maleimide
[25]
HER2-EC3
NAMPT inhibitor 4
Nicotinamide phosphoribosyltransferase (NAMPT)
Mc-Val-Ala
[25]
HER2-EC1
NAMPT inhibitor 4
Nicotinamide phosphoribosyltransferase (NAMPT)
Maleimido-caproyl
[25]
Anvatabart
ADC Info ADC Name Payload Target Linker Ref
Anvatabart pactil
Undisclosed
Undisclosed
Undisclosed
[26]
Az-LacNAc-Tras Ab7
ADC Info ADC Name Payload Target Linker Ref
HER2-gsADC-41
Monomethyl auristatin E
Microtubule (MT)
Bicyclononyne derivative 6e
[27]
HER2-gsADC-42
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6l
[27]
HER2-gsADC-43
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6m
[27]
HER2-gsADC-44
Monomethyl auristatin E
Microtubule (MT)
Noncleavable linker 6s
[27]
HER2-gsADC-45
Monomethyl auristatin E
Microtubule (MT)
Noncleavable linker 6t
[27]
Azido-tagged trastuzumab (Ab2)
ADC Info ADC Name Payload Target Linker Ref
HER2-gsADC-5
Monomethyl auristatin E
Microtubule (MT)
Azadibenzocylooctyne-amine derivative 6d
[27]
HER2-gsADC-6
Monomethyl auristatin E
Microtubule (MT)
Bicyclononyne derivative 6e
[27]
HER2-gsADC-7
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6m
[27]
HER2-gsADC-8
Monomethyl auristatin E
Microtubule (MT)
Glycosyl PEGylation linker 6r
[27]
Azido-tagged trastuzumab (Ab3)
ADC Info ADC Name Payload Target Linker Ref
HER2-gsADC-9
Monomethyl auristatin E
Microtubule (MT)
Linear alkyne 6f
[27]
HER2-gsADC-10
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6g
[27]
HER2-gsADC-11
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6h
[27]
HER2-gsADC-12
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6i
[27]
HER2-gsADC-13
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6j
[27]
HER2-gsADC-14
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6k
[27]
HER2-gsADC-15
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6l
[27]
HER2-gsADC-16
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6m
[27]
HER2-gsADC-17
Monomethyl auristatin E
Microtubule (MT)
Noncleavable linker 6t
[27]
Azido-tagged trastuzumab (Ab5)
ADC Info ADC Name Payload Target Linker Ref
HER2-gsADC-22
Monomethyl auristatin E
Microtubule (MT)
Linear alkyne 6f
[27]
HER2-gsADC-23
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6g
[27]
HER2-gsADC-24
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6h
[27]
HER2-gsADC-25
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6i
[27]
HER2-gsADC-26
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6j
[27]
HER2-gsADC-27
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6k
[27]
HER2-gsADC-28
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6l
[27]
HER2-gsADC-29
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6m
[27]
HER2-gsADC-30
Monomethyl auristatin E
Microtubule (MT)
Glycosyl PEGylation linker 6o
[27]
HER2-gsADC-31
Monomethyl auristatin E
Microtubule (MT)
Glycosyl PEGylation linker 6p
[27]
HER2-gsADC-32
Monomethyl auristatin E
Microtubule (MT)
Glycosyl PEGylation linker 6q
[27]
HER2-gsADC-33
Monomethyl auristatin E
Microtubule (MT)
Glycosyl PEGylation linker 6r
[27]
Azido-tagged trastuzumab (Ab6)
ADC Info ADC Name Payload Target Linker Ref
HER2-gsADC-34
Monomethyl auristatin E
Microtubule (MT)
Linear alkyne 6f
[27]
HER2-gsADC-35
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6g
[27]
HER2-gsADC-36
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6h
[27]
HER2-gsADC-37
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6i
[27]
HER2-gsADC-38
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6j
[27]
HER2-gsADC-39
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6k
[27]
HER2-gsADC-40
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6l
[27]
BA-130-00-01
ADC Info ADC Name Payload Target Linker Ref
LC A032D/HC
LC A032D/HC payload
Undisclosed
LC A032D/HC linker
[28]
BA-130-03-02
ADC Info ADC Name Payload Target Linker Ref
LC A032D/HC Y052K
LC A032D/HC Y052K payload
Undisclosed
LC A032D/HC Y052K linker
[28]
BA-130-03-05
ADC Info ADC Name Payload Target Linker Ref
LC A032D/HC G056K
LC A032D/HC G056K payload
Undisclosed
LC A032D/HC G056K linker
[28]
BA-130-03-06
ADC Info ADC Name Payload Target Linker Ref
LC A032D/HC T058D
LC A032D/HC T058D payload
Undisclosed
LC A032D/HC T058D linker
[28]
BA-130-03-07
ADC Info ADC Name Payload Target Linker Ref
LC A032D/HC A106E
LC A032D/HC A106E payload
Undisclosed
LC A032D/HC A106E linker
[28]
BA-130-03-08
ADC Info ADC Name Payload Target Linker Ref
LC A032D/HC S119E
LC A032D/HC S119E payload
Undisclosed
LC A032D/HC S119E linker
[28]
ADC Info ADC Name Payload Target Linker Ref
BAT-8001
Maytansinoid derivative
Microtubule (MT)
6-Maleimidocaproic acid
[29]
ADC Info ADC Name Payload Target Linker Ref
HER2 KSP-ADC 1.1
Pyrrole based kinesin spindle protein inhibitor
Kinesin-like protein KIF11 (KIF11)
Kinesin spindle protein inhibitor (KSPi)-ADC linker 1
[30]
HER2 KSP-ADC 1.2
Pyrrole based kinesin spindle protein inhibitor
Kinesin-like protein KIF11 (KIF11)
Kinesin spindle protein inhibitor (KSPi)-ADC linker 2
[30]
HER2 KSP-ADC 1.3
Pyrrole based kinesin spindle protein inhibitor
Kinesin-like protein KIF11 (KIF11)
Kinesin spindle protein inhibitor (KSPi)-ADC linker 3
[30]
HER2 KSP-ADC 1.4
Pyrrole based kinesin spindle protein inhibitor
Kinesin-like protein KIF11 (KIF11)
Kinesin spindle protein inhibitor (KSPi)-ADC linker 4
[30]
HER2 KSP-ADC 2.1
Pyrrole based kinesin spindle protein inhibitor
Kinesin-like protein KIF11 (KIF11)
Kinesin spindle protein inhibitor (KSPi)-ADC linker 5
[30]
HER2 KSP-ADC 2.2
Pyrrole based kinesin spindle protein inhibitor
Kinesin-like protein KIF11 (KIF11)
Kinesin spindle protein inhibitor (KSPi)-ADC linker 6
[30]
CHO-G2F-Tras (Ab4)
ADC Info ADC Name Payload Target Linker Ref
HER2-gsADC-18
Monomethyl auristatin E
Microtubule (MT)
ThioPz linker 6a
[27]
HER2-gsADC-19
Monomethyl auristatin E
Microtubule (MT)
2-Aminobenzamide oxime
[27]
HER2-gsADC-20
Monomethyl auristatin E
Microtubule (MT)
Hydroxylamine derivative 6c
[27]
HER2-gsADC-21
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6n
[27]
CHO-S2G2F-Tras (Ab1)
ADC Info ADC Name Payload Target Linker Ref
HER2-gsADC-1
Monomethyl auristatin E
Microtubule (MT)
ThioPz linker 6a
[27]
HER2-gsADC-2
Monomethyl auristatin E
Microtubule (MT)
2-Aminobenzamide oxime
[27]
HER2-gsADC-3
Monomethyl auristatin E
Microtubule (MT)
Hydroxylamine derivative 6c
[27]
HER2-gsADC-4
Monomethyl auristatin E
Microtubule (MT)
PEGylation linker 6n
[27]
CN105828840B_ADC-102 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-102
CN105828840B_ADC-102 payload
Undisclosed
CN105828840B_ADC-102 linker
[31]
CN105828840B_ADC-103 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-103
CN105828840B_ADC-103 payload
Undisclosed
CN105828840B_ADC-103 linker
[31]
CN105828840B_ADC-105 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-105
CN105828840B_ADC-105 payload
Undisclosed
CN105828840B_ADC-105 linker
[31]
CN105828840B_ADC-106 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-106
CN105828840B_ADC-106 payload
Undisclosed
CN105828840B_ADC-106 linker
[31]
CN105828840B_ADC-107 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-107
CN105828840B_ADC-107 payload
Undisclosed
CN105828840B_ADC-107 linker
[31]
CN105828840B_ADC-109 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-109
CN105828840B_ADC-109 payload
Undisclosed
CN105828840B_ADC-109 linker
[31]
CN105828840B_ADC-112 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-112
CN105828840B_ADC-112 payload
Undisclosed
CN105828840B_ADC-112 linker
[31]
CN105828840B_ADC-113 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-113
CN105828840B_ADC-113 payload
Undisclosed
CN105828840B_ADC-113 linker
[31]
CN105828840B_ADC-114 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-114
CN105828840B_ADC-114 payload
Undisclosed
CN105828840B_ADC-114 linker
[31]
CN105828840B_ADC-117 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-117
CN105828840B_ADC-117 payload
Undisclosed
CN105828840B_ADC-117 linker
[31]
CN105828840B_ADC-118 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-118
CN105828840B_ADC-118 payload
Undisclosed
CN105828840B_ADC-118 linker
[31]
CN105828840B_ADC-119 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-119
CN105828840B_ADC-119 payload
Undisclosed
CN105828840B_ADC-119 linker
[31]
CN105828840B_ADC-121 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-121
CN105828840B_ADC-121 payload
Undisclosed
CN105828840B_ADC-121 linker
[31]
CN105828840B_ADC-123 antibody
ADC Info ADC Name Payload Target Linker Ref
CN105828840B ADC-123
CN105828840B_ADC-123 payload
Undisclosed
CN105828840B_ADC-123 linker
[31]
Coprelotamab
ADC Info ADC Name Payload Target Linker Ref
Coprelotamab-ADC-Tb3-1
Coprelotamab-ADC-Tb3-1 payload
Undisclosed
Coprelotamab-ADC-Tb3-1 linker
[2]
Coprelotamab-ADC-Tb3-2
Coprelotamab-ADC-Tb3-2 payload
Undisclosed
Coprelotamab-ADC-Tb3-2 linker
[2]
Coprelotamab-ADC-Tb3-3
Coprelotamab-ADC-Tb3-3 payload
Undisclosed
Coprelotamab-ADC-Tb3-3 linker
[2]
Coprelotamab-ADC-Tb3-4
Coprelotamab-ADC-Tb3-4 payload
Undisclosed
Coprelotamab-ADC-Tb3-4 linker
[2]
Coprelotamab-ADC-Tb3-5
Coprelotamab-ADC-Tb3-5 payload
Undisclosed
Coprelotamab-ADC-Tb3-5 linker
[2]
Coprelotamab-ADC-Tb3-6
Coprelotamab-ADC-Tb3-6 payload
Undisclosed
Coprelotamab-ADC-Tb3-6 linker
[2]
Coprelotamab-ADC-Tb3-7
Coprelotamab-ADC-Tb3-7 payload
Undisclosed
Coprelotamab-ADC-Tb3-7 linker
[2]
Coprelotamab-ADC-Tb3-8
Coprelotamab-ADC-Tb3-8 payload
Undisclosed
Coprelotamab-ADC-Tb3-8 linker
[2]
Coprelotamab-ADC-Tb3-9
Coprelotamab-ADC-Tb3-9 payload
Undisclosed
Coprelotamab-ADC-Tb3-9 linker
[2]
Coprelotamab-ADC-Tb3-10
Coprelotamab-ADC-Tb3-10 payload
Undisclosed
Coprelotamab-ADC-Tb3-10 linker
[2]
ADC Info ADC Name Payload Target Linker Ref
DP-303c
Monomethyl auristatin E
Microtubule (MT)
PEG2-Val-Cit-PABC
[32]
ADC Info ADC Name Payload Target Linker Ref
177Lu-CHX-A"-DTPA-PODS-DVD
Lutetium-177
Undisclosed
PODS-CHX-A"-DTPA
[33]
ADC Info ADC Name Payload Target Linker Ref
DX126-262
Tubulysin B derivative
Microtubule (MT)
Undisclosed
[34]
Engineered trastuzumab
ADC Info ADC Name Payload Target Linker Ref
Trastuzumab-C239I-SG3600
N10-beta-glucuronide SG3200
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[35]
Trastuzumab-C239I-SG3400
SG3200
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[35]
Engineered HER-SG3227
SG2219
Human Deoxyribonucleic acid (hDNA)
Acetamide-PEG4-Val-Ala-PABA
[36]
Gancotamab
ADC Info ADC Name Payload Target Linker Ref
Gancotamab-ADC-Tb3-1
Gancotamab-ADC-Tb3-1 payload
Undisclosed
Gancotamab-ADC-Tb3-1 linker
[2]
Gancotamab-ADC-Tb3-2
Gancotamab-ADC-Tb3-2 payload
Undisclosed
Gancotamab-ADC-Tb3-2 linker
[2]
Gancotamab-ADC-Tb3-3
Gancotamab-ADC-Tb3-3 payload
Undisclosed
Gancotamab-ADC-Tb3-3 linker
[2]
Gancotamab-ADC-Tb3-4
Gancotamab-ADC-Tb3-4 payload
Undisclosed
Gancotamab-ADC-Tb3-4 linker
[2]
Gancotamab-ADC-Tb3-5
Gancotamab-ADC-Tb3-5 payload
Undisclosed
Gancotamab-ADC-Tb3-5 linker
[2]
Gancotamab-ADC-Tb3-6
Gancotamab-ADC-Tb3-6 payload
Undisclosed
Gancotamab-ADC-Tb3-6 linker
[2]
Gancotamab-ADC-Tb3-7
Gancotamab-ADC-Tb3-7 payload
Undisclosed
Gancotamab-ADC-Tb3-7 linker
[2]
Gancotamab-ADC-Tb3-8
Gancotamab-ADC-Tb3-8 payload
Undisclosed
Gancotamab-ADC-Tb3-8 linker
[2]
Gancotamab-ADC-Tb3-9
Gancotamab-ADC-Tb3-9 payload
Undisclosed
Gancotamab-ADC-Tb3-9 linker
[2]
Gancotamab-ADC-Tb3-10
Gancotamab-ADC-Tb3-10 payload
Undisclosed
Gancotamab-ADC-Tb3-10 linker
[2]
ADC Info ADC Name Payload Target Linker Ref
WO2022228495A1 ADC-73
WO2022228495A1 ADC-73 payload
Undisclosed
WO2022228495A1 ADC-73 linker
[37]
HER2-C Anti-ody
ADC Info ADC Name Payload Target Linker Ref
HER2-C Antibody-Compound (X)
HER2-C Antibody-Compound (X) payload
Undisclosed
HER2-C Antibody-Compound (X) linker
[38]
HER2-C Antibody-Compound (XI)
HER2-C Antibody-Compound (XI) payload
Undisclosed
HER2-C Antibody-Compound (XI) linker
[38]
HER2-C Antibody-Compound (XIV)
HER2-C Antibody-Compound (XIV) payload
Undisclosed
HER2-C Antibody-Compound (XIV) linker
[38]
HER2-C Antibody-Compound (XVIII)
HER2-C Antibody-Compound (XVIII) payload
Undisclosed
HER2-C Antibody-Compound (XVIII) linker
[38]
HER2-C Antibody-Compound (Ie)
HER2-C Antibody-Compound (Ie) payload
Undisclosed
HER2-C Antibody-Compound (Ie) linker
[38]
HER2-C Antibody-Compound (XIX)
HER2-C Antibody-Compound (XIX) payload
Undisclosed
HER2-C Antibody-Compound (XIX) linker
[38]
HER2-C Antibody-Compound (Ii)
HER2-C Antibody-Compound (Ii) payload
Undisclosed
HER2-C Antibody-Compound (Ii) linker
[38]
HER2-C Antibody-Compound (XLI)
HER2-C Antibody-Compound (XLI) payload
Undisclosed
HER2-C Antibody-Compound (XLI) linker
[38]
HER2-C Antibody-Compound (XVI)
HER2-C Antibody-Compound (XIX) payload
Undisclosed
HER2-C Antibody-Compound (XIX) linker
[38]
HER2-C Antibody-Compound (XL)
HER2-C Antibody-Compound (XL) payload
Undisclosed
HER2-C Antibody-Compound (XL) linker
[38]
HER2-C Antibody-Compound (XLII)
HER2-C Antibody-Compound (XLII) payload
Undisclosed
HER2-C Antibody-Compound (XLII) linker
[38]
HER2-C Antibody-Compound (XV)
HER2-C Antibody-Compound (XV) payload
Undisclosed
HER2-C Antibody-Compound (XV) linker
[38]
HER2-C Antibody-Compound (XLIII)
HER2-C Antibody-Compound (XLIII) payload
Undisclosed
HER2-C Antibody-Compound (XLIII) linker
[38]
Hertuzumab
ADC Info ADC Name Payload Target Linker Ref
Disitamab vedotin
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[39]
Hertuzumab vedotin
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[40]
Disitamab-ADC-Tb3-1
Disitamab-ADC-Tb3-1 payload
Undisclosed
Disitamab-ADC-Tb3-1 linker
[2]
Disitamab-ADC-Tb3-2
Disitamab-ADC-Tb3-2 payload
Undisclosed
Disitamab-ADC-Tb3-2 linker
[2]
Disitamab-ADC-Tb3-3
Disitamab-ADC-Tb3-3 payload
Undisclosed
Disitamab-ADC-Tb3-3 linker
[2]
Disitamab-ADC-Tb3-4
Disitamab-ADC-Tb3-4 payload
Undisclosed
Disitamab-ADC-Tb3-4 linker
[2]
Disitamab-ADC-Tb3-5
Disitamab-ADC-Tb3-5 payload
Undisclosed
Disitamab-ADC-Tb3-5 linker
[2]
Disitamab-ADC-Tb3-6
Disitamab-ADC-Tb3-6 payload
Undisclosed
Disitamab-ADC-Tb3-6 linker
[2]
Disitamab-ADC-Tb3-7
Disitamab-ADC-Tb3-7 payload
Undisclosed
Disitamab-ADC-Tb3-7 linker
[2]
Disitamab-ADC-Tb3-8
Disitamab-ADC-Tb3-8 payload
Undisclosed
Disitamab-ADC-Tb3-8 linker
[2]
Disitamab-ADC-Tb3-9
Disitamab-ADC-Tb3-9 payload
Undisclosed
Disitamab-ADC-Tb3-9 linker
[2]
Disitamab-ADC-Tb3-10
Disitamab-ADC-Tb3-10 payload
Undisclosed
Disitamab-ADC-Tb3-10 linker
[2]
ADC Info ADC Name Payload Target Linker Ref
ZV0203
Duostatin 5
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[41]
hu4DFabv7
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv7-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv7-BMPEO-DM1 linker
[8]
hu4DFabv8 (A121C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (A121C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (A121C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (H-A175C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (H-A175C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (H-A175C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (H-A40C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (H-A40C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (H-A40C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (H-A88C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (H-A88C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (H-A88C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (H-S119C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (H-S119C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (H-S119C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (H-S122C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (H-S122C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (H-S122C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (H-S179C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (H-S179C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (H-S179C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (L-A144C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (L-A144C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (L-A144C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (L-A43C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (L-A43C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (L-A43C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (L-S168C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (L-S168C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (L-S168C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (L-V15C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (L-V15C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (L-V15C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (V110C)
ADC Info ADC Name Payload Target Linker Ref
hu4DFabv8 (V110C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
hu4DFabv8 (V110C)-BMPEO-DM1 linker
[8]
hu4DFabv8 (V110C)-MC-MMAF
Monomethyl auristatin F
Microtubule (MT)
Maleimido-caproyl
[8]
hu4DFabv8 (V110C)-MC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Maleimido-caproyl
[8]
hu4DFabv8 (V110C)-MC-Val-Cit-PAB-MMAF
Monomethyl auristatin F
Microtubule (MT)
Mc-Val-Cit-PABC
[8]
hu4DFabv8 (V110C)-MC-Val-Cit-PAB-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[8]
Isoprenylated trastuzumab
ADC Info ADC Name Payload Target Linker Ref
LCB-ADC1
Monomethyl auristatin F
Microtubule (MT)
Isoprene-PEG3-beta-Glu-PABC
[42]
LCB-ADC3
Monomethyl auristatin F
Microtubule (MT)
Bridged PEG4-valine-alanine
[42]
LCB-ADC2
Monomethyl auristatin F
Microtubule (MT)
Isoprene-PEG3,3,3-beta-Glu-PABC
[42]
ADC Info ADC Name Payload Target Linker Ref
MRG-002
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[43]
Margetuximab
ADC Info ADC Name Payload Target Linker Ref
Margetuximab-ADC-Tb3-1
Margetuximab-ADC-Tb3-1 payload
Undisclosed
Margetuximab-ADC-Tb3-1 linker
[2]
Margetuximab-ADC-Tb3-2
Margetuximab-ADC-Tb3-2 payload
Undisclosed
Margetuximab-ADC-Tb3-2 linker
[2]
Margetuximab-ADC-Tb3-3
Margetuximab-ADC-Tb3-3 payload
Undisclosed
Margetuximab-ADC-Tb3-3 linker
[2]
Margetuximab-ADC-Tb3-4
Margetuximab-ADC-Tb3-4 payload
Undisclosed
Margetuximab-ADC-Tb3-4 linker
[2]
Margetuximab-ADC-Tb3-5
Margetuximab-ADC-Tb3-5 payload
Undisclosed
Margetuximab-ADC-Tb3-5 linker
[2]
Margetuximab-ADC-Tb3-6
Margetuximab-ADC-Tb3-6 payload
Undisclosed
Margetuximab-ADC-Tb3-6 linker
[2]
Margetuximab-ADC-Tb3-7
Margetuximab-ADC-Tb3-7 payload
Undisclosed
Margetuximab-ADC-Tb3-7 linker
[2]
Margetuximab-ADC-Tb3-8
Margetuximab-ADC-Tb3-8 payload
Undisclosed
Margetuximab-ADC-Tb3-8 linker
[2]
Margetuximab-ADC-Tb3-9
Margetuximab-ADC-Tb3-9 payload
Undisclosed
Margetuximab-ADC-Tb3-9 linker
[2]
Margetuximab-ADC-Tb3-10
Margetuximab-ADC-Tb3-10 payload
Undisclosed
Margetuximab-ADC-Tb3-10 linker
[2]
MHES0488A
ADC Info ADC Name Payload Target Linker Ref
RG-6148
Pyrrolo[2,1-c][1,4]benzodiazepine monoamide (PBD-MA)
Human Deoxyribonucleic acid (hDNA)
Methyl-disulfide linker
[44]
ADC Info ADC Name Payload Target Linker Ref
Mil40-12B
Monomethyl auristatin E
Microtubule (MT)
Maleamic methyl ester-based linker 12B
[45]
Mil40-5
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mc-Val-Ala-PABC
[46]
Mil40-6
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mal-PEG2-Val-Ala-PABC
[46]
Mil40-7
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mal-PEG4-Val-Ala-PABC
[46]
Mil40-8
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mal-PEG8-Val-Ala-PABC
[46]
Mil40-12A
Monomethyl auristatin E
Microtubule (MT)
Maleamic methyl ester-based linker 12A
[45]
Mil40-12C
Monomethyl auristatin E
Microtubule (MT)
Maleamic methyl ester-based linker 12C
[45]
Mil40-11 (DAR=7.1)
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mc-PEG8-Val-Ala-PABC
[46]
Mil40-11 (DAR=3.8)
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mc-PEG8-Val-Ala-PABC
[46]
Mil40-12B
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[45]
Cys-linker-MMAE-based ADC 11
Monomethyl auristatin E
Microtubule (MT)
Cys-11 ADC linker
[47]
Cys-linker-MMAE-based ADC 12
Monomethyl auristatin E
Microtubule (MT)
Cys-12 ADC linker
[47]
Cys-linker-MMAE-based ADC 13
Monomethyl auristatin E
Microtubule (MT)
Cys-13 ADC linker
[47]
Cys-linker-MMAE-based ADC 14
Monomethyl auristatin E
Microtubule (MT)
Cys-14 ADC linker
[47]
Cys-linker-MMAE-based ADC 15
Monomethyl auristatin E
Microtubule (MT)
Mc-PABC
[47]
Cys-linker-MMAE-based ADC 16
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[47]
ADC Mil40-6
Monomethyl auristatin E
Microtubule (MT)
Silyl ether-based linker
[48]
Mil40-15
Monomethyl auristatin E
Microtubule (MT)
Mc-PABC
[47]
Trastuzumab biosimilar mil40 12a
Monomethyl auristatin E
Microtubule (MT)
Maleamic methyl ester-based Val-Ala-PABC linker 12a
[49]
Trastuzumab biosimilar mil40 12b
Monomethyl auristatin E
Microtubule (MT)
Maleamic methyl ester-based Val-Ala-PABC linker 12b
[49]
Trastuzumab biosimilar mil40 12c
Monomethyl auristatin E
Microtubule (MT)
Maleamic methyl ester-based Val-Cit-PABC linker 12c
[49]
Modified pAcPhe trastuzumab
ADC Info ADC Name Payload Target Linker Ref
ARX-788
Monomethyl auristatin F
Microtubule (MT)
Hydroxylamine-PEG4
[50]
Modified ZHER2:2891 protein (ZHER2)
ADC Info ADC Name Payload Target Linker Ref
Pyro-Linker-ZHER2
Pyropheophorbide-a
Undisclosed
Pyro-Linker based linker
[51]
Patritumab
ADC Info ADC Name Payload Target Linker Ref
WO2022228495A1 ADC-72
WO2022228495A1 ADC-72 payload
Undisclosed
WO2022228495A1 ADC-72 linker
[37]
Pertuzumab
ADC Info ADC Name Payload Target Linker Ref
Pertuzumab zuvotolimod
Maytansinoid derivative
Microtubule (MT)
Undisclosed
[52]
WO2020063676A1 ADC-7
WO2020063676A1_ADC-7 payload
Undisclosed
WO2020063676A1_ADC-7 linker
[53]
WO2020063676A1 ADC-8
WO2020063676A1_ADC-8 payload
Undisclosed
WO2020063676A1_ADC-8 linker
[53]
WO2020063676A1 ADC-9
WO2020063676A1_ADC-9 payload
Undisclosed
WO2020063676A1_ADC-9 linker
[53]
Pertuzumab-ADC-Tb3-1
Pertuzumab-ADC-Tb3-1 payload
Undisclosed
Pertuzumab-ADC-Tb3-1 linker
[2]
Pertuzumab-ADC-Tb3-2
Pertuzumab-ADC-Tb3-2 payload
Undisclosed
Pertuzumab-ADC-Tb3-2 linker
[2]
Pertuzumab-ADC-Tb3-3
Pertuzumab-ADC-Tb3-3 payload
Undisclosed
Pertuzumab-ADC-Tb3-3 linker
[2]
Pertuzumab-ADC-Tb3-4
Pertuzumab-ADC-Tb3-4 payload
Undisclosed
Pertuzumab-ADC-Tb3-4 linker
[2]
Pertuzumab-ADC-Tb3-5
Pertuzumab-ADC-Tb3-5 payload
Undisclosed
Pertuzumab-ADC-Tb3-5 linker
[2]
Pertuzumab-ADC-Tb3-6
Pertuzumab-ADC-Tb3-6 payload
Undisclosed
Pertuzumab-ADC-Tb3-6 linker
[2]
Pertuzumab-ADC-Tb3-7
Pertuzumab-ADC-Tb3-7 payload
Undisclosed
Pertuzumab-ADC-Tb3-7 linker
[2]
Pertuzumab-ADC-Tb3-8
Pertuzumab-ADC-Tb3-8 payload
Undisclosed
Pertuzumab-ADC-Tb3-8 linker
[2]
Pertuzumab-ADC-Tb3-9
Pertuzumab-ADC-Tb3-9 payload
Undisclosed
Pertuzumab-ADC-Tb3-9 linker
[2]
Pertuzumab-ADC-Tb3-10
Pertuzumab-ADC-Tb3-10 payload
Undisclosed
Pertuzumab-ADC-Tb3-10 linker
[2]
Pertuzumab-Compound(la)
NeoDegrader P1
Protein cereblon (CRBN)
Pertuzumab-Compound(la) linker
[54]
Pertuzumab-Compound (la) DAR 8
NeoDegrader P1
Protein cereblon (CRBN)
Pertuzumab-Compound (la) DAR 8 linker
[54]
Pertuzumab-Compound(lc)
NeoDegrader P4
Protein cereblon (CRBN)
Pertuzumab-Compound(lc) linker
[54]
Pertuzumab-Compound (lc) DAR 8
NeoDegrader P4
Protein cereblon (CRBN)
Pertuzumab-Compound (lc) DAR 8 linker
[54]
Pertuzumab-Compound (le)
NeoDegrader P1
Protein cereblon (CRBN)
Pertuzumab-Compound (le) linker
[54]
Pertuzumab-Compound (lf)
NeoDegrader P6
Protein cereblon (CRBN)
Pertuzumab-Compound (lf) linker
[54]
Pertuzumab-Compound (lg)
NeoDegrader P2
Protein cereblon (CRBN)
Pertuzumab-Compound (lg) linker
[54]
Pertuzumab-Compound (lh)
NeoDegrader P13
Protein cereblon (CRBN)
Pertuzumab-Compound (lh) linker
[54]
Pertuzumab-Compound (li)
NeoDegrader P1
Protein cereblon (CRBN)
Pertuzumab-Compound (li) linker
[54]
Pertuzumab-Compound (lk)
NeoDegrader P14
Protein cereblon (CRBN)
Pertuzumab-Compound (lk) linker
[54]
Pertuzumab-Compound (ll)
NeoDegrader P14
Protein cereblon (CRBN)
Pertuzumab-Compound (ll) linker
[54]
Pertuzumab-Compound (lm)
NeoDegrader P14
Protein cereblon (CRBN)
Pertuzumab-Compound (lm) linker
[54]
Pertuzumab-Compound (X)
Pertuzumab-Compound (X) payload
Undisclosed
Pertuzumab-Compound (X) linker
[38]
Pertuzumab-Compound (XI)
Pertuzumab-Compound (XI) payload
Undisclosed
Pertuzumab-Compound (XI) linker
[38]
Pertuzumab-Compound (XIV)
Pertuzumab-Compound (XIV) payload
Undisclosed
Pertuzumab-Compound (XIV) linker
[38]
Pertuzumab-Compound (XVIII)
Pertuzumab-Compound (XVIII) payload
Undisclosed
Pertuzumab-Compound (XVIII) linker
[38]
Pertuzumab-Compound (Ie)
Pertuzumab-Compound (Ie) payload
Undisclosed
Pertuzumab-Compound (Ie) linker
[38]
Pertuzumab-Compound (XIX)
Pertuzumab-Compound (XIX) payload
Undisclosed
Pertuzumab-Compound (XIX) linker
[38]
Pertuzumab-Compound (Ii)
Pertuzumab-Compound (Ii) payload
Undisclosed
Pertuzumab-Compound (Ii) linker
[38]
Pertuzumab-Compound (XLI)
Pertuzumab-Compound (XLI) payload
Undisclosed
Pertuzumab-Compound (XLI) linker
[38]
Pertuzumab-Compound (XVI)
Pertuzumab-Compound (XIX) payload
Undisclosed
Pertuzumab-Compound (XIX) linker
[38]
Pertuzumab-Compound (XL)
Pertuzumab-Compound (XL) payload
Undisclosed
Pertuzumab-Compound (XL) linker
[38]
Pertuzumab-Compound (XLII)
Pertuzumab-Compound (XLII) payload
Undisclosed
Pertuzumab-Compound (XLII) linker
[38]
Pertuzumab-Compound (XV)
Pertuzumab-Compound (XV) payload
Undisclosed
Pertuzumab-Compound (XV) linker
[38]
Pertuzumab-Compound (lj)
NeoDegrader P1
Protein cereblon (CRBN)
Pertuzumab-Compound (lj) linker
[54]
Pertuzumab-Compound (XLIII)
Pertuzumab-Compound (XLIII) payload
Undisclosed
Pertuzumab-Compound (XLIII) linker
[38]
Pertuzumab-Compound 9
Mertansine DM1
Microtubule (MT)
Pertuzumab-Compound 9 linker
[15]
Pertuzumab-Compound 17
Mertansine DM4
Microtubule (MT)
Pertuzumab-Compound 17 linker
[15]
Pertuzumab-Compound 25
Monomethyl auristatin E
Microtubule (MT)
Pertuzumab-Compound 25 linker
[15]
Pertuzumab-Compound 31
Auristatin 0101
Microtubule (MT)
Pertuzumab-Compound 31 linker
[15]
Pertuzumab-Compound 36
Monomethyl auristatin E
Microtubule (MT)
Pertuzumab-Compound 36 linker
[15]
Pertuzumab-Compound 43
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Pertuzumab-Compound 43 linker
[15]
Pertuzumab-Compound 49
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Pertuzumab-Compound 49 linker
[15]
Pertuzumab-Compound 55
Mertansine DM1
Microtubule (MT)
Pertuzumab-Compound 55 linker
[15]
Pertuzumab-Compound 59
Mertansine DM4
Microtubule (MT)
Pertuzumab-Compound 59 linker
[15]
Pertuzumab-Compound 64
Monomethyl auristatin E
Microtubule (MT)
Pertuzumab-Compound 64 linker
[15]
Pertuzumab-Compound 69
Monomethyl auristatin E
Microtubule (MT)
Pertuzumab-Compound 69 linker
[15]
Pertuzumab-Compound 74
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Pertuzumab-Compound 74 linker
[15]
Pertuzumab-Compound 75
Monomethyl auristatin E
Microtubule (MT)
Pertuzumab-Compound 75 linker
[15]
Pertuzumab-Compound 76
Monomethyl auristatin E
Microtubule (MT)
Pertuzumab-Compound 76 linker
[15]
Pertuzumab-Compound 77
Mertansine DM1
Microtubule (MT)
Pertuzumab-Compound 77 linker
[15]
Pertuzumab-Compound 78
Auristatin 0101
Microtubule (MT)
Pertuzumab-Compound 78 linker
[15]
Pertuzumab-Compound 79
Auristatin 0101
Microtubule (MT)
Pertuzumab-Compound 79 linker
[15]
Pertuzumab-Compound 80
Mertansine DM4
Microtubule (MT)
Pertuzumab-Compound 80 linker
[15]
Pertuzumab-S239C
ADC Info ADC Name Payload Target Linker Ref
HER2-A Antibody-Compound (X)
HER2-A Antibody-Compound (X) payload
Undisclosed
HER2-A Antibody-Compound (X) linker
[38]
HER2-A Antibody-Compound (XI)
HER2-A Antibody-Compound (XI) payload
Undisclosed
HER2-A Antibody-Compound (XI) linker
[38]
HER2-A Antibody-Compound (XIV)
HER2-A Antibody-Compound (XIV) payload
Undisclosed
HER2-A Antibody-Compound (XIV) linker
[38]
HER2-A Antibody-Compound (XVIII)
HER2-A Antibody-Compound (XVIII) payload
Undisclosed
HER2-A Antibody-Compound (XVIII) linker
[38]
HER2-A Antibody-Compound (Ie)
HER2-A Antibody-Compound (Ie) payload
Undisclosed
HER2-A Antibody-Compound (Ie) linker
[38]
HER2-A Antibody-Compound (XIX)
HER2-A Antibody-Compound (XIX) payload
Undisclosed
HER2-A Antibody-Compound (XIX) linker
[38]
HER2-A Antibody-Compound (Ii)
HER2-A Antibody-Compound (Ii) payload
Undisclosed
HER2-A Antibody-Compound (Ii) linker
[38]
HER2-A Antibody-Compound (XLI)
HER2-A Antibody-Compound (XLI) payload
Undisclosed
HER2-A Antibody-Compound (XLI) linker
[38]
HER2-A Antibody-Compound (XVI)
HER2-A Antibody-Compound (XIX) payload
Undisclosed
HER2-A Antibody-Compound (XIX) linker
[38]
HER2-A Antibody-Compound (XL)
HER2-A Antibody-Compound (XL) payload
Undisclosed
HER2-A Antibody-Compound (XL) linker
[38]
HER2-A Antibody-Compound (XLII)
HER2-A Antibody-Compound (XLII) payload
Undisclosed
HER2-A Antibody-Compound (XLII) linker
[38]
Pertuzumab-S239C-Compound (XV)
Pertuzumab-S239C-Compound (XV) payload
Undisclosed
Pertuzumab-S239C-Compound (XV) linker
[38]
HER2-A Antibody-Compound (XLIII)
HER2-A Antibody-Compound (XLIII) payload
Undisclosed
HER2-A Antibody-Compound (XLIII) linker
[38]
Rat IgG2a mAb ICR12
ADC Info ADC Name Payload Target Linker Ref
Monoclonal antibody ICR12-CPG2 conjugate
Carboxypeptidase G2 (CPG2)
Undisclosed
Undisclosed
[55]
T-(kK183C+K290C)
ADC Info ADC Name Payload Target Linker Ref
PF-06804103
Auristatin 0101
Microtubule (MT)
Mc-Val-Cit-PABC
[56]
Thio Anti-HER2 hu7C2 HC L177C
ADC Info ADC Name Payload Target Linker Ref
WO2017059289A1 ADC-117
WO2017059289A1_ADC-117 payload
Undisclosed
WO2017059289A1_ADC-117 linker
[57]
Thio Anti-HER2 hu7C2 HC Y376C
ADC Info ADC Name Payload Target Linker Ref
WO2017059289A1 ADC-119
WO2017059289A1_ADC-119 payload
Undisclosed
WO2017059289A1_ADC-119 linker
[57]
Thio Anti-HER2 hu7C2 LC K149C
ADC Info ADC Name Payload Target Linker Ref
WO2017059289A1 ADC-101
WO2017059289A1_ADC-101 payload
Undisclosed
WO2017059289A1_ADC-101 linker
[57]
WO2017059289A1 ADC-102
WO2017059289A1_ADC-102 payload
Undisclosed
WO2017059289A1_ADC-102 linker
[57]
WO2017059289A1 ADC-104
WO2017059289A1_ADC-104 payload
Undisclosed
WO2017059289A1_ADC-104 linker
[57]
WO2017059289A1 ADC-106
WO2017059289A1_ADC-106 payload
Undisclosed
WO2017059289A1_ADC-106 linker
[57]
WO2017059289A1 ADC-108
WO2017059289A1_ADC-108 payload
Undisclosed
WO2017059289A1_ADC-108 linker
[57]
WO2017059289A1 ADC-109
WO2017059289A1_ADC-109 payload
Undisclosed
WO2017059289A1_ADC-109 linker
[57]
WO2017059289A1 ADC-201
WO2017059289A1_ADC-201 payload
Undisclosed
WO2017059289A1_ADC-201 linker
[57]
WO2017059289A1 ADC-203
WO2017059289A1_ADC-203 payload
Undisclosed
WO2017059289A1_ADC-203 linker
[57]
WO2017059289A1 ADC-205
WO2017059289A1_ADC-205 payload
Undisclosed
WO2017059289A1_ADC-205 linker
[57]
Thio Anti-HER2 hu7C2 LC K149C HC L177C
ADC Info ADC Name Payload Target Linker Ref
WO2017059289A1 ADC-113
WO2017059289A1_ADC-113 payload
Undisclosed
WO2017059289A1_ADC-113 linker
[57]
Thio Anti-HER2 hu7C2 LC K149C HC L177C HC Y376C
ADC Info ADC Name Payload Target Linker Ref
WO2017059289A1 ADC-114
WO2017059289A1_ADC-114 payload
Undisclosed
WO2017059289A1_ADC-114 linker
[57]
Thio hu Anti-HER2 4D5-8 HC A118C
ADC Info ADC Name Payload Target Linker Ref
WO2014159981A2 ADC-211
WO2014159981A2_ADC-211 payload
Undisclosed
WO2014159981A2_ADC-211 linker
[58]
WO2014159981A2 ADC-130
WO2014159981A2_ADC-130 payload
Undisclosed
WO2014159981A2_ADC-130 linker
[58]
WO2014159981A2 ADC-HER2-48
WO2014159981A2_ADC-HER2-48 payload
Undisclosed
WO2014159981A2_ADC-HER2-48 linker
[58]
WO2014159981A2 ADC-HER2-22
WO2014159981A2_ADC-HER2-22 payload
Undisclosed
WO2014159981A2_ADC-HER2-22 linker
[58]
Thio hu Anti-HER2 7C2 HC A140C
ADC Info ADC Name Payload Target Linker Ref
WO2017214024A1 ADC-106
WO2017214024A1_ADC-106 payload
Undisclosed
WO2017214024A1_ADC-106 linker
[59]
Thio hu Anti-HER2 7C2 LC K149C
ADC Info ADC Name Payload Target Linker Ref
WO2017214024A1 ADC-103
WO2017214024A1_ADC-103 payload
Undisclosed
WO2017214024A1_ADC-103 linker
[59]
Thio-Tmab
ADC Info ADC Name Payload Target Linker Ref
Thio-Tmab-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
Thio-Tmab-BMPEO-DM1 linker
[8]
Thio-Tr (A121C)
ADC Info ADC Name Payload Target Linker Ref
Thio-Tr (A121C)-BMPEO-DM1
Maytansinoid DM1
Microtubule (MT)
Thio-Tr (A121C)-BMPEO-DM1 linker
[8]
Tigatuzumab
ADC Info ADC Name Payload Target Linker Ref
Tigatuzumab-ADC-Tb3-1
Tigatuzumab-ADC-Tb3-1 payload
Undisclosed
Tigatuzumab-ADC-Tb3-1 linker
[2]
Tigatuzumab-ADC-Tb3-2
Tigatuzumab-ADC-Tb3-2 payload
Undisclosed
Tigatuzumab-ADC-Tb3-2 linker
[2]
Tigatuzumab-ADC-Tb3-3
Tigatuzumab-ADC-Tb3-3 payload
Undisclosed
Tigatuzumab-ADC-Tb3-3 linker
[2]
Tigatuzumab-ADC-Tb3-4
Tigatuzumab-ADC-Tb3-4 payload
Undisclosed
Tigatuzumab-ADC-Tb3-4 linker
[2]
Tigatuzumab-ADC-Tb3-5
Tigatuzumab-ADC-Tb3-5 payload
Undisclosed
Tigatuzumab-ADC-Tb3-5 linker
[2]
Tigatuzumab-ADC-Tb3-6
Tigatuzumab-ADC-Tb3-6 payload
Undisclosed
Tigatuzumab-ADC-Tb3-6 linker
[2]
Tigatuzumab-ADC-Tb3-7
Tigatuzumab-ADC-Tb3-7 payload
Undisclosed
Tigatuzumab-ADC-Tb3-7 linker
[2]
Tigatuzumab-ADC-Tb3-8
Tigatuzumab-ADC-Tb3-8 payload
Undisclosed
Tigatuzumab-ADC-Tb3-8 linker
[2]
Tigatuzumab-ADC-Tb3-9
Tigatuzumab-ADC-Tb3-9 payload
Undisclosed
Tigatuzumab-ADC-Tb3-9 linker
[2]
Tigatuzumab-ADC-Tb3-10
Tigatuzumab-ADC-Tb3-10 payload
Undisclosed
Tigatuzumab-ADC-Tb3-10 linker
[2]
Trastuzumab
ADC Info ADC Name Payload Target Linker Ref
Trastuzumab deruxtecan
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[60]
Trastuzumab emtansine
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[61]
A-166
Duostatin 5
Human Deoxyribonucleic acid (hDNA)
K-lock-Val-Cit-PABC
[62]
Trastuzumab duocarmazine
seco-DUBA
Human Deoxyribonucleic acid (hDNA)
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[63]
LCB14-0110
Monomethyl auristatin F
Microtubule (MT)
Geranyl ketone pyrophosphate oxime ligation
[64]
SHR-A1811
SHR9265
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[65]
B-003
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[66]
GQ-1001
Mertansine DM1
Microtubule (MT)
MCC-Gly6-Thr-Glu3-Pro-Leu-Ala3-Leu
[67]
BDC-1001
TORL7/8 agonist T785
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
BG based linker
[68]
SHR-A1201
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[69]
MI-130004
PM050489
Microtubule (MT)
6-(2,5-dioxopyrrol-1-yl)-N-Propylhexanamide
[70]
ST8176AA1
ST7612AA1
Histone deacetylase 1 (HDAC1)
Maleimide-thiol linker
[71]
LIN-002
Undisclosed
Undisclosed
Undisclosed
[72]
HER2 targeted DEP conjugate
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Undisclosed
[73]
Tra-IR700
IRDye 700DX
Undisclosed
Undisclosed
[74]
Anti-HER2 antibody-drug conjugate (Spirea)
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
[75]
Trastuzumab-PNU-159682 Antibody-Drug Conjugate
PNU-159682
DNA topoisomerase 2-alpha (TOP2A)
Undisclosed
[76]
PRO-1102
Exatecan
DNA topoisomerase 1 (TOP1)
Cleavable hydrophilic linker
[77]
Trastuzumab-ATAC
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Undisclosed
[78]
Trastuzumab-deBouganin
DeBouganin
Microtubule (MT)
Undisclosed
[79]
Trastuzumab-SYNtansine
Ahx-maytansine
Microtubule (MT)
BCN-HydraSpace-Val-Cit-PABC
[80]
Anti-HER2_vc-1
TLR7 agonist-1
Toll-like receptor 7 (TLR7)
Mc-Val-Cit-PABC
[81]
Tmab-SPP-DM1
Mertansine DM1
Microtubule (MT)
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)
[82]
Tmab-SSNPP-DM3
Maytansinoid DM3
Microtubule (MT)
Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)
[82]
Tmab-SSNPP-DM4
Mertansine DM4
Microtubule (MT)
Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)
[82]
Trastuzumab-AJICAP-maytansinoid
Mertansine DM1
Microtubule (MT)
AJICAP
[83]
Trastuzumab-C239I-SG3249
SG3199
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[84]
Tras-Gly5-EDA-Pnu
PNU-159682
DNA topoisomerase 2-alpha (TOP2A)
Gly5-EDA
[85]
Trastuzumab DVD-ADC
Monomethyl auristatin F
Microtubule (MT)
Hexapeptide linker ASTKGP
[86]
Trastuzumab-RSL3-NH2
RSL3-NH2
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
Mal-PEG4-DBCO-Ala-Val
[87]
Tras-Gly5-EDA-Dox
Doxorubicin
DNA topoisomerase 2-alpha (TOP2A)
Gly5-EDA
[85]
Tras-Gly5-EDA-Nemo
Nemorubicin
DNA topoisomerase 2-alpha (TOP2A)
Gly5-EDA
[85]
Tras-Gly3-Vakl-Cit-PAB-PNU-159682
PNU-159682
DNA topoisomerase 2-alpha (TOP2A)
Gly3-vcPAB
[85]
Tras-Gly5-May
Mertansine DM1
Microtubule (MT)
Gly5
[85]
Trastuzumab-SG3227
SG2219
Human Deoxyribonucleic acid (hDNA)
Acetamide-PEG4-Val-Ala-PABA
[36]
HER-SG3249
SG3199
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[88]
Site-specific HER-SG3249
SG3199
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[88]
Trastuzumab-SG3600 high DAR
N10-beta-glucuronide SG3200
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[35]
Trastuzumab vedotin
Undisclosed
Undisclosed
Undisclosed
[89]
Trastuzumab rezetecan
Undisclosed
Undisclosed
Undisclosed
[90]
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Gly-Calicheamicin
Gly-calicheamicin
Human Deoxyribonucleic acid (hDNA)
BCN-HydraSpace-Val-Cit-PABC
[80]
Trastuzumab SG-3259
SG3312
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Ala
[91]
Trastuzumab-SG3400 high DAR
SG3200
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[35]
Anti-HER2_vc-7
TLR7 agonist-7
Toll-like receptor 7 (TLR7)
Mc-Val-Cit-PABC
[81]
Anti-HER2_vc-2
TLR7 agonist-2
Toll-like receptor 7 (TLR7)
Mc-Val-Cit-PABC
[81]
TTZ-Mc-NPV-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Asn-Pro-Val-PABC
[92]
Adcitmer
Monomethyl auristatin E
Microtubule (MT)
Pyridino-caproic-Val-Cit-PABC
[93]
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
BCN-HydraSpace-Val-Cit-PABC
[80]
MF-TTZ-MMAE
Monomethyl auristatin E
Microtubule (MT)
Dibromomethyl pyridine-Val-Cit-PABC
[94]
FGM-TTZ-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[94]
NC-ADC
Monomethyl auristatin E
Microtubule (MT)
Divinylpyrimidine-PEG4
[95]
C-ADC
Monomethyl auristatin E
Microtubule (MT)
Divinylpyrimidine-PEG4-Val-Ala-PABC
[95]
Tmab-SPDP-DM1
Mertansine DM1
Microtubule (MT)
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
[82]
T-C-F (DAR 3.7)
Monomethyl auristatin F
Microtubule (MT)
Maleimido-caproyl
[96]
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-PNU-159682
PNU-159682
DNA topoisomerase 2-alpha (TOP2A)
BCN-HydraSpace-Val-Cit-PABC
[97]
Tra-Exa-PSAR10
Exatecan
DNA topoisomerase 1 (TOP1)
Mal-Exa-PSAR10
[98]
Tra-Exa-PSAR0
Exatecan
DNA topoisomerase 1 (TOP1)
Mal-Exa-PSAR0
[98]
T-N-F (DAR 3.2)
Aldehyde-tagged MMAF
Microtubule (MT)
Undisclosed
[96]
T-N-F (DAR 1.6)
Aldehyde-tagged MMAF
Microtubule (MT)
Undisclosed
[96]
Tras-ALN
Alendronate
Farnesyl pyrophosphate synthase (FDPS)
Bicyclo[6.1.0]nona-4-yne
[99]
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Duocarmycin
Duocarmycin Sa
Human Deoxyribonucleic acid (hDNA)
BCN-HydraSpace-Val-Cit-PABC
[80]
Trastuzumab-BCN-HydraSpace-Val-Ala-PABC-PBD dimer
PBD dimer 2
Human Deoxyribonucleic acid (hDNA)
BCN-HydraSpace-Val-Ala-PABC
[80]
Trastuzumab-DNA mimic 4
Q Pho-DNA mimics
Human Deoxyribonucleic acid (hDNA)
Diphenyltio-Mal-Cap
[100]
Trastuzumab-L3-TL
Triptolide
Nuclear factor NF-kappa-B p105 subunit (NFKB1)
BVP-PEG3-carbamate-PEG4
[101]
Trastuzumab-L2-TL
Triptolide
Nuclear factor NF-kappa-B p105 subunit (NFKB1)
BVP-PEG3-diamine
[101]
Trastuzumab-L1-TL
Triptolide
Nuclear factor NF-kappa-B p105 subunit (NFKB1)
BVP-PEG3-carbamate
[101]
Trastuzumab-PNUEDAGly5
PNU-159682
DNA topoisomerase 2-alpha (TOP2A)
LPETG-Gly5-EDA
[102]
ADC2-2
ADC 2-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-2 linker
[103]
ADC2-4
ADC 2-4 payload
DNA topoisomerase 1 (TOP1)
ADC 2-4 linker
[103]
ADC2-6-2
ADC 2-6-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-6-2 linker
[103]
ADC2-7-2
ADC 2-7-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-7-2 linker
[103]
ADC2-9-1
ADC 2-9-1 payload
DNA topoisomerase 1 (TOP1)
ADC 2-9-1 linker
[103]
ADC2-9-2
ADC 2-9-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-9-2 linker
[103]
ADC2-10
ADC 2-10 payload
DNA topoisomerase 1 (TOP1)
ADC 2-10 linker
[103]
ADC2-11
ADC 2-11 payload
DNA topoisomerase 1 (TOP1)
ADC 2-11 linker
[103]
ADC2-22
ADC 2-22 payload
DNA topoisomerase 1 (TOP1)
ADC 2-22 linker
[103]
ADC2-23
ADC 2-23 payload
DNA topoisomerase 1 (TOP1)
ADC 2-23 linker
[103]
ADC2-24
ADC 2-24 payload
DNA topoisomerase 1 (TOP1)
ADC 2-24 linker
[103]
ADC2-25
ADC 2-25 payload
DNA topoisomerase 1 (TOP1)
ADC 2-25 linker
[103]
ADC2-26
ADC 2-26 payload
DNA topoisomerase 1 (TOP1)
ADC 2-26 linker
[103]
ADC2-27
ADC 2-27 payload
DNA topoisomerase 1 (TOP1)
ADC 2-27 linker
[103]
ADC2-29
ADC 2-29 payload
DNA topoisomerase 1 (TOP1)
ADC 2-29 linker
[103]
ADC2-30
ADC 2-30 payload
DNA topoisomerase 1 (TOP1)
ADC 2-30 linker
[103]
ADC2-31
ADC 2-31 payload
DNA topoisomerase 1 (TOP1)
ADC 2-31 linker
[103]
ADC2-32
ADC 2-32 payload
DNA topoisomerase 1 (TOP1)
ADC 2-32 linker
[103]
ADC2-33
ADC 2-33 payload
DNA topoisomerase 1 (TOP1)
ADC 2-33 linker
[103]
ADC2-34
ADC 2-34 payload
DNA topoisomerase 1 (TOP1)
ADC 2-34 linker
[103]
ADC2-35
ADC 2-35 payload
DNA topoisomerase 1 (TOP1)
ADC 2-35 linker
[103]
ADC2-36-1
ADC 2-36-1 payload
DNA topoisomerase 1 (TOP1)
ADC 2-36-1 linker
[103]
ADC2-36-2
ADC 2-36-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-36-2 linker
[103]
ADC2-37
ADC 2-37 payload
DNA topoisomerase 1 (TOP1)
ADC 2-37 linker
[103]
ADC2-38
ADC 2-38 payload
DNA topoisomerase 1 (TOP1)
ADC 2-38 linker
[103]
ADC2-39
ADC 2-39 payload
DNA topoisomerase 1 (TOP1)
ADC 2-39 linker
[103]
ADC2-40
ADC 2-40 payload
DNA topoisomerase 1 (TOP1)
ADC 2-40 linker
[103]
ADC2-41
ADC 2-41 payload
DNA topoisomerase 1 (TOP1)
ADC 2-41 linker
[103]
ADC2-42
ADC 2-42 payload
DNA topoisomerase 1 (TOP1)
ADC 2-42 linker
[103]
ADC2-42-RO
ADC 2-42-RO payload
DNA topoisomerase 1 (TOP1)
ADC 2-42-RO linker
[103]
ADC2-43
ADC 2-43 payload
DNA topoisomerase 1 (TOP1)
ADC 2-43 linker
[103]
ADC2-44
ADC 2-44 payload
DNA topoisomerase 1 (TOP1)
ADC 2-44 linker
[103]
ADC2-45
ADC 2-45 payload
DNA topoisomerase 1 (TOP1)
ADC 2-45 linker
[103]
ADC2-46
ADC 2-46 payload
DNA topoisomerase 1 (TOP1)
ADC 2-46 linker
[103]
ADC2-47
ADC 2-47 payload
DNA topoisomerase 1 (TOP1)
ADC 2-47 linker
[103]
ADC2-48
ADC 2-48 payload
DNA topoisomerase 1 (TOP1)
ADC 2-48 linker
[103]
ADC2-49
ADC 2-49 payload
DNA topoisomerase 1 (TOP1)
ADC 2-49 linker
[103]
ADC2-50
ADC 2-50 payload
DNA topoisomerase 1 (TOP1)
ADC 2-50 linker
[103]
ADC2-51
ADC 2-51 payload
DNA topoisomerase 1 (TOP1)
ADC 2-51 linker
[103]
ADC2-53
ADC 2-53 payload
DNA topoisomerase 1 (TOP1)
ADC 2-53 linker
[103]
ADC2-54
ADC 2-54 payload
DNA topoisomerase 1 (TOP1)
ADC 2-54 linker
[103]
ADC2-55
ADC 2-55 payload
DNA topoisomerase 1 (TOP1)
ADC 2-55 linker
[103]
ADC2-56
ADC 2-56 payload
DNA topoisomerase 1 (TOP1)
ADC 2-56 linker
[103]
ADC2-57
ADC 2-57 payload
DNA topoisomerase 1 (TOP1)
ADC 2-57 linker
[103]
ADC2-58
ADC 2-58 payload
DNA topoisomerase 1 (TOP1)
ADC 2-58 linker
[103]
ADC2-59
ADC 2-59 payload
DNA topoisomerase 1 (TOP1)
ADC 2-59 linker
[103]
ADC2-60
ADC 2-60 payload
DNA topoisomerase 1 (TOP1)
ADC 2-60 linker
[103]
ADC2-61
ADC 2-61 payload
DNA topoisomerase 1 (TOP1)
ADC 2-61 linker
[103]
ADC-2-62-1
ADC 2-62-1 payload
DNA topoisomerase 1 (TOP1)
ADC 2-62-1 linker
[103]
ADC-2-62-2
ADC 2-62-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-62-2 linker
[103]
ADC-2-63-1
ADC 2-63-1 payload
DNA topoisomerase 1 (TOP1)
ADC 2-63-1 linker
[103]
ADC-2-63-2
ADC 2-63-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-63-2 linker
[103]
ADC-2-64-1
ADC 2-64-1 payload
DNA topoisomerase 1 (TOP1)
ADC 2-64-1 linker
[103]
ADC-2-64-2
ADC 2-64-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-64-2 linker
[103]
ADC-2-65-1
ADC 2-65-1 payload
DNA topoisomerase 1 (TOP1)
ADC 2-65-1 linker
[103]
ADC-2-65-2
ADC 2-65-2 payload
DNA topoisomerase 1 (TOP1)
ADC 2-65-2 linker
[103]
ADC3-1
ADC 3-1 payload
DNA topoisomerase 1 (TOP1)
ADC 3-1 linker
[103]
ADC3-2
ADC 3-2 payload
DNA topoisomerase 1 (TOP1)
ADC 3-2 linker
[103]
ADC3-3
ADC 3-3 payload
DNA topoisomerase 1 (TOP1)
ADC 3-3 linker
[103]
ADC3-4
ADC 3-4 payload
DNA topoisomerase 1 (TOP1)
ADC 3-4 linker
[103]
ADC3-5
ADC 3-5 payload
DNA topoisomerase 1 (TOP1)
ADC 3-5 linker
[103]
ADC2-A
ADC 2-A payload
DNA topoisomerase 1 (TOP1)
ADC 2-A linker
[103]
ADC2-B
ADC 2-B payload
DNA topoisomerase 1 (TOP1)
ADC 2-B linker
[103]
ADC2-12
ADC 2-12 payload
DNA topoisomerase 1 (TOP1)
ADC 2-12 linker
[103]
HER2-ADC-01 (DAR8)
HER2-ADC-01(DAR8) payload
Undisclosed
HER2-ADC-01(DAR8) linker
[2]
HER2-ADC-02 (DAR8)
HER2-ADC-02(DAR8) payload
Undisclosed
HER2-ADC-02(DAR8) linker
[2]
HER2-ADC-03 (DAR8)
HER2-ADC-03(DAR8) payload
Undisclosed
HER2-ADC-03(DAR8) linker
[2]
HER2-ADC-04 (DAR8)
HER2-ADC-04(DAR8) payload
Undisclosed
HER2-ADC-04(DAR8) linker
[2]
HER2-ADC-05 (DAR8)
HER2-ADC-05(DAR8) payload
Undisclosed
HER2-ADC-05(DAR8) linker
[2]
HER2-ADC-06 (DAR8)
HER2-ADC-06(DAR8) payload
Undisclosed
HER2-ADC-06(DAR8) linker
[2]
HER2-ADC-07 (DAR8)
HER2-ADC-07(DAR8) payload
Undisclosed
HER2-ADC-07(DAR8) linker
[2]
HER2-ADC-08 (DAR8)
HER2-ADC-08(DAR8) payload
Undisclosed
HER2-ADC-08(DAR8) linker
[2]
HER2-ADC-09 (DAR8)
HER2-ADC-09(DAR8) payload
Undisclosed
HER2-ADC-09(DAR8) linker
[2]
HER2-ADC-10 (DAR8)
HER2-ADC-10(DAR8) payload
Undisclosed
HER2-ADC-10(DAR8) linker
[2]
WO2020063676A1 ADC-1
WO2020063676A1_ADC-1 payload
Undisclosed
WO2020063676A1_ADC-1 linker
[53]
WO2020063676A1 ADC-2
WO2020063676A1_ADC-2 payload
Undisclosed
WO2020063676A1_ADC-2 linker
[53]
WO2020063676A1 ADC-3
WO2020063676A1_ADC-3 payload
Undisclosed
WO2020063676A1_ADC-3 linker
[53]
WO2020063676A1 ADC-4
WO2020063676A1_ADC-4 payload
Undisclosed
WO2020063676A1_ADC-4 linker
[53]
WO2020063676A1 ADC-5
WO2020063676A1_ADC-5 payload
Undisclosed
WO2020063676A1_ADC-5 linker
[53]
WO2020063676A1 ADC-6
WO2020063676A1_ADC-6 payload
Undisclosed
WO2020063676A1_ADC-6 linker
[53]
WO2020063676A1 ADC-10
WO2020063676A1_ADC-10 payload
Undisclosed
WO2020063676A1_ADC-10 linker
[53]
WO2020063676A1 ADC-11
WO2020063676A1_ADC-11 payload
Undisclosed
WO2020063676A1_ADC-11 linker
[53]
WO2020063676A1 ADC-12
WO2020063676A1_ADC-12 payload
Undisclosed
WO2020063676A1_ADC-12 linker
[53]
WO2020063676A1 ADC-13
WO2020063676A1_ADC-13 payload
Undisclosed
WO2020063676A1_ADC-13 linker
[53]
WO2020063676A1 ADC-14
WO2020063676A1_ADC-14 payload
Undisclosed
WO2020063676A1_ADC-14 linker
[53]
WO2020063676A1 ADC-15
WO2020063676A1_ADC-15 payload
Undisclosed
WO2020063676A1_ADC-15 linker
[53]
WO2020063676A1 ADC-16
WO2020063676A1_ADC-16 payload
Undisclosed
WO2020063676A1_ADC-16 linker
[53]
WO2020063676A1 ADC-17
WO2020063676A1_ADC-17 payload
Undisclosed
WO2020063676A1_ADC-17 linker
[53]
WO2020063676A1 ADC-18
WO2020063676A1_ADC-18 payload
Undisclosed
WO2020063676A1_ADC-18 linker
[53]
WO2020063676A1 ADC-19
WO2020063676A1_ADC-19 payload
Undisclosed
WO2020063676A1_ADC-19 linker
[53]
WO2020063676A1 ADC-20
WO2020063676A1_ADC-20 payload
Undisclosed
WO2020063676A1_ADC-20 linker
[53]
WO2020063676A1 ADC-21
WO2020063676A1_ADC-21 payload
Undisclosed
WO2020063676A1_ADC-21 linker
[53]
WO2020063676A1 ADC-22
WO2020063676A1_ADC-22 payload
Undisclosed
WO2020063676A1_ADC-22 linker
[53]
WO2020063676A1 ADC-23
WO2020063676A1_ADC-23 payload
Undisclosed
WO2020063676A1_ADC-23 linker
[53]
WO2020063676A1 ADC-24
WO2020063676A1_ADC-24 payload
Undisclosed
WO2020063676A1_ADC-24 linker
[53]
Trastuzumab-Compound (la) DAR 1.6
NeoDegrader P1
Protein cereblon (CRBN)
Trastuzumab-Compound (la) DAR 1.6 linker
[54]
Trastuzumab-Compound (la) DAR 8
NeoDegrader P1
Protein cereblon (CRBN)
Trastuzumab-Compound (la) DAR 8 linker
[54]
Trastuzumab-Compound (Ib) DAR1.5
NeoDegrader P3
Protein cereblon (CRBN)
Trastuzumab-Compound (Ib) DAR1.5 linker
[54]
Trastuzumab-Compound (lc)
NeoDegrader P4
Protein cereblon (CRBN)
Trastuzumab-Compound (lc) linker
[54]
Trastuzumab-Compound (lc) DAR 8
NeoDegrader P4
Protein cereblon (CRBN)
Trastuzumab-Compound (lc) DAR 8 linker
[54]
Trastuzumab-Compound (ld) DAR 1.6
NeoDegrader P1
Protein cereblon (CRBN)
Trastuzumab-Compound (ld) DAR 1.6 linker
[54]
Trastuzumab-Compound (le)
NeoDegrader P1
Protein cereblon (CRBN)
Trastuzumab-Compound (le) linker
[54]
Trastuzumab-Compound (lf)
NeoDegrader P6
Protein cereblon (CRBN)
Trastuzumab-Compound (lf) linker
[54]
Trastuzumab-Compound (lg)
NeoDegrader P2
Protein cereblon (CRBN)
Trastuzumab-Compound (lg) linker
[54]
Trastuzumab-Compound (lh)
NeoDegrader P13
Protein cereblon (CRBN)
Trastuzumab-Compound (lh) linker
[54]
Trastuzumab-Compound (li)
NeoDegrader P1
Protein cereblon (CRBN)
Trastuzumab-Compound (li) linker
[54]
Trastuzumab-Compound (lk)
NeoDegrader P14
Protein cereblon (CRBN)
Trastuzumab-Compound (lk) linker
[54]
Trastuzumab-Compound (ll)
NeoDegrader P14
Protein cereblon (CRBN)
Trastuzumab-Compound (ll) linker
[54]
Trastuzumab-Compound (lm)
NeoDegrader P14
Protein cereblon (CRBN)
Trastuzumab-Compound (lm) linker
[54]
WO2017089895A1 ADC1
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC1 linker
[104]
WO2017089895A1 ADC2
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC2 linker
[104]
WO2017089895A1 ADC3
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC3 linker
[104]
WO2017089895A1 ADC4
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC4 linker
[104]
WO2017089895A1 ADC5
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC5 linker
[104]
WO2017089895A1 ADC6
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC6 linker
[104]
WO2017089895A1 ADC7
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC7 linker
[104]
WO2017089895A1 ADC8
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC8 linker
[104]
WO2017089895A1 ADC9
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC9 linker
[104]
WO2017089895A1 ADC10
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC10 linker
[104]
WO2017089895A1 ADC11
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC11 linker
[104]
WO2017089895A1 ADC12
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC12 linker
[104]
WO2017089895A1 ADC13
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC13 linker
[104]
WO2017089895A1 ADC14
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC14 linker
[104]
WO2017089895A1 ADC15
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC15 linker
[104]
WO2017089895A1 ADC16
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC16 linker
[104]
WO2017089895A1 ADC17
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC17 linker
[104]
WO2017089895A1 ADC18
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC18 linker
[104]
WO2017089895A1 ADC19
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC19 linker
[104]
WO2017089895A1 ADC20
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC20 linker
[104]
WO2017089895A1 ADC86
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC86 linker
[104]
WO2017089895A1 ADC87
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC87 linker
[104]
WO2017089895A1 ADC23
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC23 linker
[104]
WO2017089895A1 ADC24
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC24 linker
[104]
WO2017089895A1 ADC25
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC25 linker
[104]
WO2017089895A1 ADC26
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC26 linker
[104]
WO2017089895A1 ADC27
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC27 linker
[104]
WO2017089895A1 ADC28
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC28 linker
[104]
WO2017089895A1 ADC29
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC29 linker
[104]
WO2017089895A1 ADC30
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC30 linker
[104]
WO2017089895A1 ADC31
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC31 linker
[104]
WO2017089895A1 ADC32
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC32 linker
[104]
WO2017089895A1 ADC33
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC33 linker
[104]
WO2017089895A1 ADC34
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC34 linker
[104]
WO2017089895A1 ADC35
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC35 linker
[104]
WO2017089895A1 ADC36
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC36 linker
[104]
WO2017089895A1 ADC37
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC37 linker
[104]
WO2017089895A1 ADC38
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC38 linker
[104]
WO2017089895A1 ADC39
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC39 linker
[104]
WO2017089895A1 ADC40
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC40 linker
[104]
WO2017089895A1 ADC41
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC41 linker
[104]
WO2017089895A1 ADC42
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC42 linker
[104]
WO2017089895A1 ADC43
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC43 linker
[104]
WO2017089895A1 ADC44
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC44 linker
[104]
WO2017089895A1 ADC45
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC45 linker
[104]
WO2017089895A1 ADC46
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC46 linker
[104]
WO2017089895A1 ADC47
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC47 linker
[104]
WO2017089895A1 ADC48
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC48 linker
[104]
WO2017089895A1 ADC49
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC49 linker
[104]
WO2017089895A1 ADC50
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC50 linker
[104]
WO2017089895A1 ADC51
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC51 linker
[104]
WO2017089895A1 ADC52
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC52 linker
[104]
WO2017089895A1 ADC53
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC53 linker
[104]
WO2017089895A1 ADC54
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC54 linker
[104]
WO2017089895A1 ADC55
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC55 linker
[104]
WO2017089895A1 ADC76
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC76 linker
[104]
WO2017089895A1 ADC88
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC88 linker
[104]
WO2017089895A1 ADC89
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC89 linker
[104]
WO2017089895A1 ADC90
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC90 linker
[104]
WO2017089895A1 ADC91
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC91 linker
[104]
WO2017089895A1 ADC60
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC60 linker
[104]
WO2017089895A1 ADC61
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC61 linker
[104]
WO2017089895A1 ADC62
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC62 linker
[104]
WO2017089895A1 ADC63
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC63 linker
[104]
WO2017089895A1 ADC77
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC77 linker
[104]
HER2-B Antibody-Compound (X)
HER2-B Antibody-Compound (X) payload
Undisclosed
HER2-B Antibody-Compound (X) linker
[38]
HER2-B Antibody-Compound (XI)
HER2-B Antibody-Compound (XI) payload
Undisclosed
HER2-B Antibody-Compound (XI) linker
[38]
HER2-B Antibody-Compound (XIV)
HER2-B Antibody-Compound (XIV) payload
Undisclosed
HER2-B Antibody-Compound (XIV) linker
[38]
HER2-B Antibody-Compound (XVIII)
HER2-B Antibody-Compound (XVIII) payload
Undisclosed
HER2-B Antibody-Compound (XVIII) linker
[38]
HER2-B Antibody-Compound (Ie)
HER2-B Antibody-Compound (Ie) payload
Undisclosed
HER2-B Antibody-Compound (Ie) linker
[38]
HER2-B Antibody-Compound (XIX)
HER2-B Antibody-Compound (XIX) payload
Undisclosed
HER2-B Antibody-Compound (XIX) linker
[38]
HER2-B Antibody-Compound (Ii)
HER2-B Antibody-Compound (Ii) payload
Undisclosed
HER2-B Antibody-Compound (Ii) linker
[38]
HER2-B Antibody-Compound (XLI)
HER2-B Antibody-Compound (XLI) payload
Undisclosed
HER2-B Antibody-Compound (XLI) linker
[38]
HER2-B Antibody-Compound (XVI)
HER2-B Antibody-Compound (XIX) payload
Undisclosed
HER2-B Antibody-Compound (XIX) linker
[38]
HER2-B Antibody-Compound (XL)
HER2-B Antibody-Compound (XL) payload
Undisclosed
HER2-B Antibody-Compound (XL) linker
[38]
HER2-B Antibody-Compound (XLII)
HER2-B Antibody-Compound (XLII) payload
Undisclosed
HER2-B Antibody-Compound (XLII) linker
[38]
Trastuzumab-Compound (XV)
Trastuzumab-Compound (XV) payload
Undisclosed
Trastuzumab-Compound (XV) linker
[38]
WO2013055987A1 Tmab-101
SG2000
Human Deoxyribonucleic acid (hDNA)
WO2013055987A1_Tmab-101 linker
[105]
WO2013055987A1 Tmab-102
SG2000
Human Deoxyribonucleic acid (hDNA)
WO2013055987A1_Tmab-102 linker
[105]
WO2013055987A1 Tmab-104
SG2000
Human Deoxyribonucleic acid (hDNA)
WO2013055987A1_Tmab-104 linker
[105]
WO2013055987A1 Tmab-110
SG2000
Human Deoxyribonucleic acid (hDNA)
WO2013055987A1_Tmab-110 linker
[105]
WO2014159981A2 ADC-110
WO2014159981A2_ADC-110 payload
Undisclosed
WO2014159981A2_ADC-110 linker
[58]
WO2014159981A2 ADC-120
WO2014159981A2_ADC-120 payload
Undisclosed
WO2014159981A2_ADC-120 linker
[58]
ADC-II-1
ADC-II-1 payload
Undisclosed
ADC-II-1 linker
[106]
ADC-II-5
ADC-II-5 payload
Undisclosed
ADC-II-5 linker
[106]
ADC-II-9
ADC-II-9 payload
Undisclosed
ADC-II-9 linker
[106]
ADC-II-13
ADC-II-13 payload
Undisclosed
ADC-II-13 linker
[106]
ADC-I-1
ADC-I-1 payload
Undisclosed
ADC-I-1 linker
[106]
ADC-III-1
ADC-III-1 payload
Undisclosed
ADC-III-1 linker
[106]
ADC-III-9
ADC-III-9 payload
Undisclosed
ADC-III-9 linker
[106]
Trastuzumab-Gelonin
Gelonin
Ribosome (RB)
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
[107]
Trastuzumab-Man-beta-1,4GlcNAc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Man-beta-1,4-GlcNAc
[108]
Trastuzumab-Glc-beta-1,4GlcNAc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Glc-beta-1,4GlcNAc
[108]
Trastuzumab-Gal-beta-1,4GlcNAc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Gal-beta-1,4-GlcNAc
[108]
Trastuzumab-MMAE conjugate DAR2
Monomethyl auristatin E
Microtubule (MT)
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB
[109]
Trastuzumab-MMAE conjugate DAR4
Monomethyl auristatin E
Microtubule (MT)
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB
[109]
Trastuzumab-MMAE conjugate DAR6
Monomethyl auristatin E
Microtubule (MT)
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB
[109]
Trastuzumab-MMAE conjugate DAR8
Monomethyl auristatin E
Microtubule (MT)
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB
[109]
Trastuzumab-MMAE conjugate DAR12
Monomethyl auristatin E
Microtubule (MT)
Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB
[109]
Trastuzumab imbotolimod
Undisclosed
Undisclosed
Undisclosed
[110]
Trastuzumab botidotin
Undisclosed
Undisclosed
Undisclosed
[111]
T-K-F (DAR 3.9)
Monomethyl auristatin F
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[96]
Trastuzumab-G5-PNU
PNU-159682
DNA topoisomerase 2-alpha (TOP2A)
Gly5-FITC
[85]
CRD-5500 antibody-drug conjugate
CRD5500
Stimulator of interferon genes protein (STING1)
Undisclosed
[112]
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Calicheamicin
N-acetyl-gamma-calicheamicin
Human Deoxyribonucleic acid (hDNA)
BCN-HydraSpace-Val-Cit-PABC
[80]
MYX2449
N-Myristolytransferase inhibitor (NMTi)
Glycylpeptide N-tetradecanoyltransferase 1 (NMT1)
Undisclosed
[113]
Trastuzumab-L6
MF-6
DNA topoisomerase 1 (TOP1)
Bridged PEG4-valine-alanine
[114]
ADC Trast-7
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
[115]
ADC Trast-10
Monomethyl auristatin E
Microtubule (MT)
Bis-BCN-modified Val-Cit-PABC linker 10
[115]
ADC Trast-14
PBD dimer 3
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[115]
ADC Trast-11
PBD dimer 3
Human Deoxyribonucleic acid (hDNA)
Bis-BCN-modified Val-Cit-PABC linker 10
[115]
Trastuzumab-MCC-CpG conjugate
Differentiated TLR-9 agonist (T-CpG)
Toll-like receptor 9 (TLR9)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[116]
Trastuzumab-T1000-exatecan
Exatecan
DNA topoisomerase 1 (TOP1)
Undisclosed
[117]
Trastuzumab-NGM-PROTAC conjugate
BRD4 PROTAC 3
Bromodomain-containing protein 4 (BRD4)
NGM based linker
[118]
Trastuzumab-iCME
Membrane-impermable colchinolmethyl ether (iCME) cytotoxin
Microtubule (MT)
Pacific blue fluorophore-SH based linker
[119]
IgG1 (trastuzumab)-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[11]
Trastuzumab-DNA conjugate
DNA mimics
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[120]
OHPAS ADC-1
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Ortho-hydroxy-protected aryl sulfate
[121]
OHPAS ADC-2
SG2000
Human Deoxyribonucleic acid (hDNA)
Ortho-hydroxy-protected aryl sulfate
[121]
OHPAS ADC-3
seco-CBI-indole
Human Deoxyribonucleic acid (hDNA)
Ortho-hydroxy-protected aryl sulfate
[121]
OHPAS ADC-4
CBI-dimer-beta-Gal
Human Deoxyribonucleic acid (hDNA)
Ortho-hydroxy-protected aryl sulfate
[121]
Trastuzumab/nab-paclitaxel
Paclitaxel
Microtubule (MT)
Undisclosed
[122]
Docetaxel-trastuzumab
Docetaxel
Microtubule (MT)
Undisclosed
[123]
Trastuzumab-PC4AP-DOX
Doxorubicin
DNA topoisomerase 2-alpha (TOP2A)
Photocaged C4AP
[124]
T (Anti-HER2)-30.2060
Amanitin 30.206
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mc-Val-Ala-PABC
[23]
T (Anti-HER2)-30.2867
Amanitin 30.2867
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Maleimido-caproyl
[23]
Trastuzumab-Compound (lj)
NeoDegrader P1
Protein cereblon (CRBN)
Trastuzumab-Compound (lj) linker
[54]
WO2017089895A1 ADC21
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
WO2017089895A1_ADC21 linker
[104]
WO2017089895A1 ADC22
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
WO2017089895A1_ADC22 linker
[104]
WO2017089895A1 ADC56
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
WO2017089895A1_ADC56 linker
[104]
WO2017089895A1 ADC57
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
WO2017089895A1_ADC57 linker
[104]
WO2017089895A1 ADC58
Alpha-amanitin+Monomethyl auristatin F
Undisclosed
WO2017089895A1_ADC58 linker
[104]
WO2017089895A1 ADC59
Alpha-amanitin+Monomethyl auristatin F
Undisclosed
WO2017089895A1_ADC59 linker
[104]
HER2-B Antibody-Compound (XLIII)
HER2-B Antibody-Compound (XLIII) payload
Undisclosed
HER2-B Antibody-Compound (XLIII) linker
[38]
WO2022078260A1 ADC-1
Ln-D9
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-1 linker
[125]
WO2022078260A1 ADC-2
Ln-D1
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-2 linker
[125]
WO2022078260A1 ADC-3
Ln-D2
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-3 linker
[125]
WO2022078260A1 ADC-4
Ln-D4
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-4 linker
[125]
WO2022078260A1 ADC-5
Ln-D5
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-5 linker
[125]
WO2022078260A1 ADC-6
Ln-D6
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-6 linker
[125]
WO2022078260A1 ADC-7
Ln-D7
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-7 linker
[125]
WO2022078260A1 ADC-8
Ln-D8
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-8 linker
[125]
WO2021249228A1 ADC-1
WO2021249228A1_ADC-1 payload
Undisclosed
WO2021249228A1_ADC-1 linker
[126]
WO2021249228A1 ADC-2
WO2021249228A1_ADC-2 payload
Undisclosed
WO2021249228A1_ADC-2 linker
[126]
WO2021249228A1 ADC-3
WO2021249228A1_ADC-3 payload
Undisclosed
WO2021249228A1_ADC-3 linker
[126]
WO2021249228A1 ADC-4
WO2021249228A1_ADC-4 payload
Undisclosed
WO2021249228A1_ADC-4 linker
[126]
WO2021249228A1 ADC-5
WO2021249228A1_ADC-5 payload
Undisclosed
WO2021249228A1_ADC-5 linker
[126]
WO2021249228A1 ADC-6
WO2021249228A1_ADC-6 payload
Undisclosed
WO2021249228A1_ADC-6 linker
[126]
WO2021249228A1 ADC-7
WO2021249228A1_ADC-7 payload
Undisclosed
WO2021249228A1_ADC-7 linker
[126]
WO2021249228A1 ADC-8
WO2021249228A1_ADC-8 payload
Undisclosed
WO2021249228A1_ADC-8 linker
[126]
WO2021249228A1 ADC-9
WO2021249228A1_ADC-9 payload
Undisclosed
WO2021249228A1_ADC-9 linker
[126]
WO2021249228A1 ADC-10
WO2021249228A1_ADC-10 payload
Undisclosed
WO2021249228A1_ADC-10 linker
[126]
WO2021249228A1 ADC-11
WO2021249228A1_ADC-11 payload
Undisclosed
WO2021249228A1_ADC-11 linker
[126]
WO2021249228A1 ADC-12
WO2021249228A1_ADC-12 payload
Undisclosed
WO2021249228A1_ADC-12 linker
[126]
WO2021249228A1 ADC-13
WO2021249228A1_ADC-13 payload
Undisclosed
WO2021249228A1_ADC-13 linker
[126]
WO2021249228A1 ADC-14
WO2021249228A1_ADC-14 payload
Undisclosed
WO2021249228A1_ADC-14 linker
[126]
WO2021249228A1 ADC-15
WO2021249228A1_ADC-15 payload
Undisclosed
WO2021249228A1_ADC-15 linker
[126]
WO2021249228A1 ADC-16
WO2021249228A1_ADC-16 payload
Undisclosed
WO2021249228A1_ADC-16 linker
[126]
WO2021249228A1 ADC-17
WO2021249228A1_ADC-17 payload
Undisclosed
WO2021249228A1_ADC-17 linker
[126]
WO2021249228A1 ADC-18
WO2021249228A1_ADC-18 payload
Undisclosed
WO2021249228A1_ADC-18 linker
[126]
WO2021249228A1 ADC-19
WO2021249228A1_ADC-19 payload
Undisclosed
WO2021249228A1_ADC-19 linker
[126]
WO2021249228A1 ADC-20
WO2021249228A1_ADC-20 payload
Undisclosed
WO2021249228A1_ADC-20 linker
[126]
WO2021249228A1 ADC-21
WO2021249228A1_ADC-21 payload
Undisclosed
WO2021249228A1_ADC-21 linker
[126]
WO2021249228A1 ADC-22
WO2021249228A1_ADC-22 payload
Undisclosed
WO2021249228A1_ADC-22 linker
[126]
WO2021249228A1 ADC-23
WO2021249228A1_ADC-23 payload
Undisclosed
WO2021249228A1_ADC-23 linker
[126]
WO2021249228A1 ADC-24
WO2021249228A1_ADC-24 payload
Undisclosed
WO2021249228A1_ADC-24 linker
[126]
WO2021249228A1 ADC-25
WO2021249228A1_ADC-25 payload
Undisclosed
WO2021249228A1_ADC-25 linker
[126]
WO2021249228A1 ADC-26
WO2021249228A1_ADC-26 payload
Undisclosed
WO2021249228A1_ADC-26 linker
[126]
WO2021249228A1 ADC-27
WO2021249228A1_ADC-27 payload
Undisclosed
WO2021249228A1_ADC-27 linker
[126]
WO2021249228A1 ADC-28
WO2021249228A1_ADC-28 payload
Undisclosed
WO2021249228A1_ADC-28 linker
[126]
WO2021249228A1 ADC-29
WO2021249228A1_ADC-29 payload
Undisclosed
WO2021249228A1_ADC-29 linker
[126]
WO2021249228A1 ADC-30
WO2021249228A1_ADC-30 payload
Undisclosed
WO2021249228A1_ADC-30 linker
[126]
WO2021249228A1 ADC-31
WO2021249228A1_ADC-31 payload
Undisclosed
WO2021249228A1_ADC-31 linker
[126]
WO2021249228A1 ADC-32
WO2021249228A1_ADC-32 payload
Undisclosed
WO2021249228A1_ADC-32 linker
[126]
WO2021249228A1 ADC-33
WO2021249228A1_ADC-33 payload
Undisclosed
WO2021249228A1_ADC-33 linker
[126]
WO2021249228A1 ADC-34
WO2021249228A1_ADC-34 payload
Undisclosed
WO2021249228A1_ADC-34 linker
[126]
WO2021249228A1 ADC-35
WO2021249228A1_ADC-35 payload
Undisclosed
WO2021249228A1_ADC-35 linker
[126]
WO2021249228A1 ADC-36
WO2021249228A1_ADC-36 payload
Undisclosed
WO2021249228A1_ADC-36 linker
[126]
WO2021249228A1 ADC-37
WO2021249228A1_ADC-37 payload
Undisclosed
WO2021249228A1_ADC-37 linker
[126]
WO2021249228A1 ADC-38
WO2021249228A1_ADC-38 payload
Undisclosed
WO2021249228A1_ADC-38 linker
[126]
WO2021249228A1 ADC-39
WO2021249228A1_ADC-39 payload
Undisclosed
WO2021249228A1_ADC-39 linker
[126]
WO2021249228A1 ADC-40
WO2021249228A1_ADC-40 payload
Undisclosed
WO2021249228A1_ADC-40 linker
[126]
WO2021249228A1 ADC-41
WO2021249228A1_ADC-41 payload
Undisclosed
WO2021249228A1_ADC-41 linker
[126]
WO2021249228A1 ADC-42
WO2021249228A1_ADC-42 payload
Undisclosed
WO2021249228A1_ADC-42 linker
[126]
WO2021249228A1 ADC-43
WO2021249228A1_ADC-43 payload
Undisclosed
WO2021249228A1_ADC-43 linker
[126]
WO2021249228A1 ADC-44
WO2021249228A1_ADC-44 payload
Undisclosed
WO2021249228A1_ADC-44 linker
[126]
WO2021249228A1 ADC-45
WO2021249228A1_ADC-45 payload
Undisclosed
WO2021249228A1_ADC-45 linker
[126]
WO2021249228A1 ADC-46
WO2021249228A1_ADC-46 payload
Undisclosed
WO2021249228A1_ADC-46 linker
[126]
WO2021249228A1 ADC-47
WO2021249228A1_ADC-47 payload
Undisclosed
WO2021249228A1_ADC-47 linker
[126]
WO2021249228A1 ADC-48
WO2021249228A1_ADC-48 payload
Undisclosed
WO2021249228A1_ADC-48 linker
[126]
WO2021249228A1 ADC-49
WO2021249228A1_ADC-49 payload
Undisclosed
WO2021249228A1_ADC-49 linker
[126]
WO2021249228A1 ADC-50
WO2021249228A1_ADC-50 payload
Undisclosed
WO2021249228A1_ADC-50 linker
[126]
WO2021249228A1 ADC-51
WO2021249228A1_ADC-51 payload
Undisclosed
WO2021249228A1_ADC-51 linker
[126]
WO2021249228A1 ADC-52
WO2021249228A1_ADC-52 payload
Undisclosed
WO2021249228A1_ADC-52 linker
[126]
WO2021249228A1 ADC-53
WO2021249228A1_ADC-53 payload
Undisclosed
WO2021249228A1_ADC-53 linker
[126]
WO2021249228A1 ADC-54
WO2021249228A1_ADC-54 payload
Undisclosed
WO2021249228A1_ADC-54 linker
[126]
WO2021249228A1 ADC-55
WO2021249228A1_ADC-55 payload
Undisclosed
WO2021249228A1_ADC-55 linker
[126]
WO2021249228A1 ADC-56
WO2021249228A1_ADC-56 payload
Undisclosed
WO2021249228A1_ADC-56 linker
[126]
WO2021249228A1 ADC-57
WO2021249228A1_ADC-57 payload
Undisclosed
WO2021249228A1_ADC-57 linker
[126]
WO2021249228A1 ADC-58
WO2021249228A1_ADC-58 payload
Undisclosed
WO2021249228A1_ADC-58 linker
[126]
WO2021249228A1 ADC-59
WO2021249228A1_ADC-59 payload
Undisclosed
WO2021249228A1_ADC-59 linker
[126]
WO2021249228A1 ADC-60
WO2021249228A1_ADC-60 payload
Undisclosed
WO2021249228A1_ADC-60 linker
[126]
WO2021249228A1 ADC-61
WO2021249228A1_ADC-61 payload
Undisclosed
WO2021249228A1_ADC-61 linker
[126]
WO2022228495A1 ADC-67
WO2022228495A1 ADC-67 payload
Undisclosed
WO2022228495A1 ADC-67 linker
[37]
WO2022228495A1 ADC-68
WO2022228495A1 ADC-68 payload
Undisclosed
WO2022228495A1 ADC-68 linker
[37]
WO2022228495A1 ADC-69
WO2022228495A1 ADC-69 payload
Undisclosed
WO2022228495A1 ADC-69 linker
[37]
WO2022228495A1 ADC-70
WO2022228495A1 ADC-70 payload
Undisclosed
WO2022228495A1 ADC-70 linker
[37]
WO2022228495A1 ADC-71
WO2022228495A1 ADC-71 payload
Undisclosed
WO2022228495A1 ADC-71 linker
[37]
WO2022228495A1 ADC-74
WO2022228495A1 ADC-74 payload
Undisclosed
WO2022228495A1 ADC-74 linker
[37]
WO2022228495A1 ADC-75
WO2022228495A1 ADC-75 payload
Undisclosed
WO2022228495A1 ADC-75 linker
[37]
HER2-MMAU ADC
Glucuronyl-monomethyl-auristatin E (MMAU)
Microtubule (MT)
Mc-Val-Cit-PABC
[127]
PF-06888667
SW-163D
Human Deoxyribonucleic acid (hDNA)
AcLys-Val-Cit-PABC-DMAE
[128]
TTZ-1-MMAE
Monomethyl auristatin E
Microtubule (MT)
DSPh-Val-Ala-PABC
[129]
TTZ-2-MMAE
Monomethyl auristatin E
Microtubule (MT)
DSPh-Val-Cit-PABC
[129]
TTZ-3-MMAE
Monomethyl auristatin E
Microtubule (MT)
DSPh-PEG12-Val-Ala-PABC
[129]
TTZ-4-MMAE
Monomethyl auristatin E
Microtubule (MT)
DSPh-PEG12-Val-Cit-PABC
[129]
Trastuzumab-DVP-linker-MMAE 1
Monomethyl auristatin E
Microtubule (MT)
DVP-based linker 1f
[130]
Trastuzumab-Val-Cit linker-MMAE 2
Monomethyl auristatin E
Microtubule (MT)
Val-Cit linker 2e
[130]
Trastuzumab-DVP-linker-MMAE 3
Monomethyl auristatin E
Microtubule (MT)
DVP-based linker 3
[130]
Trastuzumab-DVP-linker-MMAE 4
Monomethyl auristatin E
Microtubule (MT)
DVP-based linker 4
[130]
Trastuzumab-Me-PRX conjugate
Methylated-beta-Cyclodextrin/Pluronic P103-based polyrotaxane (Me-PRX)
Undisclosed
Phenyl maleimide PEG2
[131]
T-PBA
PBD-based payload 37b3
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Ala
[132]
HER2-acetal-ADC 11
Monomethyl auristatin F
Microtubule (MT)
Clravable-acetal based linker 11
[133]
HER2-acetal-ADC 12
Monomethyl auristatin F
Microtubule (MT)
Clravable-TAMRA-acetal based linker 12
[133]
HER2-azide-alkyne MMAE conjugate
Monomethyl auristatin E
Microtubule (MT)
Azide-alkyne based linker 10a
[134]
HER2-cyclopropene-tetrazine MMAE conjugate
Monomethyl auristatin E
Microtubule (MT)
Cyclopropene-tetrazine based linker 10b
[134]
HER2-norbornene-tetrazine MMAE conjugate
Monomethyl auristatin E
Microtubule (MT)
Norbornene-tetrazine based linker 10c
[134]
T-FcBP-DM1
Mertansine DM1
Microtubule (MT)
N-terminal norbornene group pFcBP linker
[135]
T-D8-1508
AZ-1508
Microtubule (MT)
Cysteine D8
[136]
T-D6-1508
AZ-1508
Microtubule (MT)
Cysteine D6
[136]
T-D4-1508
AZ-1508
Microtubule (MT)
Cysteine D4
[136]
T-D2-1508
AZ-1508
Microtubule (MT)
Cysteine D2
[136]
HER2 ADC-18
Monomethyl auristatin E
Microtubule (MT)
Vinylsulfonamide based linker 15
[137]
HER2 ADC-19
Monomethyl auristatin E
Microtubule (MT)
Vinylsulfonamide based linker 16
[137]
HER2 ADC-20
Monomethyl auristatin E
Microtubule (MT)
Vinylsulfonamide based linker 17
[137]
T-DM1-IR700
Mertansine DM1 plus IRDye700DX
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[138]
HER2-gsADC-46
Monomethyl auristatin E
Microtubule (MT)
ThioPz linker 6a
[27]
HER2-gsADC-47
Monomethyl auristatin E
Microtubule (MT)
Hydroxylamine derivative 6c
[27]
HER2-gsADC-48
Monomethyl auristatin E
Microtubule (MT)
2-Aminobenzamide oxime
[27]
HER2-gsADC-49
Monomethyl auristatin E
Microtubule (MT)
Azadibenzocylooctyne-amine derivative 6d
[27]
HER2-gsADC-50
Monomethyl auristatin E
Microtubule (MT)
2-Aminobenzamidoxime without core-fucosylation
[27]
T-DM1-2.6
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[27]
Trastuzumab-amanitin 1
Beta-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-Amanitin1 linker
[139]
Trastuzumab-alpha-amanitin conjugate 3
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-alpha-amanitin conjugate 3 linker
[139]
Trastuzumab-alpha-amanitin conjugate 4
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-alpha-amanitin conjugate 4 linker
[139]
Trastuzumab-alpha-amanitin conjugate 7
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-alpha-amanitin conjugate 7 linker
[139]
Trastuzumab-alpha-amanitin conjugate 10
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-alpha-amanitin conjugate 10 linker
[139]
Trastuzumab-alpha-amanitin conjugate 11
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-alpha-amanitin conjugate 11 linker
[139]
Trastuzumab-alpha-amanitin conjugate 14
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-alpha-amanitin conjugate 14 linker
[139]
Trastuzumab-alpha-amanitin conjugate 15
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-alpha-amanitin conjugate 15 linker
[139]
Trastuzumab-amanitin 3
Beta-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-Amanitin3 linker
[139]
Trastuzumab-amanitin 4
Beta-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Trastuzumab-Amanitin4 linker
[139]
Her-30.0643
HDP 30.0643
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Her-30.0643 linker
[140]
Her-30.1033
HDP 30.1033
Undisclosed
Her-30.1033 linker
[140]
Her-30.1036
HDP 30.1036
Undisclosed
Her-30.1036 linker
[140]
Her-30.1165
HDP 30.1165
Undisclosed
Her-30.1165 linker
[140]
Her-30.0132
HDP 30.0132
Undisclosed
Her-30.0132 linker
[140]
Her-30.0134
HDP 30.0134
Undisclosed
Her-30.0134 linker
[140]
Her-30.0741
HDP 30.0741
Undisclosed
Her-30.0741 linker
[140]
Her-30.0743
HDP 30.0743
Undisclosed
Her-30.0743 linker
[140]
Trastuzumab-E-13
Trastuzumab-E-13 payload
Undisclosed
Trastuzumab-E-13 linker
[141]
Trastuzumab-G-13
Trastuzumab-G-13 payload
Undisclosed
Trastuzumab-G-13 linker
[141]
Trastuzumab-E-11
Trastuzumab-E-11 payload
Undisclosed
Trastuzumab-E-11 linker
[141]
Trastuzumab-E-12
Trastuzumab-E-12 payload
Undisclosed
Trastuzumab-E-12 payload
[141]
Trastuzumab-G-12
Trastuzumab-G-12 payload
Undisclosed
Trastuzumab-G-12E-11
[141]
Trastuzumab-F-13
Trastuzumab-F-13 payload
Undisclosed
Trastuzumab-F-13E-12
[141]
Trastuzumab-E-15
Trastuzumab-E-15 payload
Undisclosed
Trastuzumab-E-15G-12
[141]
Trastuzumab-G-15
Trastuzumab-G-15 payload
Undisclosed
Trastuzumab-G-15F-13
[141]
Trastuzumab-F-61
Trastuzumab-F-61 payload
Undisclosed
Trastuzumab-F-61E-15
[141]
Trastuzumab-F-62
Trastuzumab-F-62 payload
Undisclosed
Trastuzumab-F-62G-15
[141]
Trastuzumab-F-63
Trastuzumab-F-63 payload
Undisclosed
Trastuzumab-F-63F-61
[141]
WO2017089890A1 ADC1
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC1 linker
[142]
WO2017089890A1 ADC2
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC2 linker
[142]
WO2017089890A1 ADC3
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC3 linker
[142]
WO2017089890A1 ADC4
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC4 linker
[142]
WO2017089890A1 ADC5
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC5 linker
[142]
WO2017089890A1 ADC6
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC6 linker
[142]
WO2017089890A1 ADC7
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC7 linker
[142]
WO2017089890A1 ADC8
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC8 linker
[142]
WO2017089890A1 ADC9
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC9 linker
[142]
WO2017089890A1 ADC10
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC10 linker
[142]
WO2017089890A1 ADC11
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC11 linker
[142]
WO2017089890A1 ADC12
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC12 linker
[142]
WO2017089890A1 ADC13
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC13 linker
[142]
WO2017089890A1 ADC14
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC14 linker
[142]
WO2017089890A1 ADC15
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC15 linker
[142]
WO2017089890A1 ADC16
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC16 linker
[142]
WO2017089890A1 ADC17
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC17 linker
[142]
WO2017089890A1 ADC18
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC18 linker
[142]
WO2017089890A1 ADC19
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC19 linker
[142]
WO2017089890A1 ADC20
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC20 linker
[142]
WO2017089890A1 ADC86
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC86 linker
[142]
WO2017089890A1 ADC87
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC87 linker
[142]
WO2017089890A1 ADC23
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC23 linker
[142]
WO2017089890A1 ADC24
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC24 linker
[142]
WO2017089890A1 ADC25
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC25 linker
[142]
WO2017089890A1 ADC26
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC26 linker
[142]
WO2017089890A1 ADC27
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC27 linker
[142]
WO2017089890A1 ADC28
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC28 linker
[142]
WO2017089890A1 ADC29
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC29 linker
[142]
WO2017089890A1 ADC30
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC30 linker
[142]
WO2017089890A1 ADC31
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC31 linker
[142]
WO2017089890A1 ADC32
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC32 linker
[142]
WO2017089890A1 ADC33
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC33 linker
[142]
WO2017089890A1 ADC34
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC34 linker
[142]
WO2017089890A1 ADC35
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC35 linker
[142]
WO2017089890A1 ADC36
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC36 linker
[142]
WO2017089890A1 ADC37
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC37 linker
[142]
WO2017089890A1 ADC38
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC38 linker
[142]
WO2017089890A1 ADC39
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC39 linker
[142]
WO2017089890A1 ADC40
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC40 linker
[142]
WO2017089890A1 ADC41
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC41 linker
[142]
WO2017089890A1 ADC42
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC42 linker
[142]
WO2017089890A1 ADC43
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC43 linker
[142]
WO2017089890A1 ADC44
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC44 linker
[142]
WO2017089890A1 ADC45
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC45 linker
[142]
WO2017089890A1 ADC46
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC46 linker
[142]
WO2017089890A1 ADC47
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC47 linker
[142]
WO2017089890A1 ADC48
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC48 linker
[142]
WO2017089890A1 ADC49
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC49 linker
[142]
WO2017089890A1 ADC50
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC50 linker
[142]
WO2017089890A1 ADC51
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC51 linker
[142]
WO2017089890A1 ADC52
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC52 linker
[142]
WO2017089890A1 ADC53
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC53 linker
[142]
WO2017089890A1 ADC54
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC54 linker
[142]
WO2017089890A1 ADC55
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC55 linker
[142]
WO2017089890A1 ADC76
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC76 linker
[142]
WO2017089890A1 ADC88
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC88 linker
[142]
WO2017089890A1 ADC89
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC89 linker
[142]
WO2017089890A1 ADC90
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC90 linker
[142]
WO2017089890A1 ADC91
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC91 linker
[142]
WO2017089890A1 ADC60
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC60 linker
[142]
WO2017089890A1 ADC61
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC61 linker
[142]
WO2017089890A1 ADC62
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC62 linker
[142]
WO2017089890A1 ADC63
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC63 linker
[142]
WO2017089890A1 ADC77
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC77 linker
[142]
WO2017089890A1 ADC21
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
WO2017089890A1_ADC21 linker
[142]
WO2017089890A1 ADC22
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
WO2017089890A1_ADC22 linker
[142]
WO2017089890A1 ADC56
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
WO2017089890A1_ADC56 linker
[142]
WO2017089890A1 ADC57
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
WO2017089890A1_ADC57 linker
[142]
WO2017089890A1 ADC58
Alpha-amanitin+Monomethyl auristatin E
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G); Microtubule (MT)
WO2017089890A1_ADC58 linker
[142]
WO2017089890A1 ADC59
Alpha-amanitin+Monomethyl auristatin E
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G); Microtubule (MT)
WO2017089890A1_ADC59 linker
[142]
WO2017089890A1 ADC78
Alpha-amanitin+Monomethyl auristatin E
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G); Microtubule (MT)
WO2017089890A1_ADC78 linker
[142]
WO2018098269A2 conjugate 25
WO2018098269A2_conjugate 25 payload
Undisclosed
WO2018098269A2_conjugate 25 linker
[143]
WO2018098269A2 conjugate 28
WO2018098269A2_conjugate 28 payload
Undisclosed
WO2018098269A2_conjugate 28 linker
[143]
WO2018098269A2 conjugate 31A
WO2018098269A2_conjugate 31A payload
Undisclosed
WO2018098269A2_conjugate 31A linker
[143]
WO2018098269A2 conjugate 34A
WO2018098269A2_conjugate 34A payload
Undisclosed
WO2018098269A2_conjugate 34A linker
[143]
WO2018098269A2 conjugate 43A
WO2018098269A2_conjugate 43A payload
Undisclosed
WO2018098269A2_conjugate 43A linker
[143]
WO2018098269A2 conjugate 46A
WO2018098269A2_conjugate 46A payload
Undisclosed
WO2018098269A2_conjugate 46A linker
[143]
WO2018098269A2 conjugate 48
WO2018098269A2_conjugate 48 payload
Undisclosed
WO2018098269A2_conjugate 48 linker
[143]
WO2018098269A2 conjugate 50
WO2018098269A2_conjugate 50 payload
Undisclosed
WO2018098269A2_conjugate 50 linker
[143]
WO2018098269A2 conjugate 52
WO2018098269A2_conjugate 52 payload
Undisclosed
WO2018098269A2_conjugate 52 linker
[143]
WO2018098269A2 conjugate 67
WO2018098269A2_conjugate 67 payload
Undisclosed
WO2018098269A2_conjugate 67 linker
[143]
WO2018098269A2 conjugate 68
WO2018098269A2_conjugate 68 payload
Undisclosed
WO2018098269A2_conjugate 68 linker
[143]
WO2018098269A2 conjugate 46B
WO2018098269A2_conjugate 46B payload
Undisclosed
WO2018098269A2_conjugate 46B linker
[143]
WO2018098269A2 conjugate 43B
WO2018098269A2_conjugate 43B payload
Undisclosed
WO2018098269A2_conjugate 43B linker
[143]
WO2018098269A2 conjugate 34B
WO2018098269A2_conjugate 34B payload
Undisclosed
WO2018098269A2_conjugate 34B linker
[143]
WO2018098269A2 conjugate 31B
WO2018098269A2_conjugate 31B payload
Undisclosed
WO2018098269A2_conjugate 31B linker
[143]
WO2015004400A1 ADC-1
WO2015004400A1 ADC-1 payload
Undisclosed
WO2015004400A1 ADC-1 linker
[144]
WO2015004400A1 ADC-2
WO2015004400A1 ADC-2 payload
Undisclosed
WO2015004400A1 ADC-2 linker
[144]
WO2015004400A1 ADC-3
WO2015004400A1 ADC-3 payload
Undisclosed
WO2015004400A1 ADC-3 linker
[144]
WO2015004400A1 ADC-4
WO2015004400A1 ADC-4 payload
Undisclosed
WO2015004400A1 ADC-4 linker
[144]
WO2015004400A1 ADC-5
WO2015004400A1 ADC-5 payload
Undisclosed
WO2015004400A1 ADC-5 linker
[144]
WO2015004400A1 ADC-6
WO2015004400A1 ADC-6 payload
Undisclosed
WO2015004400A1 ADC-6 linker
[144]
WO2015004400A1 ADC-7
WO2015004400A1 ADC-7 payload
Undisclosed
WO2015004400A1 ADC-7 linker
[144]
WO2015004400A1 ADC-8
WO2015004400A1 ADC-8 payload
Undisclosed
WO2015004400A1 ADC-8 linker
[144]
Trastuzumab-Compound 9
Mertansine DM1
Microtubule (MT)
Trastuzumab-Compound 9 linker
[15]
Trastuzumab-Compound 17
Mertansine DM4
Microtubule (MT)
Trastuzumab-Compound 17 linker
[15]
Trastuzumab-Compound 25
Monomethyl auristatin E
Microtubule (MT)
Trastuzumab-Compound 25 linker
[15]
Trastuzumab-Compound 31
Auristatin 0101
Microtubule (MT)
Trastuzumab-Compound 31 linker
[15]
Trastuzumab-Compound 36
Monomethyl auristatin E
Microtubule (MT)
Trastuzumab-Compound 36 linker
[15]
Trastuzumab-Compound 43
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Trastuzumab-Compound 43 linker
[15]
Trastuzumab-Compound 49
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Trastuzumab-Compound 49 linker
[15]
Trastuzumab-Compound 55
Mertansine DM1
Microtubule (MT)
Trastuzumab-Compound 55 linker
[15]
Trastuzumab-Compound 59
Mertansine DM4
Microtubule (MT)
Trastuzumab-Compound 59 linker
[15]
Trastuzumab-Compound 64
Monomethyl auristatin E
Microtubule (MT)
Trastuzumab-Compound 64 linker
[15]
Trastuzumab-Compound 69
Monomethyl auristatin E
Microtubule (MT)
Trastuzumab-Compound 69 linker
[15]
Trastuzumab-Compound 74
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Trastuzumab-Compound 74 linker
[15]
Trastuzumab-Compound 75
Monomethyl auristatin E
Microtubule (MT)
Trastuzumab-Compound 75 linker
[15]
Trastuzumab-Compound 76
Monomethyl auristatin E
Microtubule (MT)
Trastuzumab-Compound 76 linker
[15]
Trastuzumab-Compound 77
Mertansine DM1
Microtubule (MT)
Trastuzumab-Compound 77 linker
[15]
Trastuzumab-Compound 78
Auristatin 0101
Microtubule (MT)
Trastuzumab-Compound 78 linker
[15]
Trastuzumab-Compound 79
Auristatin 0101
Microtubule (MT)
Trastuzumab-Compound 79 linker
[15]
Trastuzumab-Compound 80
Mertansine DM4
Microtubule (MT)
Trastuzumab-Compound 80 linker
[15]
CN114917361A ADC-2
CN114917361A ADC-2 payload
Undisclosed
CN114917361A ADC-2 linker
[145]
CN114917361A ADC-7
CN114917361A ADC-7 payload
Undisclosed
CN114917361A ADC-7 linker
[145]
CN114917361A ADC-14
CN114917361A ADC-14 payload
Undisclosed
CN114917361A ADC-14 linker
[145]
CN114917361A ADC-17
CN114917361A ADC-17 payload
Undisclosed
CN114917361A ADC-17 linker
[145]
CN114917361A ADC-22
CN114917361A ADC-22 payload
Undisclosed
CN114917361A ADC-22 linker
[145]
CN114917361A ADC-28
CN114917361A ADC-28 payload
Undisclosed
CN114917361A ADC-28 linker
[145]
CN114917361A ADC-31
CN114917361A ADC-31 payload
Undisclosed
CN114917361A ADC-31 linker
[145]
CN114917361A ADC-34
CN114917361A ADC-34 payload
Undisclosed
CN114917361A ADC-34 linker
[145]
CN114917361A ADC-37
CN114917361A ADC-37 payload
Undisclosed
CN114917361A ADC-37 linker
[145]
CN114917361A ADC-42
CN114917361A ADC-42 payload
Undisclosed
CN114917361A ADC-42 linker
[145]
CN114917361A ADC-45
CN114917361A ADC-45 payload
Undisclosed
CN114917361A ADC-45 linker
[145]
CN114917361A ADC-48
CN114917361A ADC-48 payload
Undisclosed
CN114917361A ADC-48 linker
[145]
CN114917361A ADC-51
CN114917361A ADC-51 payload
Undisclosed
CN114917361A ADC-51 linker
[145]
CN114917361A ADC-56
CN114917361A ADC-56 payload
Undisclosed
CN114917361A ADC-56 linker
[145]
CN114917361A ADC-59
CN114917361A ADC-59 payload
Undisclosed
CN114917361A ADC-59 linker
[145]
CN114917361A ADC-62
CN114917361A ADC-62 payload
Undisclosed
CN114917361A ADC-62 linker
[145]
CN114917361A ADC-65
CN114917361A ADC-65 payload
Undisclosed
CN114917361A ADC-65 linker
[145]
CN114917361A ADC-68
CN114917361A ADC-68 payload
Undisclosed
CN114917361A ADC-68 linker
[145]
CN114917361A ADC-71
CN114917361A ADC-71 payload
Undisclosed
CN114917361A ADC-71 linker
[145]
CN114917361A ADC-74
CN114917361A ADC-74 payload
Undisclosed
CN114917361A ADC-74 linker
[145]
CN114917361A ADC-77
CN114917361A ADC-77 payload
Undisclosed
CN114917361A ADC-77 linker
[145]
CN114917361A ADC-80
CN114917361A ADC-80 payload
Undisclosed
CN114917361A ADC-80 linker
[145]
CN114917361A ADC-83
CN114917361A ADC-83 payload
Undisclosed
CN114917361A ADC-83 linker
[145]
CN109641910A ADC-1
CN109641910A ADC-1 payload
Undisclosed
CN109641910A ADC-1 linker
[146]
CN109641910A ADC-2
CN109641910A ADC-2 payload
Undisclosed
CN109641910A ADC-2 linker
[146]
CN109641910A ADC-3
CN109641910A ADC-3 payload
Undisclosed
CN109641910A ADC-3 linker
[146]
CN109641910A ADC-4
CN109641910A ADC-4 payload
Undisclosed
CN109641910A ADC-4 linker
[146]
CN109641910A ADC-5
CN109641910A ADC-5 payload
Undisclosed
CN109641910A ADC-5 linker
[146]
CN109641910A ADC-6
CN109641910A ADC-6 payload
Undisclosed
CN109641910A ADC-6 linker
[146]
CN109641910A ADC-7
CN109641910A ADC-7 payload
Undisclosed
CN109641910A ADC-7 linker
[146]
CN109641910A ADC-8
CN109641910A ADC-8 payload
Undisclosed
CN109641910A ADC-8 linker
[146]
CN109641910A ADC-9
CN109641910A ADC-9 payload
Undisclosed
CN109641910A ADC-9 linker
[146]
CN109641910A ADC-10
CN109641910A ADC-10 payload
Undisclosed
CN109641910A ADC-10 linker
[146]
CN109641910A ADC-11
CN109641910A ADC-11 payload
Undisclosed
CN109641910A ADC-11 linker
[146]
CN109641910A ADC-12
CN109641910A ADC-12 payload
Undisclosed
CN109641910A ADC-12 linker
[146]
CN109641910A ADC-13
CN109641910A ADC-13 payload
Undisclosed
CN109641910A ADC-13 linker
[146]
CN109641910A ADC-14
CN109641910A ADC-14 payload
Undisclosed
CN109641910A ADC-14 linker
[146]
CN109641910A ADC-15
CN109641910A ADC-15 payload
Undisclosed
CN109641910A ADC-15 linker
[146]
CN109641910A ADC-16
CN109641910A ADC-16 payload
Undisclosed
CN109641910A ADC-16 linker
[146]
CN105051032B ADC-I-5
CN105051032B_ADC-I-5 payload
Undisclosed
CN105051032B_ADC-I-5 linker
[147]
CN105051032B ADC-I-6
CN105051032B_ADC-I-6 payload
Undisclosed
CN105051032B_ADC-I-6 linker
[147]
CN105051032B ADC-I-7
CN105051032B_ADC-I-7 payload
Undisclosed
CN105051032B_ADC-I-7 linker
[147]
CN105051032B ADC-I-8
CN105051032B_ADC-I-8 payload
Undisclosed
CN105051032B_ADC-I-8 linker
[147]
CN105051032B ADC-I-9
CN105051032B_ADC-I-9 payload
Undisclosed
CN105051032B_ADC-I-9 linker
[147]
CN105051032B ADC-I-10
CN105051032B_ADC-I-10 payload
Undisclosed
CN105051032B_ADC-I-10 linker
[147]
CN105051032B ADC-I-11
CN105051032B_ADC-I-11 payload
Undisclosed
CN105051032B_ADC-I-11 linker
[147]
CN105051032B ADC-I-12
CN105051032B_ADC-I-12 payload
Undisclosed
CN105051032B_ADC-I-12 linker
[147]
CN105051032B ADC-I-13
CN105051032B_ADC-I-13 payload
Undisclosed
CN105051032B_ADC-I-13 linker
[147]
CN105051032B ADC-I-14
CN105051032B_ADC-I-14 payload
Undisclosed
CN105051032B_ADC-I-14 linker
[147]
CN105051032B ADC-I-15
CN105051032B_ADC-I-15 payload
Undisclosed
CN105051032B_ADC-I-15 linker
[147]
CN105051032B ADC-I-16
CN105051032B_ADC-I-16 payload
Undisclosed
CN105051032B_ADC-I-16 linker
[147]
CN105051032B ADC-I-17
CN105051032B_ADC-I-17 payload
Undisclosed
CN105051032B_ADC-I-17 linker
[147]
CN105051032B ADC-I-18
CN105051032B_ADC-I-18 payload
Undisclosed
CN105051032B_ADC-I-18 linker
[147]
CN105051032B ADC-I-19
CN105051032B_ADC-I-19 payload
Undisclosed
CN105051032B_ADC-I-19 linker
[147]
CN105051032B ADC-I-20
CN105051032B_ADC-I-20 payload
Undisclosed
CN105051032B_ADC-I-20 linker
[147]
CN105051032B ADC-I-21
CN105051032B_ADC-I-21 payload
Undisclosed
CN105051032B_ADC-I-21 linker
[147]
CN105051032B ADC-I-22
CN105051032B_ADC-I-22 payload
Undisclosed
CN105051032B_ADC-I-22 linker
[147]
CN105051032B ADC-I-23
CN105051032B_ADC-I-23 payload
Undisclosed
CN105051032B_ADC-I-23 linker
[147]
CN105051032B ADC-I-24
CN105051032B_ADC-I-24 payload
Undisclosed
CN105051032B_ADC-I-24 linker
[147]
CN105051032B ADC-I-25
CN105051032B_ADC-I-25 payload
Undisclosed
CN105051032B_ADC-I-25 linker
[147]
CN105051032B ADC-I-26
CN105051032B_ADC-I-26 payload
Undisclosed
CN105051032B_ADC-I-26 linker
[147]
CN105051032B ADC-I-27
CN105051032B_ADC-I-27 payload
Undisclosed
CN105051032B_ADC-I-27 linker
[147]
CN105051032B ADC-I-28
CN105051032B_ADC-I-28 payload
Undisclosed
CN105051032B_ADC-I-28 linker
[147]
CN105051032B ADC-I-29
CN105051032B_ADC-I-29 payload
Undisclosed
CN105051032B_ADC-I-29 linker
[147]
CN105051032B ADC-I-30
CN105051032B_ADC-I-30 payload
Undisclosed
CN105051032B_ADC-I-30 linker
[147]
CN105051032B ADC-I-31
CN105051032B_ADC-I-31 payload
Undisclosed
CN105051032B_ADC-I-31 linker
[147]
CN105051032B ADC-I-32
CN105051032B_ADC-I-32 payload
Undisclosed
CN105051032B_ADC-I-32 linker
[147]
CN105051032B ADC-I-33
CN105051032B_ADC-I-33 payload
Undisclosed
CN105051032B_ADC-I-33 linker
[147]
CN105051032B ADC-I-34
CN105051032B_ADC-I-34 payload
Undisclosed
CN105051032B_ADC-I-34 linker
[147]
CN105051032B ADC-I-35
CN105051032B_ADC-I-35 payload
Undisclosed
CN105051032B_ADC-I-35 linker
[147]
CN105051032B ADC-I-36
CN105051032B_ADC-I-36 payload
Undisclosed
CN105051032B_ADC-I-36 linker
[147]
CN105051032B ADC-I-37
CN105051032B_ADC-I-37 payload
Undisclosed
CN105051032B_ADC-I-37 linker
[147]
CN105051032B ADC-I-38
CN105051032B_ADC-I-38 payload
Undisclosed
CN105051032B_ADC-I-38 linker
[147]
CN105051032B ADC-I-39
CN105051032B_ADC-I-39 payload
Undisclosed
CN105051032B_ADC-I-39 linker
[147]
CN105051032B ADC-I-40
CN105051032B_ADC-I-40 payload
Undisclosed
CN105051032B_ADC-I-40 linker
[147]
CN105051032B ADC-I-41
CN105051032B_ADC-I-41 payload
Undisclosed
CN105051032B_ADC-I-41 linker
[147]
WO2014068443A1 ADC1
WO2014068443A1_ADC1 payload
Undisclosed
WO2014068443A1_ADC1 linker
[148]
WO2014068443A1 ADC2
WO2014068443A1_ADC2 payload
Undisclosed
WO2014068443A1_ADC2 linker
[148]
WO2014068443A1 ADC3
WO2014068443A1_ADC3 payload
Undisclosed
WO2014068443A1_ADC3 linker
[148]
WO2014068443A1 ADC4
WO2014068443A1_ADC4 payload
Undisclosed
WO2014068443A1_ADC4 linker
[148]
WO2014068443A1 ADC5
WO2014068443A1_ADC5 payload
Undisclosed
WO2014068443A1_ADC5 linker
[148]
WO2014068443A1 ADC6
WO2014068443A1_ADC6 payload
Undisclosed
WO2014068443A1_ADC6 linker
[148]
WO2014068443A1 ADC7
WO2014068443A1_ADC7 payload
Undisclosed
WO2014068443A1_ADC7 linker
[148]
WO2014068443A1 ADC8
WO2014068443A1_ADC8 payload
Undisclosed
WO2014068443A1_ADC8 linker
[148]
WO2014068443A1 ADC9
WO2014068443A1_ADC9 payload
Undisclosed
WO2014068443A1_ADC9 linker
[148]
WO2014068443A1 ADC10
WO2014068443A1_ADC10 payload
Undisclosed
WO2014068443A1_ADC10 linker
[148]
WO2014068443A1 ADC11
WO2014068443A1_ADC11 payload
Undisclosed
WO2014068443A1_ADC11 linker
[148]
WO2014068443A1 ADC12
WO2014068443A1_ADC12 payload
Undisclosed
WO2014068443A1_ADC12 linker
[148]
WO2014068443A1 ADC13
WO2014068443A1_ADC13 payload
Undisclosed
WO2014068443A1_ADC13 linker
[148]
WO2014068443A1 ADC14
WO2014068443A1_ADC14 payload
Undisclosed
WO2014068443A1_ADC14 linker
[148]
WO2014068443A1 ADC15
WO2014068443A1_ADC15 payload
Undisclosed
WO2014068443A1_ADC15 linker
[148]
WO2014068443A1 ADC16
WO2014068443A1_ADC16 payload
Undisclosed
WO2014068443A1_ADC16 linker
[148]
WO2014068443A1 ADC17
WO2014068443A1_ADC17 payload
Undisclosed
WO2014068443A1_ADC17 linker
[148]
WO2014068443A1 ADC18
WO2014068443A1_ADC18 payload
Undisclosed
WO2014068443A1_ADC18 linker
[148]
WO2014068443A1 ADC19
WO2014068443A1_ADC19 payload
Undisclosed
WO2014068443A1_ADC19 linker
[148]
WO2014068443A1 ADC20
WO2014068443A1_ADC20 payload
Undisclosed
WO2014068443A1_ADC20 linker
[148]
WO2014068443A1 ADC21
WO2014068443A1_ADC21 payload
Undisclosed
WO2014068443A1_ADC21 linker
[148]
WO2014068443A1 ADC22
WO2014068443A1_ADC22 payload
Undisclosed
WO2014068443A1_ADC22 linker
[148]
WO2014068443A1 ADC23
WO2014068443A1_ADC23 payload
Undisclosed
WO2014068443A1_ADC23 linker
[148]
WO2014068443A1 ADC24
WO2014068443A1_ADC24 payload
Undisclosed
WO2014068443A1_ADC24 linker
[148]
WO2014068443A1 ADC25
WO2014068443A1_ADC25 payload
Undisclosed
WO2014068443A1_ADC25 linker
[148]
WO2014068443A1 ADC26
WO2014068443A1_ADC26 payload
Undisclosed
WO2014068443A1_ADC26 linker
[148]
WO2014068443A1 ADC27
WO2014068443A1_ADC27 payload
Undisclosed
WO2014068443A1_ADC27 linker
[148]
WO2014068443A1 ADC28
WO2014068443A1_ADC28 payload
Undisclosed
WO2014068443A1_ADC28 linker
[148]
WO2014068443A1 ADC29
WO2014068443A1_ADC29 payload
Undisclosed
WO2014068443A1_ADC29 linker
[148]
WO2014068443A1 ADC30
WO2014068443A1_ADC30 payload
Undisclosed
WO2014068443A1_ADC30 linker
[148]
WO2014068443A1 ADC31
WO2014068443A1_ADC31 payload
Undisclosed
WO2014068443A1_ADC31 linker
[148]
WO2014068443A1 ADC32
WO2014068443A1_ADC32 payload
Undisclosed
WO2014068443A1_ADC32 linker
[148]
WO2014068443A1 ADC33
WO2014068443A1_ADC33 payload
Undisclosed
WO2014068443A1_ADC33 linker
[148]
WO2014068443A1 ADC34
WO2014068443A1_ADC34 payload
Undisclosed
WO2014068443A1_ADC34 linker
[148]
WO2014068443A1 ADC35
WO2014068443A1_ADC35 payload
Undisclosed
WO2014068443A1_ADC35 linker
[148]
WO2014068443A1 ADC36
WO2014068443A1_ADC36 payload
Undisclosed
WO2014068443A1_ADC36 linker
[148]
WO2014068443A1 ADC37
WO2014068443A1_ADC37 payload
Undisclosed
WO2014068443A1_ADC37 linker
[148]
WO2014068443A1 ADC38
WO2014068443A1_ADC38 payload
Undisclosed
WO2014068443A1_ADC38 linker
[148]
WO2014068443A1 ADC39
WO2014068443A1_ADC39 payload
Undisclosed
WO2014068443A1_ADC39 linker
[148]
WO2014068443A1 ADC40
WO2014068443A1_ADC40 payload
Undisclosed
WO2014068443A1_ADC40 linker
[148]
WO2014068443A1 ADC41
WO2014068443A1_ADC41 payload
Undisclosed
WO2014068443A1_ADC41 linker
[148]
WO2014068443A1 ADC42
WO2014068443A1_ADC42 payload
Undisclosed
WO2014068443A1_ADC42 linker
[148]
WO2014068443A1 ADC43
WO2014068443A1_ADC43 payload
Undisclosed
WO2014068443A1_ADC43 linker
[148]
WO2014068443A1 ADC44
WO2014068443A1_ADC44 payload
Undisclosed
WO2014068443A1_ADC44 linker
[148]
WO2014068443A1 ADC45
WO2014068443A1_ADC45 payload
Undisclosed
WO2014068443A1_ADC45 linker
[148]
WO2014068443A1 ADC46
WO2014068443A1_ADC46 payload
Undisclosed
WO2014068443A1_ADC46 linker
[148]
WO2014068443A1 ADC47
WO2014068443A1_ADC47 payload
Undisclosed
WO2014068443A1_ADC47 linker
[148]
WO2014068443A1 ADC48
WO2014068443A1_ADC48 payload
Undisclosed
WO2014068443A1_ADC48 linker
[148]
WO2014068443A1 ADC49
WO2014068443A1_ADC49 payload
Undisclosed
WO2014068443A1_ADC49 linker
[148]
WO2014068443A1 ADC50
WO2014068443A1_ADC50 payload
Undisclosed
WO2014068443A1_ADC50 linker
[148]
WO2014068443A1 ADC51
WO2014068443A1_ADC51 payload
Undisclosed
WO2014068443A1_ADC51 linker
[148]
WO2014068443A1 ADC52
WO2014068443A1_ADC52 payload
Undisclosed
WO2014068443A1_ADC52 linker
[148]
WO2014068443A1 ADC53
WO2014068443A1_ADC53 payload
Undisclosed
WO2014068443A1_ADC53 linker
[148]
WO2014068443A1 ADC54
WO2014068443A1_ADC54 payload
Undisclosed
WO2014068443A1_ADC54 linker
[148]
WO2014068443A1 ADC55
WO2014068443A1_ADC55 payload
Undisclosed
WO2014068443A1_ADC55 linker
[148]
WO2014068443A1 ADC56
WO2014068443A1_ADC56 payload
Undisclosed
WO2014068443A1_ADC56 linker
[148]
WO2014068443A1 ADC57
WO2014068443A1_ADC57 payload
Undisclosed
WO2014068443A1_ADC57 linker
[148]
WO2014068443A1 ADC58
WO2014068443A1_ADC58 payload
Undisclosed
WO2014068443A1_ADC58 linker
[148]
WO2014068443A1 ADC59
WO2014068443A1_ADC59 payload
Undisclosed
WO2014068443A1_ADC59 linker
[148]
WO2014068443A1 ADC60
WO2014068443A1_ADC60 payload
Undisclosed
WO2014068443A1_ADC60 linker
[148]
WO2014068443A1 ADC61
WO2014068443A1_ADC61 payload
Undisclosed
WO2014068443A1_ADC61 linker
[148]
WO2014068443A1 ADC62
WO2014068443A1_ADC62 payload
Undisclosed
WO2014068443A1_ADC62 linker
[148]
WO2014068443A1 ADC63
WO2014068443A1_ADC63 payload
Undisclosed
WO2014068443A1_ADC63 linker
[148]
WO2014068443A1 ADC64
WO2014068443A1_ADC64 payload
Undisclosed
WO2014068443A1_ADC64 linker
[148]
WO2014068443A1 ADC65
WO2014068443A1_ADC65 payload
Undisclosed
WO2014068443A1_ADC65 linker
[148]
WO2014068443A1 ADC66
WO2014068443A1_ADC66 payload
Undisclosed
WO2014068443A1_ADC66 linker
[148]
WO2014068443A1 ADC67
WO2014068443A1_ADC67 payload
Undisclosed
WO2014068443A1_ADC67 linker
[148]
WO2014068443A1 ADC68
WO2014068443A1_ADC68 payload
Undisclosed
WO2014068443A1_ADC68 linker
[148]
WO2014068443A1 ADC69
WO2014068443A1_ADC69 payload
Undisclosed
WO2014068443A1_ADC69 linker
[148]
WO2014068443A1 ADC70
WO2014068443A1_ADC70 payload
Undisclosed
WO2014068443A1_ADC70 linker
[148]
WO2014068443A1 ADC71
WO2014068443A1_ADC71 payload
Undisclosed
WO2014068443A1_ADC71 linker
[148]
WO2014068443A1 ADC72
WO2014068443A1_ADC72 payload
Undisclosed
WO2014068443A1_ADC72 linker
[148]
WO2014068443A1 ADC73
WO2014068443A1_ADC73 payload
Undisclosed
WO2014068443A1_ADC73 linker
[148]
WO2014068443A1 ADC74
WO2014068443A1_ADC74 payload
Undisclosed
WO2014068443A1_ADC74 linker
[148]
WO2014068443A1 ADC75
WO2014068443A1_ADC75 payload
Undisclosed
WO2014068443A1_ADC75 linker
[148]
WO2014068443A1 ADC76
WO2014068443A1_ADC76 payload
Undisclosed
WO2014068443A1_ADC76 linker
[148]
WO2014068443A1 ADC77
WO2014068443A1_ADC77 payload
Undisclosed
WO2014068443A1_ADC77 linker
[148]
WO2014068443A1 ADC78
WO2014068443A1_ADC78 payload
Undisclosed
WO2014068443A1_ADC78 linker
[148]
WO2014068443A1 ADC79
WO2014068443A1_ADC79 payload
Undisclosed
WO2014068443A1_ADC79 linker
[148]
WO2014068443A1 ADC80
WO2014068443A1_ADC80 payload
Undisclosed
WO2014068443A1_ADC80 linker
[148]
WO2014068443A1 ADC81
WO2014068443A1_ADC81 payload
Undisclosed
WO2014068443A1_ADC81 linker
[148]
WO2014068443A1 ADC82
WO2014068443A1_ADC82 payload
Undisclosed
WO2014068443A1_ADC82 linker
[148]
WO2014068443A1 ADC83
WO2014068443A1_ADC83 payload
Undisclosed
WO2014068443A1_ADC83 linker
[148]
WO2014068443A1 ADC84
WO2014068443A1_ADC84 payload
Undisclosed
WO2014068443A1_ADC84 linker
[148]
TAA-013
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[149]
ADCT-502
SG3199
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[150]
Trastuzumab-dTSPEG-MMAF
Monomethyl auristatin F
Microtubule (MT)
dTSPEG
[151]
Trastuzumab A114C
ADC Info ADC Name Payload Target Linker Ref
Neolymphostin ADC 21
Neolymphostin A
3-Phosphoinositide-dependent protein kinase 1 (PDPK1)
Mc-Val-Cit-PABC-DMEA
[152]
Neolymphostin ADC 22
Neolymphostin A
3-Phosphoinositide-dependent protein kinase 1 (PDPK1)
PEG4-DMEA
[152]
Neolymphostin ADC 23
Neolymphostin A
3-Phosphoinositide-dependent protein kinase 1 (PDPK1)
Mc-Val-Cit-PABC
[152]
Neolymphostin ADC 24
Neolymphostin A
3-Phosphoinositide-dependent protein kinase 1 (PDPK1)
N-Methoxycarbonylmaleimide
[152]
Trastuzumab D265C
ADC Info ADC Name Payload Target Linker Ref
T-D265C-CN-Pro-amanitin
CN-Pro-dideoxy-alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mal-Val-Ala-PAB
[153]
T-D265C-NH2-Pro-amanitin
NH2-Pro-dideoxy-alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mc-Val-Ala-PABC
[153]
T-D265C-OH-Pro-amanitin
OH-Pro-dideoxy-alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Mc-Val-Ala-PABC
[153]
Trastuzumab I253Q
ADC Info ADC Name Payload Target Linker Ref
Trastuzumab I253Q-MMAE
Monomethyl auristatin E
Microtubule (MT)
Dansylcadaverine-BCN based linker
[154]
Trastuzumab deglycosylated WT-MMAE
Monomethyl auristatin E
Microtubule (MT)
Dansylcadaverine deglycosylated-BCN based linker
[154]
Trastuzumab N297A
ADC Info ADC Name Payload Target Linker Ref
ADC MMAE/F 4+2
Monomethyl auristatin E+Monomethyl auristatin F
Microtubule (MT)
DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC
[155]
ADC MMAE/F 2+4
Monomethyl auristatin E+Monomethyl auristatin F
Microtubule (MT)
DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC
[155]
ADC MMAE/F 2+2
Monomethyl auristatin E+Monomethyl auristatin F
Microtubule (MT)
DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC
[155]
Trastuzumab scFv
ADC Info ADC Name Payload Target Linker Ref
scFv(Herceptin)-PE-STXA
PE15-Stx 2a
Eukaryotic elongation factor 2 (EEF2)
Undisclosed
[156]
scFv (Herceptin)-PE
Pseudomonas exotoxin PE38
Eukaryotic elongation factor 2 (EEF2)
Undisclosed
[156]
scFv(trastuzumab)-PE38KDEL
Pseudomonas exotoxin PE38
Eukaryotic elongation factor 2 (EEF2)
Undisclosed
[11]
Trastuzumab-AL1
ADC Info ADC Name Payload Target Linker Ref
IgG1 (trastuzumab)-AL1-MMAE
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
[11]
Trastuzumab-CpHK
ADC Info ADC Name Payload Target Linker Ref
T-CpHK-Tet-ADC
Monomethyl auristatin E
Microtubule (MT)
Tetrazine-PEG5-Val-Ala-PABC
[157]
T-CpHK-Mal-ADC
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[157]
Trastuzumab-Flexmab
ADC Info ADC Name Payload Target Linker Ref
Trastuzumab-Flexmab-SG3710
SG3199
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[84]
WO2015095301A2 ADC-1 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-1
WO2015095301A2 ADC-1 payload
Undisclosed
WO2015095301A2 ADC-1 linker
[6]
WO2015095301A2 ADC-10 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-10
WO2015095301A2 ADC-10 payload
Undisclosed
WO2015095301A2 ADC-10 linker
[6]
WO2015095301A2 ADC-11 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-11
WO2015095301A2 ADC-11 payload
Undisclosed
WO2015095301A2 ADC-11 linker
[6]
WO2015095301A2 ADC-12 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-12
WO2015095301A2 ADC-12 payload
Undisclosed
WO2015095301A2 ADC-12 linker
[6]
WO2015095301A2 ADC-13 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-13
WO2015095301A2 ADC-13 payload
Undisclosed
WO2015095301A2 ADC-13 linker
[6]
WO2015095301A2 ADC-14 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-14
WO2015095301A2 ADC-14 payload
Undisclosed
WO2015095301A2 ADC-14 linker
[6]
WO2015095301A2 ADC-15 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-15
WO2015095301A2 ADC-15 payload
Undisclosed
WO2015095301A2 ADC-15 linker
[6]
WO2015095301A2 ADC-16 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-16
WO2015095301A2 ADC-16 payload
Undisclosed
WO2015095301A2 ADC-16 linker
[6]
WO2015095301A2 ADC-17 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-17
WO2015095301A2 ADC-17 payload
Undisclosed
WO2015095301A2 ADC-17 linker
[6]
WO2015095301A2 ADC-18 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-18
WO2015095301A2 ADC-18 payload
Undisclosed
WO2015095301A2 ADC-18 linker
[6]
WO2015095301A2 ADC-19 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-19
WO2015095301A2 ADC-19 payload
Undisclosed
WO2015095301A2 ADC-19 linker
[6]
WO2015095301A2 ADC-2 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-2
WO2015095301A2 ADC-2 payload
Undisclosed
WO2015095301A2 ADC-2 linker
[6]
WO2015095301A2 ADC-20 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-20
WO2015095301A2 ADC-20 payload
Undisclosed
WO2015095301A2 ADC-20 linker
[6]
WO2015095301A2 ADC-21 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-21
WO2015095301A2 ADC-21 payload
Undisclosed
WO2015095301A2 ADC-21 linker
[6]
WO2015095301A2 ADC-22 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-22
WO2015095301A2 ADC-22 payload
Undisclosed
WO2015095301A2 ADC-22 linker
[6]
WO2015095301A2 ADC-23 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-23
WO2015095301A2 ADC-23 payload
Undisclosed
WO2015095301A2 ADC-23 linker
[6]
WO2015095301A2 ADC-24 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-24
WO2015095301A2 ADC-24 payload
Undisclosed
WO2015095301A2 ADC-24 linker
[6]
WO2015095301A2 ADC-25 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-25
WO2015095301A2 ADC-25 payload
Undisclosed
WO2015095301A2 ADC-25 linker
[6]
WO2015095301A2 ADC-26 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-26
WO2015095301A2 ADC-26 payload
Undisclosed
WO2015095301A2 ADC-26 linker
[6]
WO2015095301A2 ADC-27 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-27
WO2015095301A2 ADC-27 payload
Undisclosed
WO2015095301A2 ADC-27 linker
[6]
WO2015095301A2 ADC-3 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-3
WO2015095301A2 ADC-3 payload
Undisclosed
WO2015095301A2 ADC-3 linker
[6]
WO2015095301A2 ADC-4 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-4
WO2015095301A2 ADC-4 payload
Undisclosed
WO2015095301A2 ADC-4 linker
[6]
WO2015095301A2 ADC-5 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-5
WO2015095301A2 ADC-5 payload
Undisclosed
WO2015095301A2 ADC-5 linker
[6]
WO2015095301A2 ADC-6 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-6
WO2015095301A2 ADC-6 payload
Undisclosed
WO2015095301A2 ADC-6 linker
[6]
WO2015095301A2 ADC-7 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-7
WO2015095301A2 ADC-7 payload
Undisclosed
WO2015095301A2 ADC-7 linker
[6]
WO2015095301A2 ADC-8 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-8
WO2015095301A2 ADC-8 payload
Undisclosed
WO2015095301A2 ADC-8 linker
[6]
WO2015095301A2 ADC-9 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015095301A2 ADC-9
WO2015095301A2 ADC-9 payload
Undisclosed
WO2015095301A2 ADC-9 linker
[6]
WO2015189791A1 ADC-1 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-1
WO2015189791A1 ADC-1 payload
Undisclosed
WO2015189791A1 ADC-1 linker
[7]
WO2015189791A1 ADC-10 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-10
WO2015189791A1 ADC-10 payload
Undisclosed
WO2015189791A1 ADC-10 linker
[7]
WO2015189791A1 ADC-11 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-11
WO2015189791A1 ADC-11 payload
Undisclosed
WO2015189791A1 ADC-11 linker
[7]
WO2015189791A1 ADC-12 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-12
WO2015189791A1 ADC-12 payload
Undisclosed
WO2015189791A1 ADC-12 linker
[7]
WO2015189791A1 ADC-13 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-13
WO2015189791A1 ADC-13 payload
Undisclosed
WO2015189791A1 ADC-13 linker
[7]
WO2015189791A1 ADC-14 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-14
WO2015189791A1 ADC-14 payload
Undisclosed
WO2015189791A1 ADC-14 linker
[7]
WO2015189791A1 ADC-15 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-15
WO2015189791A1 ADC-15 payload
Undisclosed
WO2015189791A1 ADC-15 linker
[7]
WO2015189791A1 ADC-16 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-16
WO2015189791A1 ADC-16 payload
Undisclosed
WO2015189791A1 ADC-16 linker
[7]
WO2015189791A1 ADC-17 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-17
WO2015189791A1 ADC-17 payload
Undisclosed
WO2015189791A1 ADC-17 linker
[7]
WO2015189791A1 ADC-18 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-18
WO2015189791A1 ADC-18 payload
Undisclosed
WO2015189791A1 ADC-18 linker
[7]
WO2015189791A1 ADC-19 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-19
WO2015189791A1 ADC-19 payload
Undisclosed
WO2015189791A1 ADC-19 linker
[7]
WO2015189791A1 ADC-2 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-2
WO2015189791A1 ADC-2 payload
Undisclosed
WO2015189791A1 ADC-2 linker
[7]
WO2015189791A1 ADC-20 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-20
WO2015189791A1 ADC-20 payload
Undisclosed
WO2015189791A1 ADC-20 linker
[7]
WO2015189791A1 ADC-21 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-21
WO2015189791A1 ADC-21 payload
Undisclosed
WO2015189791A1 ADC-21 linker
[7]
WO2015189791A1 ADC-22 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-22
WO2015189791A1 ADC-22 payload
Undisclosed
WO2015189791A1 ADC-22 linker
[7]
WO2015189791A1 ADC-23 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-23
WO2015189791A1 ADC-23 payload
Undisclosed
WO2015189791A1 ADC-23 linker
[7]
WO2015189791A1 ADC-24 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-24
WO2015189791A1 ADC-24 payload
Undisclosed
WO2015189791A1 ADC-24 linker
[7]
WO2015189791A1 ADC-25 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-25
WO2015189791A1 ADC-25 payload
Undisclosed
WO2015189791A1 ADC-25 linker
[7]
WO2015189791A1 ADC-26 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-26
WO2015189791A1 ADC-26 payload
Undisclosed
WO2015189791A1 ADC-26 linker
[7]
WO2015189791A1 ADC-3 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-3
WO2015189791A1 ADC-3 payload
Undisclosed
WO2015189791A1 ADC-3 linker
[7]
WO2015189791A1 ADC-38 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-38
WO2015189791A1 ADC-38 payload
Undisclosed
WO2015189791A1 ADC-38 linker
[7]
WO2015189791A1 ADC-39 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-39
WO2015189791A1 ADC-39 payload
Undisclosed
WO2015189791A1 ADC-39 linker
[7]
WO2015189791A1 ADC-4 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-4
WO2015189791A1 ADC-4 payload
Undisclosed
WO2015189791A1 ADC-4 linker
[7]
WO2015189791A1 ADC-41 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-41
WO2015189791A1 ADC-41 payload
Undisclosed
WO2015189791A1 ADC-41 linker
[7]
WO2015189791A1 ADC-42 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-42
WO2015189791A1 ADC-42 payload
Undisclosed
WO2015189791A1 ADC-42 linker
[7]
WO2015189791A1 ADC-43 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-43
WO2015189791A1 ADC-43 payload
Undisclosed
WO2015189791A1 ADC-43 linker
[7]
WO2015189791A1 ADC-44 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-44
WO2015189791A1 ADC-44 payload
Undisclosed
WO2015189791A1 ADC-44 linker
[7]
WO2015189791A1 ADC-45 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-45
WO2015189791A1 ADC-45 payload
Undisclosed
WO2015189791A1 ADC-45 linker
[7]
WO2015189791A1 ADC-46 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-46
WO2015189791A1 ADC-46 payload
Undisclosed
WO2015189791A1 ADC-46 linker
[7]
WO2015189791A1 ADC-47 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-47
WO2015189791A1 ADC-47 payload
Undisclosed
WO2015189791A1 ADC-47 linker
[7]
WO2015189791A1 ADC-48 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-48
WO2015189791A1 ADC-48 payload
Undisclosed
WO2015189791A1 ADC-48 linker
[7]
WO2015189791A1 ADC-49 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-49
WO2015189791A1 ADC-49 payload
Undisclosed
WO2015189791A1 ADC-49 linker
[7]
WO2015189791A1 ADC-5 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-5
WO2015189791A1 ADC-5 payload
Undisclosed
WO2015189791A1 ADC-5 linker
[7]
WO2015189791A1 ADC-50 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-50
WO2015189791A1 ADC-50 payload
Undisclosed
WO2015189791A1 ADC-50 linker
[7]
WO2015189791A1 ADC-51 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-51
WO2015189791A1 ADC-51 payload
Undisclosed
WO2015189791A1 ADC-51 linker
[7]
WO2015189791A1 ADC-52 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-52
WO2015189791A1 ADC-52 payload
Undisclosed
WO2015189791A1 ADC-52 linker
[7]
WO2015189791A1 ADC-53 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-53
WO2015189791A1 ADC-53 payload
Undisclosed
WO2015189791A1 ADC-53 linker
[7]
WO2015189791A1 ADC-54 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-54
WO2015189791A1 ADC-54 payload
Undisclosed
WO2015189791A1 ADC-54 linker
[7]
WO2015189791A1 ADC-55 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-55
WO2015189791A1 ADC-55 payload
Undisclosed
WO2015189791A1 ADC-55 linker
[7]
WO2015189791A1 ADC-56 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-56
WO2015189791A1 ADC-56 payload
Undisclosed
WO2015189791A1 ADC-56 linker
[7]
WO2015189791A1 ADC-57 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-57
WO2015189791A1 ADC-57 payload
Undisclosed
WO2015189791A1 ADC-57 linker
[7]
WO2015189791A1 ADC-58 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-58
WO2015189791A1 ADC-58 payload
Undisclosed
WO2015189791A1 ADC-58 linker
[7]
WO2015189791A1 ADC-59 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-59
WO2015189791A1 ADC-59 payload
Undisclosed
WO2015189791A1 ADC-59 linker
[7]
WO2015189791A1 ADC-6 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-6
WO2015189791A1 ADC-6 payload
Undisclosed
WO2015189791A1 ADC-6 linker
[7]
WO2015189791A1 ADC-60 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-60
WO2015189791A1 ADC-60 payload
Undisclosed
WO2015189791A1 ADC-60 linker
[7]
WO2015189791A1 ADC-62 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-62
WO2015189791A1 ADC-62 payload
Undisclosed
WO2015189791A1 ADC-62 linker
[7]
WO2015189791A1 ADC-65 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-65
WO2015189791A1 ADC-65 payload
Undisclosed
WO2015189791A1 ADC-65 linker
[7]
WO2015189791A1 ADC-7 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-7
WO2015189791A1 ADC-7 payload
Undisclosed
WO2015189791A1 ADC-7 linker
[7]
WO2015189791A1 ADC-8 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-8
WO2015189791A1 ADC-8 payload
Undisclosed
WO2015189791A1 ADC-8 linker
[7]
WO2015189791A1 ADC-9 antibody
ADC Info ADC Name Payload Target Linker Ref
WO2015189791A1 ADC-9
WO2015189791A1 ADC-9 payload
Undisclosed
WO2015189791A1 ADC-9 linker
[7]
ADC Info ADC Name Payload Target Linker Ref
XMT-1522
Auristatin F hydroxypropylamide (AF-HPA)
Microtubule (MT)
Fleximer polymer
[158]
Zanidatamab
ADC Info ADC Name Payload Target Linker Ref
Zanidatamab-ADC-Tb3-1
Zanidatamab-ADC-Tb3-1 payload
Undisclosed
Zanidatamab-ADC-Tb3-1 linker
[2]
Zanidatamab-ADC-Tb3-2
Zanidatamab-ADC-Tb3-2 payload
Undisclosed
Zanidatamab-ADC-Tb3-2 linker
[2]
Zanidatamab-ADC-Tb3-3
Zanidatamab-ADC-Tb3-3 payload
Undisclosed
Zanidatamab-ADC-Tb3-3 linker
[2]
Zanidatamab-ADC-Tb3-4
Zanidatamab-ADC-Tb3-4 payload
Undisclosed
Zanidatamab-ADC-Tb3-4 linker
[2]
Zanidatamab-ADC-Tb3-5
Zanidatamab-ADC-Tb3-5 payload
Undisclosed
Zanidatamab-ADC-Tb3-5 linker
[2]
Zanidatamab-ADC-Tb3-6
Zanidatamab-ADC-Tb3-6 payload
Undisclosed
Zanidatamab-ADC-Tb3-6 linker
[2]
Zanidatamab-ADC-Tb3-7
Zanidatamab-ADC-Tb3-7 payload
Undisclosed
Zanidatamab-ADC-Tb3-7 linker
[2]
Zanidatamab-ADC-Tb3-8
Zanidatamab-ADC-Tb3-8 payload
Undisclosed
Zanidatamab-ADC-Tb3-8 linker
[2]
Zanidatamab-ADC-Tb3-9
Zanidatamab-ADC-Tb3-9 payload
Undisclosed
Zanidatamab-ADC-Tb3-9 linker
[2]
Zanidatamab-ADC-Tb3-10
Zanidatamab-ADC-Tb3-10 payload
Undisclosed
Zanidatamab-ADC-Tb3-10 linker
[2]
ZHER2-ABD
ADC Info ADC Name Payload Target Linker Ref
ZHER2-ABD-mcMMAF
Monomethyl auristatin F
Microtubule (MT)
Maleimido-caproyl
[159]
ZHER2-ABD-mcMMAE
Monomethyl auristatin E
Microtubule (MT)
Maleimido-caproyl
[159]
ZHER2:342-Cupid-His
ADC Info ADC Name Payload Target Linker Ref
ZHER2:342-Cupid-His-Ax-SiPc
Silicon Phthalocyanine
Undisclosed
Psyche-Ax
[160]
Zr-labeled trastuzumab
ADC Info ADC Name Payload Target Linker Ref
89Zr-DFO-T-DM1
Mertansine DM1
Microtubule (MT)
Undisclosed
[121]
Undisclosed
ADC Info ADC Name Payload Target Linker Ref
DB-1303
P1003
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[161]
IBI-354
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
PODS-CHX-A"-DTPA
[162]
FDA-022
Topoisomerase I inhibitor
DNA topoisomerase 1 (TOP1)
Undisclosed
[163]
ALT-P7
Undisclosed
Undisclosed
Undisclosed
[164]
BAT-8010
Undisclosed
Undisclosed
Undisclosed
[165]
BL-M07D1
Undisclosed
Undisclosed
Undisclosed
[166]
GB-251
Undisclosed
Undisclosed
Undisclosed
[34]
GQ-1005
Undisclosed
Undisclosed
Undisclosed
[167]
GQ-1007
Undisclosed
Undisclosed
Undisclosed
[167]
BI-CON-02
Undisclosed
Undisclosed
Undisclosed
[168]
XMT-2056
Undisclosed
Undisclosed
Undisclosed
[169]
ZV-0203
Undisclosed
Undisclosed
Undisclosed
[41]
ZV203
Undisclosed
Undisclosed
Undisclosed
[170]
FDA022-BB05
Undisclosed
Undisclosed
Undisclosed
[171]
Recombinant anti-HER2 humanized mAb-DM1
Undisclosed
Undisclosed
Undisclosed
[172]
HS630
Mertansine DM1
Microtubule (MT)
Undisclosed
[173]
MT-5111
Shiga toxin B subunit (StxB)
Ribosome (RB)
Undisclosed
[173]
KM254-ADC
Undisclosed
Undisclosed
Undisclosed
[174]
Xl-250
Undisclosed
Undisclosed
Undisclosed
[175]
Anti-HER2 antibody-drug conjugate (XDCExplorer)
Undisclosed
Undisclosed
Undisclosed
[176]
YB1-ADC-HER2
Undisclosed
Undisclosed
Undisclosed
[177]
Biparatopic HER2/HER2 antibody drug conjugate
Undisclosed
Undisclosed
Undisclosed
[178]
Anti-HER2-4AP ADC
Undisclosed
Undisclosed
Undisclosed
[179]
Anti-HER2 antibody drug conjugate (NBE-Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[180]
Anti-HER2 antibody-drug conjugate (Mersana Therapeutics/Genentech)
Undisclosed
Undisclosed
Undisclosed
[181]
Second Generation HER2-Directed Antibody-Drug conjugate
Undisclosed
Undisclosed
Undisclosed
[182]
Chloromethylbenz-Indoline Dimer Antibody Drug conjugate
Undisclosed
Undisclosed
Undisclosed
[183]
XB3-001
Undisclosed
Undisclosed
Undisclosed
[184]
ANT-043
Undisclosed
Undisclosed
Undisclosed
[185]
AbGn-110
Undisclosed
Undisclosed
Undisclosed
[186]
CTAT-ADC
Mertansine DM1
Microtubule (MT)
Undisclosed
[187]
Humanized Anti-HER2 Mab-Maytansine Conjugate
Mertansine DM1
Microtubule (MT)
Undisclosed
[188]
DAN-311
Camptothecin
DNA topoisomerase 1 (TOP1)
Undisclosed
[189]
SMP-656
Eribulin
Microtubule (MT)
Unique hydrophilic Linker
[190]
JAB-BX400
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
[191]
QBK249-G
Undisclosed
Undisclosed
Undisclosed
[192]
Mabion-HER2 ADC
Undisclosed
Undisclosed
Undisclosed
[193]
Antibody drug conjugate targeting HER2 (IntoCell)
Undisclosed
Undisclosed
Undisclosed
[194]
TE-1218
Undisclosed
Undisclosed
Undisclosed
[195]
TE-1112
Undisclosed
Undisclosed
Undisclosed
[196]
Antibody-drug conjugate (Scripps)
Undisclosed
Undisclosed
Undisclosed
[197]
Tissue/Disease specific Abundances of This Antigen
Tissue specific Abundances of This Antigen
ICD Disease Classification 01
Click to Show/Hide the 1 Disease of This Class
Bacterial infection [ICD-11: 1A00-1C4Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Gingival
The Specific Disease Bacterial infection of gingival
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.012604643; Fold-change: -0.227313462; Z-score: -0.343912121
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 02
Click to Show/Hide the 22 Disease of This Class
Brain cancer [ICD-11: 2A00]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Brainstem
The Specific Disease Glioma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.198499823; Fold-change: 0.206253875; Z-score: 1.788174987
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue White matter
The Specific Disease Glioma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.205668842; Fold-change: -0.145158484; Z-score: -0.935526231
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Brainstem
The Specific Disease Neuroectodermal tumor
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.010609917; Fold-change: 0.220914299; Z-score: 0.586649079
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Nervous
The Specific Disease Brain cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.000474019; Fold-change: -0.143646903; Z-score: -0.35944008
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Chronic myeloid leukemia [ICD-11: 2A20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Polycythemia vera
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.239499347; Fold-change: -0.01603947; Z-score: -0.077605035
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Whole blood
The Specific Disease Myelofibrosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.328573514; Fold-change: 0.125386027; Z-score: 0.624530572
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
MyeloDysplastic syndromes [ICD-11: 2A37]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Myelodysplastic syndromes
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.876154929; Fold-change: -0.001779038; Z-score: -0.011801104
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.016265287; Fold-change: -0.192996315; Z-score: -2.408343389
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Lymphoma [ICD-11: 2A90- 2A85]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Tonsil
The Specific Disease Lymphoma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.336092708; Fold-change: -0.161654757; Z-score: -0.815441813
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Gastric cancer [ICD-11: 2B72]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Gastric
The Specific Disease Gastric cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.002782765; Fold-change: 0.585165915; Z-score: 4.114824985
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 1.49E-08; Fold-change: 0.204756047; Z-score: 0.891446921
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Colon cancer [ICD-11: 2B90]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Colon
The Specific Disease Colon cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 2.99E-17; Fold-change: -0.616192168; Z-score: -0.880827727
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.780532435; Fold-change: 0.108718842; Z-score: 0.155182797
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Pancreatic cancer [ICD-11: 2C10]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Pancreas
The Specific Disease Pancreatic cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.302298466; Fold-change: 0.069838359; Z-score: 0.150669986
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.782977459; Fold-change: -0.164975563; Z-score: -0.417006613
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Liver cancer [ICD-11: 2C12]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Liver
The Specific Disease Liver cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.151225689; Fold-change: -0.073324858; Z-score: -0.157294246
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.589664963; Fold-change: -0.014761025; Z-score: -0.042519418
The Expression Level of Disease Section Compare with the Other Disease Section p-value: 0.790092503; Fold-change: -0.187685505; Z-score: -0.549772705
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Lung cancer [ICD-11: 2C25]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Lung
The Specific Disease Lung cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.000713882; Fold-change: -0.126046922; Z-score: -0.191222969
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.00351809; Fold-change: -0.110186279; Z-score: -0.139814236
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Melanoma [ICD-11: 2C30]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Melanoma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.084824536; Fold-change: -0.263316526; Z-score: -0.576627257
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sarcoma [ICD-11: 2C35]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Muscle
The Specific Disease Sarcoma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 4.42E-31; Fold-change: -0.276885656; Z-score: -0.852405448
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.259415131; Fold-change: -0.443169741; Z-score: -1.219076625
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Breast cancer [ICD-11: 2C60]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Breast
The Specific Disease Breast cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 3.50E-77; Fold-change: 0.490641074; Z-score: 1.120664442
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 6.69E-13; Fold-change: 0.354032542; Z-score: 0.624640369
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Ovarian cancer [ICD-11: 2C73]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Ovarian
The Specific Disease Ovarian cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.000490484; Fold-change: 0.452221886; Z-score: 1.023085171
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.230081828; Fold-change: 0.231462076; Z-score: 0.282151742
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Cervical cancer [ICD-11: 2C77]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Cervical
The Specific Disease Cervical cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.345734004; Fold-change: -0.049608938; Z-score: -0.166248044
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Uterine cancer [ICD-11: 2C78]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Endometrium
The Specific Disease Uterine cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.001385853; Fold-change: 0.067334425; Z-score: 0.152081835
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.354861587; Fold-change: -0.327056014; Z-score: -0.929317632
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Prostate cancer [ICD-11: 2C82]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Prostate
The Specific Disease Prostate cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.3644208; Fold-change: -0.229524506; Z-score: -0.380870565
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Bladder cancer [ICD-11: 2C94]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bladder
The Specific Disease Bladder cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.005674059; Fold-change: -1.257324423; Z-score: -2.049440451
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Retina cancer [ICD-11: 2D02]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Uvea
The Specific Disease Retinoblastoma tumor
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.002329625; Fold-change: -0.210164449; Z-score: -1.148894756
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Thyroid cancer [ICD-11: 2D10]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Thyroid
The Specific Disease Thyroid cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.015374496; Fold-change: -0.319937123; Z-score: -0.422489008
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.001631218; Fold-change: 0.076546714; Z-score: 0.128533682
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Adrenal cancer [ICD-11: 2D11]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Adrenal cortex
The Specific Disease Adrenocortical carcinoma
The Expression Level of Disease Section Compare with the Other Disease Section p-value: 0.415860724; Fold-change: -0.202615461; Z-score: -0.567346037
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Head and neck cancer [ICD-11: 2D42]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Head and neck
The Specific Disease Head and neck cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 3.48E-14; Fold-change: -0.647032029; Z-score: -0.778337569
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Pituitary cancer [ICD-11: 2F37]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Pituitary
The Specific Disease Pituitary gonadotrope tumor
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.177027061; Fold-change: 0.440620349; Z-score: 1.078664346
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Pituitary
The Specific Disease Pituitary cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.011812526; Fold-change: 0.402855648; Z-score: 1.136818895
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 03
Click to Show/Hide the 1 Disease of This Class
Thrombocytopenia [ICD-11: 3B64]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Thrombocytopenia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.164692605; Fold-change: 0.306015177; Z-score: 2.917723025
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 04
Click to Show/Hide the 2 Disease of This Class
Lupus erythematosus [ICD-11: 4A40]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Lupus erythematosus
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.160823912; Fold-change: -0.041599592; Z-score: -0.10423713
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Autoimmune disease [ICD-11: 4A4Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral monocyte
The Specific Disease Autoimmune uveitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.003990889; Fold-change: -0.212237911; Z-score: -1.02247083
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 05
Click to Show/Hide the 1 Disease of This Class
Hyperlipoproteinaemia [ICD-11: 5C80]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Familial hypercholesterolemia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.729031358; Fold-change: -0.002339739; Z-score: -0.008971821
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 06
Click to Show/Hide the 1 Disease of This Class
Schizophrenia [ICD-11: 6A20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Superior temporal cortex
The Specific Disease Schizophrenia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.590381771; Fold-change: 0.076709251; Z-score: 0.633074754
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 08
Click to Show/Hide the 3 Disease of This Class
Multiple sclerosis [ICD-11: 8A40]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Spinal cord
The Specific Disease Multiple sclerosis
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.339474391; Fold-change: -0.058653767; Z-score: -0.163399879
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Plasmacytoid dendritic cells
The Specific Disease Multiple sclerosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.231347716; Fold-change: 0.455635147; Z-score: 1.059625839
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Epilepsy [ICD-11: 8A60]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peritumoral cortex
The Specific Disease Epilepsy
The Expression Level of Disease Section Compare with the Other Disease Section p-value: 0.140242702; Fold-change: -0.577465457; Z-score: -2.115352885
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Cerebral ischaemic stroke [ICD-11: 8B11]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Cardioembolic Stroke
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.290174239; Fold-change: -0.022015206; Z-score: -0.118569253
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Peripheral blood
The Specific Disease Ischemic stroke
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.345010718; Fold-change: 0.091438346; Z-score: 0.447284726
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 1
Click to Show/Hide the 6 Disease of This Class
HIV [ICD-11: 1C60-1C62]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue White matter
The Specific Disease HIV
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.083904363; Fold-change: -0.102806679; Z-score: -0.601202519
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Influenza [ICD-11: 1E30]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Influenza
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.570012539; Fold-change: 0.014892846; Z-score: 0.06072158
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Chronic hepatitis C [ICD-11: 1E51.1]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Chronic hepatitis C
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.33670919; Fold-change: -0.113133125; Z-score: -0.786218208
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sepsis [ICD-11: 1G40-1G41]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Sepsis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.571000136; Fold-change: 0.019826642; Z-score: 0.070614896
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Septic shock [ICD-11: 1G41]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Septic shock
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.08996159; Fold-change: -0.066621954; Z-score: -0.207458618
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Pediatric respiratory syncytial virus infection [ICD-11: CA40.11]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Pediatric respiratory syncytial virus infection
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.164764309; Fold-change: -0.016702498; Z-score: -0.100450506
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 11
Click to Show/Hide the 6 Disease of This Class
Essential hypertension [ICD-11: BA00]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Essential hypertension
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.404421238; Fold-change: -0.076886403; Z-score: -4.941160538
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Myocardial infarction [ICD-11: BA41]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Myocardial infarction
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.051581685; Fold-change: 0.23189577; Z-score: 0.594795506
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Coronary artery disease [ICD-11: BA8Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Coronary artery disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.179643487; Fold-change: -0.246267417; Z-score: -1.468327955
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Aortic stenosis [ICD-11: BB70]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Calcified aortic valve
The Specific Disease Aortic stenosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.222126141; Fold-change: 0.294382577; Z-score: 0.893994387
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Arteriosclerosis [ICD-11: BD40]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Arteriosclerosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.885425763; Fold-change: 0.03950334; Z-score: 0.182468621
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Aneurysm [ICD-11: BD50]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Intracranial artery
The Specific Disease Aneurysm
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.099496449; Fold-change: -0.107553045; Z-score: -0.262160942
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 12
Click to Show/Hide the 8 Disease of This Class
Immunodeficiency [ICD-11: 4A00-4A20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Immunodeficiency
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.033956855; Fold-change: 0.187194317; Z-score: 1.523728854
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Apnea [ICD-11: 7A40]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Hyperplastic tonsil
The Specific Disease Apnea
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.037096291; Fold-change: -0.25612559; Z-score: -1.968075476
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Olive pollen allergy [ICD-11: CA08.00]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Olive pollen allergy
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.086119151; Fold-change: 0.117471138; Z-score: 1.381634816
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Chronic rhinosinusitis [ICD-11: CA0A]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Sinus mucosa
The Specific Disease Chronic rhinosinusitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.316251629; Fold-change: 0.09873195; Z-score: 0.282647993
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Chronic obstructive pulmonary disease [ICD-11: CA22]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Lung
The Specific Disease Chronic obstructive pulmonary disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.513249565; Fold-change: -0.028829707; Z-score: -0.087820065
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Small airway epithelium
The Specific Disease Chronic obstructive pulmonary disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.007670236; Fold-change: -0.499952426; Z-score: -0.662223305
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Asthma [ICD-11: CA23]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Nasal and bronchial airway
The Specific Disease Asthma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 5.59E-07; Fold-change: -0.283948459; Z-score: -0.222916785
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Human rhinovirus infection [ICD-11: CA42]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Nasal Epithelium
The Specific Disease Human rhinovirus infection
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.979233674; Fold-change: -0.036684358; Z-score: -0.105191898
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Idiopathic pulmonary fibrosis [ICD-11: CB03.4]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Lung
The Specific Disease Idiopathic pulmonary fibrosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.356082728; Fold-change: 0.057857538; Z-score: 0.135520535
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 13
Click to Show/Hide the 5 Disease of This Class
Periodontal disease [ICD-11: DA0C]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Gingival
The Specific Disease Periodontal disease
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.012251837; Fold-change: -0.324126129; Z-score: -0.476765602
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Eosinophilic gastritis [ICD-11: DA42.2]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Gastric antrum
The Specific Disease Eosinophilic gastritis
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.095313105; Fold-change: 0.247413617; Z-score: 1.360766367
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Liver failure [ICD-11: DB99.7-DB99.8]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Liver
The Specific Disease Liver failure
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.017481405; Fold-change: -0.298951991; Z-score: -1.220916592
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Ulcerative colitis [ICD-11: DD71]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Colon mucosal
The Specific Disease Ulcerative colitis
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.742423766; Fold-change: -0.058447298; Z-score: -0.234895268
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Irritable bowel syndrome [ICD-11: DD91.0]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Rectal colon
The Specific Disease Irritable bowel syndrome
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.178049459; Fold-change: -0.06551847; Z-score: -0.255841339
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 14
Click to Show/Hide the 5 Disease of This Class
Atopic dermatitis [ICD-11: EA80]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Atopic dermatitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.080307916; Fold-change: -0.132912034; Z-score: -0.685778056
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Psoriasis [ICD-11: EA90]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Psoriasis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.245279233; Fold-change: -0.172649165; Z-score: -0.302502826
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 1.89E-41; Fold-change: 0.537445296; Z-score: 2.230434432
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Vitiligo [ICD-11: ED63.0]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Vitiligo
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.354648452; Fold-change: 0.093244905; Z-score: 0.516508092
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Alopecia [ICD-11: ED70]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin from scalp
The Specific Disease Alopecia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.145406491; Fold-change: 0.060466136; Z-score: 0.229385077
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sensitive skin [ICD-11: EK0Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Sensitive skin
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.49598425; Fold-change: 0.317323593; Z-score: 0.581470041
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 15
Click to Show/Hide the 6 Disease of This Class
Osteoarthritis [ICD-11: FA00-FA0Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Synovial
The Specific Disease Osteoarthritis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.596294683; Fold-change: 0.00074721; Z-score: 0.002162212
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Arthropathy [ICD-11: FA00-FA5Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Arthropathy
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.648891763; Fold-change: -0.016919758; Z-score: -0.07783617
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Arthritis [ICD-11: FA20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Arthritis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.343640269; Fold-change: 0.001201018; Z-score: 0.004816102
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Rheumatoid arthritis [ICD-11: FA20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Synovial
The Specific Disease Rheumatoid arthritis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.246599282; Fold-change: 0.175239639; Z-score: 0.34416949
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Ankylosing spondylitis [ICD-11: FA92.0Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Pheripheral blood
The Specific Disease Ankylosing spondylitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.175614566; Fold-change: 0.113731949; Z-score: 0.480934006
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Osteoporosis [ICD-11: FB83]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Osteoporosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.040103439; Fold-change: 0.880556385; Z-score: 4.944408728
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 16
Click to Show/Hide the 2 Disease of This Class
Endometriosis [ICD-11: GA10]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Endometrium
The Specific Disease Endometriosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.888712642; Fold-change: -0.093771761; Z-score: -0.25632236
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Interstitial cystitis [ICD-11: GC00.3]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bladder
The Specific Disease Interstitial cystitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.001496637; Fold-change: -1.138266278; Z-score: -2.988495247
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 19
Click to Show/Hide the 1 Disease of This Class
Preterm birth [ICD-11: KA21.4Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Myometrium
The Specific Disease Preterm birth
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.710402149; Fold-change: -0.05864976; Z-score: -0.66030011
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 2
Click to Show/Hide the 8 Disease of This Class
Acute myelocytic leukemia [ICD-11: 2A60]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Acute myelocytic leukemia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.114727383; Fold-change: -0.048984373; Z-score: -0.251540805
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Myeloma [ICD-11: 2A83]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Myeloma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.021335399; Fold-change: 0.095198056; Z-score: 0.629065446
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Peripheral blood
The Specific Disease Myeloma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.350893053; Fold-change: 0.086227385; Z-score: 0.462021531
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Oral cancer [ICD-11: 2B6E]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Oral
The Specific Disease Oral cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.015079995; Fold-change: -0.213915921; Z-score: -0.382167512
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 4.78E-09; Fold-change: -0.716067055; Z-score: -0.786617541
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Esophagal cancer [ICD-11: 2B70]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Esophagus
The Specific Disease Esophagal cancer
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.740405247; Fold-change: -0.275644435; Z-score: -0.514688212
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Rectal cancer [ICD-11: 2B92]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Rectal colon
The Specific Disease Rectal cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.957525087; Fold-change: -0.117135726; Z-score: -0.225945024
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 1.05E-05; Fold-change: -1.049229149; Z-score: -3.975480307
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Skin cancer [ICD-11: 2C30-2C3Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Skin cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 4.76E-07; Fold-change: -0.485984665; Z-score: -0.748907119
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 1.11E-14; Fold-change: 0.232655645; Z-score: 0.637166891
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Renal cancer [ICD-11: 2C90-2C91]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Kidney
The Specific Disease Renal cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.292109361; Fold-change: -0.24493717; Z-score: -0.235064848
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 2.68E-15; Fold-change: -0.803082274; Z-score: -1.443359315
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Ureter cancer [ICD-11: 2C92]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Urothelium
The Specific Disease Ureter cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.931225005; Fold-change: 0.052255676; Z-score: 0.241930943
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 20
Click to Show/Hide the 2 Disease of This Class
Simpson golabi behmel syndrome [ICD-11: LD2C]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Adipose
The Specific Disease Simpson golabi behmel syndrome
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.899369522; Fold-change: -0.100631075; Z-score: -0.675234335
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Tuberous sclerosis complex [ICD-11: LD2D.2]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Perituberal
The Specific Disease Tuberous sclerosis complex
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.146893491; Fold-change: -0.103328516; Z-score: -0.998804448
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 3
Click to Show/Hide the 3 Disease of This Class
Anemia [ICD-11: 3A00-3A9Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Anemia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.821558408; Fold-change: 0.112263687; Z-score: 0.543197774
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sickle cell disease [ICD-11: 3A51.0-3A51.3]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Sickle cell disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.279092273; Fold-change: 0.212385394; Z-score: 0.715113871
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Thrombocythemia [ICD-11: 3B63]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Thrombocythemia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.54298711; Fold-change: -0.10208841; Z-score: -0.524650255
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 4
Click to Show/Hide the 4 Disease of This Class
Scleroderma [ICD-11: 4A42.Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Scleroderma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.043075833; Fold-change: 0.191472642; Z-score: 0.883395266
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sjogren syndrome [ICD-11: 4A43]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Salivary gland
The Specific Disease Sjogren syndrome
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.472694164; Fold-change: -0.305825893; Z-score: -1.034130527
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.035986035; Fold-change: -0.263974907; Z-score: -1.937527694
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Behcet disease [ICD-11: 4A62]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Behcet disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.743109111; Fold-change: 0.129191687; Z-score: 0.49013054
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Autosomal dominant monocytopenia [ICD-11: 4B04]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Autosomal dominant monocytopenia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.581617339; Fold-change: -0.080421466; Z-score: -0.364055736
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 5
Click to Show/Hide the 5 Disease of This Class
Type 2 diabetes [ICD-11: 5A11]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Liver
The Specific Disease Type 2 diabetes
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.087601114; Fold-change: -0.165683016; Z-score: -0.989682647
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Polycystic ovary syndrome [ICD-11: 5A80.1]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Vastus lateralis muscle
The Specific Disease Polycystic ovary syndrome
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.124863857; Fold-change: -0.16439822; Z-score: -0.938655765
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Obesity [ICD-11: 5B81]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Subcutaneous Adipose
The Specific Disease Obesity
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.084778678; Fold-change: -0.122947928; Z-score: -0.787037488
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Pompe disease [ICD-11: 5C51.3]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Biceps muscle
The Specific Disease Pompe disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.917500139; Fold-change: -0.003189095; Z-score: -0.024864192
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Batten disease [ICD-11: 5C56.1]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Batten disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.977461639; Fold-change: 0.025667446; Z-score: 0.153646914
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 6
Click to Show/Hide the 2 Disease of This Class
Autism [ICD-11: 6A02]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Autism
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.017930814; Fold-change: -0.115092535; Z-score: -0.528873069
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Anxiety disorder [ICD-11: 6B00-6B0Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Anxiety disorder
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.028470494; Fold-change: 0.051639545; Z-score: 0.251367933
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 8
Click to Show/Hide the 7 Disease of This Class
Parkinson disease [ICD-11: 8A00]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Substantia nigra
The Specific Disease Parkinson disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.470919115; Fold-change: -0.088008934; Z-score: -0.243685685
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Huntington disease [ICD-11: 8A01]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Huntington disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.243429319; Fold-change: 0.115488831; Z-score: 0.793933744
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Alzheimer disease [ICD-11: 8A20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Entorhinal cortex
The Specific Disease Alzheimer disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.606874505; Fold-change: -0.03918006; Z-score: -0.140924602
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Seizure [ICD-11: 8A60-8A6Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Seizure
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.628096184; Fold-change: 0.137136895; Z-score: 0.534471432
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Lateral sclerosis [ICD-11: 8B60.4]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Lateral sclerosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.301723855; Fold-change: -0.165174188; Z-score: -0.477732012
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Cervical spinal cord
The Specific Disease Lateral sclerosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.683230296; Fold-change: 0.004772728; Z-score: 0.034888825
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Muscular atrophy [ICD-11: 8C70]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Muscle
The Specific Disease Muscular atrophy
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.019006642; Fold-change: -0.251477117; Z-score: -0.966091571
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Myopathy [ICD-11: 8C70.6]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Muscle
The Specific Disease Myopathy
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.356468651; Fold-change: -0.119099861; Z-score: -0.303362323
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
References
Ref 1 Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics. 2021 Nov 3;13(11):1847.
Ref 2 Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.
Ref 3 Utilization of the Angiopep platform to enable brain penetration of therapeutic mAbs or Antibody-Drug Conjugates for treatment of brain tumors. Cancer Res (2014) 74 (19_Supplement): 2657.
Ref 4 Effect of vitamin D analog (1alpha hydroxy D5) immunoconjugated to Her-2 antibody on breast cancer. Int J Cancer. 2004 Mar 1;108(6):922-9. doi: 10.1002/ijc.11590.
Ref 5 Antibody Conjugation of a Chimeric BET Degrader Enables in?vivo Activity. ChemMedChem. 2020 Jan 7;15(1):17-25. doi: 10.1002/cmdc.201900497. Epub 2019 Nov 14.
Ref 6 Cytotoxic peptides and conjugates thereof.
Ref 7 Auristatin derivatives and conjugates thereof.
Ref 8 Cysteine engineered antibodies and conjugates.
Ref 9 Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation. Bioconjug Chem. 2022 Jun 15;33(6):1192-1200.
Ref 10 Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody-Drug Conjugates Revealing Key Insights into Structure-Activity Relationships. J Med Chem. 2023 Jan 26;66(2):1562-1573. doi: 10.1021/acs.jmedchem.2c01771.
Ref 11 Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. MAbs. 2019 Jan;11(1):153-165. doi: 10.1080/19420862.2018.1541370. Epub 2018 Nov 8.
Ref 12 Phosphate based linkers for intracellular delivery of drug conjugates; 2015-10-08.
Ref 13 Introduction to basic information on ADC drug ADC2202
Ref 14 Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates. Mol Cancer Ther. 2018 Mar;17(3):677-685. doi: 10.1158/1535-7163.MCT-17-0697. Epub 2018 Jan 18.
Ref 15 Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 16 Antibody drug conjugate and application thereof.
Ref 17 Site-specific antibody-drug conjugation through glycoengineering.
Ref 18 Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. Nat Commun. 2018 Jun 28;9(1):2512. doi: 10.1038/s41467-018-04982-3.
Ref 19 Tridentate connexon and use thereof.
Ref 20 Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. PLoS One. 2020 Sep 28;15(9):e0239813. doi: 10.1371/journal.pone.0239813. eCollection 2020.
Ref 21 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0378.
Ref 22 Stable and Potent Selenomab-Drug Conjugates. Cell Chem Biol. 2017 Apr 20;24(4):433-442.e6. doi: 10.1016/j.chembiol.2017.02.012.
Ref 23 Amatoxin antibody-drug conjugates and uses thereof; 2020-10-29.
Ref 24 Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry. Bioconjug Chem. 2015 Nov 18;26(11):2249-60. doi: 10.1021/acs.bioconjchem.5b00359.
Ref 25 A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy. Bioconjug Chem. 2022 Jun 15;33(6):1210-1221.
Ref 26 Introduction to basic information on ADC Anvatabart pactil.
Ref 27 Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody-Drug Conjugates. J Med Chem. 2023 Jan 12;66(1):1011-1026. doi: 10.1021/acs.jmedchem.2c01812. Epub 2022 Dec 30.
Ref 28 Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof; 2021-07-29.
Ref 29 Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. Cancer Commun (Lond). 2021 Feb;41(2):171-182.
Ref 30 Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class. Angew Chem Int Ed Engl. 2018 Nov 12;57(46):15243-15247. doi: 10.1002/anie.201807619. Epub 2018 Oct 15.
Ref 31 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
Ref 32 An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index. Onco Targets Ther. 2022 Apr 8;15:331-343.
Ref 33 Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate. Mol Pharm. 2023 Jan 2;20(1):775-782. doi: 10.1021/acs.molpharmaceut.2c00700. Epub 2022 Nov 15.
Ref 34 Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Mol Ther. 2023 Mar 22:S1525-0016(23)00140-5. doi: 10.1016/j.ymthe.2023.03.019.
Ref 35 Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual -glucuronide and dipeptide triggers. Eur J Med Chem. 2019 Oct 1;179:591-607.
Ref 36 Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin. Bioorg Med Chem Lett. 2017 Mar 1;27(5):1154-1158.
Ref 37 Preparation method for antibody-drug conjugate, and application; 2022-11-03.
Ref 38 Linkers for use in antibody drug conjugates; 2023-03-16.
Ref 39 Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Jan 1;27(1):43-51. doi: 10.1158/1078-0432.CCR-20-2488. Epub 2020 Oct 27.
Ref 40 Antibody-Drug Conjugates Used in Breast Cancers. J Oncol. 2021 Jun 24;2021:9927433. doi: 10.1155/2021/9927433. eCollection 2021.
Ref 41 Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors; NCT05423977.
Ref 42 An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. Adv Sci (Weinh). 2021 Dec;8(23):e2102414. doi: 10.1002/advs.202102414. Epub 2021 Oct 18.
Ref 43 Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. Antib Ther. 2021 Aug 28;4(3):175-184.
Ref 44 DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecol Oncol. 2021 Nov;163(2):334-341. doi: 10.1016/j.ygyno.2021.08.014. Epub 2021 Aug 25.
Ref 45 Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index. Drug Deliv. 2022 Dec;29(1):754-766.
Ref 46 Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates. Drug Deliv. 2021 Dec;28(1):2603-2617.
Ref 47 Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety. Cancers (Basel). 2020 Mar 21;12(3):744. doi: 10.3390/cancers12030744.
Ref 48 Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy. Cancers (Basel). 2019 Jul 8;11(7):957. doi: 10.3390/cancers11070957.
Ref 49 Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index. Drug Deliv. 2022 Dec;29(1):754-766. doi: 10.1080/10717544.2022.2039807.
Ref 50 Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clin Cancer Res. 2022 Jun 29:OF1-OF10.
Ref 51 Anti-HER2 Affibody-Conjugated Photosensitizer for Tumor Targeting Photodynamic Therapy. Mol Pharm. 2020 May 4;17(5):1546-1557. doi: 10.1021/acs.molpharmaceut.9b01247. Epub 2020 Apr 16.
Ref 52 SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. Journal of Clinical Oncology 2020 38:15_suppl, 3110-3110.
Ref 53 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof; 2020-04-02.
Ref 54 Neodegrader conjugates; 2021-10-07.
Ref 55 Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. 1994 Oct 1;54(19):5171-7.
Ref 56 PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. Mol Cancer Ther. 2020 Oct;19(10):2068-2078.
Ref 57 Pyrrolobenzodiazepine antibody drug conjugates and methods of use; 2017-04-06.
Ref 58 Pyrrolobenzodiazepines and conjugates thereof; 2015-04-09.
Ref 59 Silvestrol antibody-drug conjugates and methods of use; 2017-12-14.
Ref 60 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5.
Ref 61 Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer. 2022 Oct;10(10):e005119.
Ref 62 Phase I study of A166, an antibodydrug conjugate in advanced HER2-expressing solid tumours. NPJ Breast Cancer. 2023 Apr 18;9(1):28. doi: 10.1038/s41523-023-00522-5.
Ref 63 Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019 Dec 1;183:111682. doi: 10.1016/j.ejmech.2019.111682.
Ref 64 Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody-Drug Conjugate. Molecules. 2020 Mar 26;25(7):1515.
Ref 65 SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles. Cancer Res (2023) 83 (8_Supplement): LB031.
Ref 66 Phase I Clinical Trial on the Safety, Tolerability, Pharmacokinetics of B003 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer, NCT03953833
Ref 67 GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency. Cancer Res (2023) 83 (7_Supplement): 2702. doi: 10.1158/1538-7445.AM2023-2702.
Ref 68 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors; NCT04278144.
Ref 69 Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study. Anticancer Drugs. 2023 Jul 1;34(6):763-774.
Ref 70 MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors. Mol Cancer Ther. 2018 Apr;17(4):786-794. doi: 10.1158/1535-7163.MCT-17-0795. Epub 2018 Feb 13.
Ref 71 ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1. Front Oncol. 2020 Jan 23;9:1534. doi: 10.3389/fonc.2019.01534.
Ref 72 Introduction to basic information on ADC drug LIN-002.
Ref 73 HER2-targeted DEP SN-38 ADC outperforms in HER2+ human cancer model (ASX announcement); 2023
Ref 74 Fluorescence Imaging of Tumor-Accumulating Antibody-IR700 Conjugates Prior to Near-Infrared Photoimmunotherapy (NIR-PIT) Using a Commercially Available Camera Designed for Indocyanine Green. Mol Pharm. 2021 Mar 1;18(3):1238-1246. doi: 10.1021/acs.molpharmaceut.0c01107. Epub 2021 Jan 27.
Ref 75 Spirea secures more capital to develop nextgeneration ADC cancer therapeutics; 2020
Ref 76 A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019 Jan 21;7(1):16. doi: 10.1186/s40425-018-0464-1.
Ref 77 The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity. Cancer Res (2022) 82 (12_Supplement): 1758.
Ref 78 Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023 Jan 17;16(1):3. doi: 10.1186/s13045-022-01397-y.
Ref 79 Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. J Immunother. 2016 Apr;39(3):117-26. doi: 10.1097/CJI.0000000000000115.
Ref 80 Enzymatic glycan remodeling-metal free click (GlycoConnect) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering. MAbs. 2022 Jan-Dec;14(1):2078466.
Ref 81 Design and Characterization of Immune-Stimulating Imidazo[4,5-c]quinoline Antibody-Drug Conjugates. Mol Pharm. 2022 Sep 5;19(9):3228-3241.
Ref 82 Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008 Nov 15;68(22):9280-90.
Ref 83 Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP. Front Biosci (Landmark Ed). 2022 Aug 5;27(8):234.
Ref 84 Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer. MAbs. 2019 Apr;11(3):500-515.
Ref 85 Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. Mol Cancer Ther. 2017 May;16(5):879-892.
Ref 86 A new immunochemical strategy for triple-negative breast cancer therapy. Sci Rep. 2021 Jul 21;11(1):14875.
Ref 87 The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead. Eur J Med Chem. 2022 Dec 15;244:114863.
Ref 88 Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett. 2016 May 24;7(11):983-987.
Ref 89 Introduction to basic information on ADC drug trastuzumab vedotin.
Ref 90 Introduction to basic information on ADC drug Trastuzumab rezetecan.
Ref 91 BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg Med Chem Lett. 1997;7(17):2235-2238.
Ref 92 Develop highly specific cell engager constructs with improved function and safety by understanding target-effector cell avidity.
Ref 93 Adcitmer , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. Br J Dermatol. 2022 Feb;186(2):295-306. doi: 10.1111/bjd.20770.
Ref 94 Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. Bioconjug Chem. 2022 Feb 16;33(2):418-426. doi: 10.1021/acs.bioconjchem.2c00015. Epub 2022 Feb 1.
Ref 95 Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability. Chem Commun (Camb). 2022 Feb 8;58(12):1962-1965. doi: 10.1039/d1cc06766d.
Ref 96 N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability. MAbs. 2021 Jan-Dec;13(1):1914885. doi: 10.1080/19420862.2021.1914885.
Ref 97 Non-Genetic Generation of Antibody Conjugates Based on Chemoenzymatic Tyrosine Click Chemistry. Bioconjug Chem. 2021 Oct 20;32(10):2167-2172. doi: 10.1021/acs.bioconjchem.1c00351. Epub 2021 Sep 14.
Ref 98 Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel). 2021 Mar 9;14(3):247. doi: 10.3390/ph14030247.
Ref 99 Harnessing the power of antibodies to fight bone metastasis. Sci Adv. 2021 Jun 23;7(26):eabf2051. doi: 10.1126/sciadv.abf2051.
Ref 100 Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells. Pharmaceuticals (Basel). 2021 Jun 28;14(7):624. doi: 10.3390/ph14070624.
Ref 101 Site-specific construction of triptolide-based antibody-drug conjugates. Bioorg Med Chem. 2021 Dec 1;51:116497. doi: 10.1016/j.bmc.2021.116497. Epub 2021 Nov 10.
Ref 102 Binding protein drug conjugates comprising anthracycline derivatives; 2016-06-30.
Ref 103 Antibody drug conjugates; 2023-07-06.
Ref 104 Antibody-drug conjugates comprising branched linkers and methods related thereto; 2017-06-01.
Ref 105 Pyrrolobenzodiazepines and conjugates thereof; 2013-04-18.
Ref 106 Antitumor compound, and preparation method therefor and use thereof; 2022-04-07.
Ref 107 Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin. Mol Cancer Ther. 2022 Oct 7;21(10):1573-1582.
Ref 108 Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation. Bioconjug Chem. 2022 Jun 15;33(6):1179-1191.
Ref 109 General and Robust Chemoenzymatic Method for Glycan-Mediated Site-Specific Labeling and Conjugation of Antibodies: Facile Synthesis of Homogeneous Antibody-Drug Conjugates. ACS Chem Biol. 2021 Nov 19;16(11):2502-2514.
Ref 110 Introduction to basic information on ADC drug trastuzumab imbotolimod.
Ref 111 Introduction to basic information on ADC drug trastuzumab botidotin.
Ref 112 CRD5500: A versatile small molecule STING agonist amenable to bioconjugation as an ADC. Cancer Res (2019) 79 (13_Supplement): LB-061.
Ref 113 N-Myristolytransferase (NMT) inhibitors as novel potent payloads for antibody drug conjugates. Cancer Res (2023) 83 (7_Supplement): 2635.
Ref 114 A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells. MAbs. 2023 Jan-Dec;15(1):2220466. doi: 10.1080/19420862.2023.2220466.
Ref 115 Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology. Bioconjug Chem. 2023 Mar 15;34(3):538-548. doi: 10.1021/acs.bioconjchem.2c00611. Epub 2023 Mar 1.
Ref 116 Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue. PLoS One. 2023 Mar 13;18(3):e0282831. doi: 10.1371/journal.pone.0282831. eCollection 2023.
Ref 117 Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023 Apr 3;13(4):950-973. doi: 10.1158/2159-8290.CD-22-1368.
Ref 118 Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. ACS Chem Biol. 2020 Jun 19;15(6):1306-1312. doi: 10.1021/acschembio.0c00285. Epub 2020 Apr 30.
Ref 119 Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive Peptide. ACS Omega. 2019 Jul 31;4(7):12955-12968. doi: 10.1021/acsomega.9b01585. eCollection 2019 Jul 31.
Ref 120 Aptamer-Directed Conjugation of DNA to Therapeutic Antibodies. Bioconjug Chem. 2019 Aug 21;30(8):2127-2135. doi: 10.1021/acs.bioconjchem.9b00363. Epub 2019 Jul 12.
Ref 121 Aryl Sulfate is a Useful Motif for Conjugating and Releasing Phenolic Molecules: Sulfur Fluorine Exchange Click Chemistry Enables Discovery of Ortho-Hydroxy-Protected Aryl Sulfate Linker. Bioconjug Chem. 2019 Jul 17;30(7):1957-1968. doi: 10.1021/acs.bioconjchem.9b00340. Epub 2019 Jun 28.
Ref 122 Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor?2-positive gastric cancer. Oncol Rep. 2018 Mar;39(3):1396-1404. doi: 10.3892/or.2018.6201. Epub 2018 Jan 9.
Ref 123 Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anticancer Drugs. 2020 Jun;31(5):463-472. doi: 10.1097/CAD.0000000000000878.
Ref 124 A light-responsive, self-immolative linker for controlled drug delivery via peptide- and protein-drug conjugates. Chem Sci. 2019 Aug 19;10(39):8973-8980. doi: 10.1039/c9sc03016f. eCollection 2019 Oct 21.
Ref 125 Camptothecin derivative and ligand-drug conjugate thereof; 2022-04-21.
Ref 126 Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof; 2021-12-16.
Ref 127 Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility. Antibodies (Basel). 2018 Mar 22;7(2):15. doi: 10.3390/antib7020015.
Ref 128 Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates. Bioconjug Chem. 2019 Jan 16;30(1):200-209. doi: 10.1021/acs.bioconjchem.8b00843. Epub 2018 Dec 13.
Ref 129 Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates. Org Biomol Chem. 2018 Mar 14;16(11):1882-1889. doi: 10.1039/c7ob02780j.
Ref 130 Peroxide-cleavable linkers for antibody-drug conjugates. Chem Commun (Camb). 2023 Feb 9;59(13):1841-1844. doi: 10.1039/d2cc06677g.
Ref 131 An antibody-supermolecule conjugate for tumor-specific targeting of tumoricidal methylated -cyclodextrin-threaded polyrotaxanes. J Mater Chem B. 2020 Aug 21;8(31):6975-6987. doi: 10.1039/d0tb00575d. Epub 2020 Jun 23.
Ref 132 Design, Synthesis, and Bioevaluation of a Novel Hybrid Molecular Pyrrolobenzodiazepine-Anthracenecarboxyimide as a Payload for Antibody-Drug Conjugate. J Med Chem. 2022 Sep 8;65(17):11679-11702. doi: 10.1021/acs.jmedchem.2c00471. Epub 2022 Aug 18.
Ref 133 A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Antibody-Drug Conjugates with High Potency and Selectivity. Bioconjug Chem. 2022 Oct 19;33(10):1860-1866. doi: 10.1021/acs.bioconjchem.2c00314. Epub 2022 Sep 15.
Ref 134 One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling. Bioconjug Chem. 2021 Aug 18;32(8):1888-1897. doi: 10.1021/acs.bioconjchem.1c00314. Epub 2021 Aug 5.
Ref 135 Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation. Org Lett. 2020 Nov 6;22(21):8419-8423. doi: 10.1021/acs.orglett.0c03049. Epub 2020 Oct 19.
Ref 136 Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site. Int J Mol Sci. 2020 Sep 19;21(18):6882. doi: 10.3390/ijms21186882.
Ref 137 Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates. Bioorg Med Chem. 2020 Dec 1;28(23):115793. doi: 10.1016/j.bmc.2020.115793. Epub 2020 Oct 6.
Ref 138 Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect. Bioeng Transl Med. 2022 Aug 21;7(3):e10388. doi: 10.1002/btm2.10388. eCollection 2022 Sep.
Ref 139 Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy.
Ref 140 Amatoxin derivatives.
Ref 141 Antibody-drug-conjugate and its use for the treatment of cancer.
Ref 142 Conjugates comprising self-immolative groups and methods related thereto.
Ref 143 Peptide-containing linkers for antibody-drug conjugates.
Ref 144 Novel antibody-drug conjugates and the use of same in therapy.
Ref 145 Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen.
Ref 146 Pyrrolobenzodiazepines and conjugates thereof.
Ref 147 Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same.
Ref 148 Spliceostatin analogs.
Ref 149 TAA013 a trastuzumab antibody drug conjugate phase I dose escalation study in recurrent her2 positive breast cancer. Cancer Res (2021) 81 (4_Supplement): PS10-51.
Ref 150 Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors. Cancer Res (2017) 77 (13_Supplement): 52. doi: 10.1158/1538-7445.AM2017-52.
Ref 151 Antibody-drug conjugates and related compounds, compositions, and methods.
Ref 152 Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity. Bioorg Med Chem Lett. 2019 Apr 1;29(7):943-947. doi: 10.1016/j.bmcl.2019.01.009. Epub 2019 Jan 11.
Ref 153 Design, Synthesis, and Biochemical Evaluation of Alpha-Amanitin Derivatives Containing Analogs of the trans-Hydroxyproline Residue for Potential Use in Antibody-Drug Conjugates. Chemistry. 2021 Jul 16;27(40):10282-10292. doi: 10.1002/chem.202101373. Epub 2021 Jun 18.
Ref 154 Tag-free, specific conjugation of glycosylated IgG1 antibodies using microbial transglutaminase. RSC Adv. 2022 Nov 22;12(52):33510-33515. doi: 10.1039/d2ra05630e. eCollection 2022 Nov 22.
Ref 155 Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021 Jun 10;12(1):3528.
Ref 156 Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins. J Steroid Biochem Mol Biol. 2020 Jun;200:105651. doi: 10.1016/j.jsbmb.2020.105651. Epub 2020 Mar 5.
Ref 157 Cyclopentadiene as a Multifunctional Reagent for Normal- and Inverse-Electron Demand Diels-Alder Bioconjugation. Bioconjug Chem. 2022 Sep 21;33(9):1609-1619.
Ref 158 Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate. Cancer Res (2017) 77 (13_Supplement): 48.
Ref 159 Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. J Control Release. 2023 Mar;355:515-527. doi: 10.1016/j.jconrel.2023.02.005. Epub 2023 Feb 14.
Ref 160 Pathological complete remission of relapsed tumor by photo-activating antibody-mimetic drug conjugate treatment. Cancer Sci. 2022 Dec;113(12):4350-4362.
Ref 161 Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study. Journal of Clinical Oncology 2023 41:16_suppl, 3023-3023.
Ref 162 A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors; NCT05636215.
Ref 163 A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors; NCT05564858.
Ref 164 Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients; NCT03281824.
Ref 165 Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients; NCT05848466.
Ref 166 BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models. Cancer Res (2023) 83 (7_Supplement): 2643.
Ref 167 Genequantum biopharmaceutical company product pipeline
Ref 168 Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab; NCT03062007.
Ref 169 XMT-2056, a HER2-targeted STING agonist antibody-drug conjugate, exhibits ADCC function that synergizes with STING pathway activation and contributes to anti-tumor responses. Cancer Res (2023) 83 (7_Supplement): 4423.
Ref 170 Introduction to basic information on ADC drug ZV203; 6 Jan 2020.
Ref 171 Fudan-zhangjiang bio-pharmaceutic company indicative announcement
Ref 172 Introduction to basic information on recombinant anti-HER2 humanized monoclonal antibody-DM1(Qilu Pharmaceutical Co., Ltd.).
Ref 173 Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antib Ther. 2022 Jan 27;5(1):18-29. doi: 10.1093/abt/tbac001.
Ref 174 Sihuan pharmaceutical holdings group annual presentation; 2020
Ref 175 Introduction to basic information on ADC drug xl-250.
Ref 176 Introduction to basic information on ADC drug Anti-HER2 antibody-drug conjugate(XDCExplorer)
Ref 177 YB1 pharmaceutical company product pipeline
Ref 178 Introduction to basic information on biparatopic HER2 x HER2 antibody drug conjugate(Regeneron Pharmaceuticals).
Ref 179 Introduction to basic information on ADC drug Anti-HER2-4AP ADC(Catalent Biologics)
Ref 180 Introduction to basic information on anti-HER2 antibody drug conjugates(NBE-Therapeutics).
Ref 181 Introduction to basic information on anti-HER2 antibody-drug conjugate(Mersana Therapeutics/Genentech).
Ref 182 A second-generation antibody-drug conjugate to treat HER2-positive breast cancer. Lancet. 2023 Jan 14;401(10371):80-81. doi: 10.1016/S0140-6736(22)02534-X. Epub 2022 Dec 7.
Ref 183 Introduction to basic information on ADC drug Chloromethylbenz-Indoline Dimer Antibody Drug conjugate
Ref 184 Bioasis and wuxi biologics announce initial strategic collaboration for the development and manufacturing of xB3-001, the companys lead investigational candidate to treat brain cancer; 2018
Ref 185 Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors. Cancer Res (2021) 81 (13_Supplement): 909.
Ref 186 ADC review: basic information about ABGN-110.
Ref 187 Antibody drug conjugate using CTAT linker technology shows superior efficacy in xenograft trial; 2015
Ref 188 Introduction to basic information on humanized anti-HER2 mab-maytansine conjugate(Anhui Anke Biotechnology/Wuxi Pharmatech).
Ref 189 An investigational next generation ADC (DAN-311) is highly effective in HER2-low breast cancer models. Cancer Res (2022) 82 (4_Supplement): P2-13-09.
Ref 190 Xiling yuan pharmaceutical company product pipeline
Ref 191 A JAB-X1800/JAB-BX400 introduction by Jacobio Pharmaceuticals.
Ref 192 Quadira Biosciences AG company product pipeline
Ref 193 Introduction to basic information on ADC drug Mabion-HER2 ADC
Ref 194 Intocell biotechnology company product pipeline
Ref 195 Introduction to basic information on ADC drug TE-1218.
Ref 196 Introduction to basic information on ADC drug TE-1112.
Ref 197 Introduction to basic information on ADC drug Antibody-drug conjugate (Scripps).

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.